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ABSTRACT 
Hypertension is a major risk factor for stroke, ischaemic heart disease, and the development of heart failure. 
Hypertension-induced heart failure is usually preceded by the development of left ventricular hypertrophy 
(LVH), which represents an adaptive and compensatory response to the increased cardiac workload. 
Biomechanical stress and neurohumoral activation are the most important triggers of pathologic hypertrophy 
and the transition of cardiac hypertrophy to heart failure. Non-clinical and clinical studies have also revealed 
derangements of energy metabolism in hypertensive heart failure. The goal of this study was to investigate in 
experimental models the molecular mechanisms and signalling pathways involved in hypertension-induced 
heart failure with special emphasis on local renin-angiotensin-aldosterone system (RAAS), cardiac metabolism, 
and calcium sensitizers, a novel class of inotropic agents used currently in the treatment of acute 
decompensated heart failure. 
Two different animal models of hypertensive heart failure were used in the present study, i.e. hypertensive and 
salt-sensitive Dahl/Rapp rats on a high salt diet (a salt-sensitive model of hypertensive heart failure) and double 
transgenic rats (dTGR) harboring human renin and human angiotensinogen genes (a transgenic model of 
hypertensive heart failure with increased local RAAS activity). The influence of angiotensin II (Ang II) on cardiac 
substrate utilization and cardiac metabolomic profile was investigated by using gas chromatography coupled to 
time-of-flight mass spectrometry to detect 247 intermediary metabolites. 
It was found that Ang II could alter cardiac metabolomics both in normotensive and hypertensive rats in an Ang 
II receptor type 1 (AT1)-dependent manner. A distinct substrate use from fatty acid oxidation towards glycolysis 
was found in dTGR. Altered cardiac substrate utilization in dTGR was associated with mitochondrial 
dysfunction. Cardiac expression of the redox-sensitive metabolic sensor sirtuin1 (SIRT1) was increased in dTGR. 
Resveratrol supplementation prevented cardiovascular mortality and ameliorated Ang II-induced cardiac 
remodeling in dTGR via blood pressure-dependent pathways and mechanisms linked to increased 
mitochondrial biogenesis. Resveratrol dose-dependently increased SIRT1 activity in vitro. Oral levosimendan 
treatment was also found to improve survival and systolic function in dTGR via blood pressure-independent 
mechanisms, and ameliorate Ang II-induced coronary and cardiomyocyte damage. Finally, using Dahl/Rapp rats 
it was demonstrated that oral levosimendan as well as the AT1 receptor antagonist valsartan improved survival 
and prevented cardiac remodeling. The beneficial effects of levosimendan were associated with improved 
diastolic function without significantly improved systolic changes. These positive effects were potentiated 
when the drug combination was administered. 
In conclusion, the present study points to an important role for local RAAS in the pathophysiology of 
hypertension-induced heart failure as well as its involvement as a regulator of cardiac substrate utilization and 
mitochondrial function. Our findings suggest a therapeutic role for natural polyphenol resveratrol and calcium 
sensitizer, levosimendan, and the novel drug combination of valsartan and levosimendan, in prevention of 
hypertension-induced heart failure. The present study also provides a better understanding of the 
pathophysiology of hypertension-induced heart failure, and may help identify potential targets for novel 
therapeutic interventions. 
10 
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1. INTRODUCTION 
Heart failure (HF) is a pathophysiological condition in which the heart is unable to pump blood at the 
rate commensurate with the requirements of the metabolizing tissues or can do so only from an 
elevated filling pressure. (Dickstein et al., 2008) Hypertensive HF emerges as a consequence of 
hypertension and subsequent changes, and is typically characterized by compromised diastolic 
function, but preserved systolic function. An important step is the transition from cardiac 
hypertrophy to HF, characterized by the failure of this maladaptive mechanism to maintain sufficient 
cardiac output. (Tocci, 2008)(Meredith and Ostergren, 2006) Examination of hospitalized patients has 
revealed HF to be associated with many pre-existing major risk factors such as ischemic heart 
disease, myocardial infarction (MI), hypertension, cardiac valvular disease, peripheral vascular 
disease, chronic renal failure, diabetes. (Lee, 2004)(Schocken et al., 2008)) In addition, minor risk 
factors contributing to failure of the heart are smoking, high dietary salt intake, sedentary lifestyle, 
obesity. (for review see (Dupree, 2009)) Moreover there are genetic and behavioral as well as 
psychosocial factors which infuence the development of HF. (for review see (Spruill, 2010))  
There are an estimated 23 million people with HF worldwide and there has been an increase in the 
number of hospitalization incidents with a resulting increase in health care expenditures. (for review 
see (Dupree, 2009)) The number of adults suffering from HF is 2 % whereas 6-10 % rate is observed in 
elderly people living in developed countries. (Dickstein et al.,2008) 
In 75 % of cases, acute decompensation occurs in a patient with known chronic HF; 25 % have new-
onset HF (Fonarow, 2003). It is important to note that more than one-third of patients experiencing 
acute decompensated HF will have preserved systolic function, though the prognosis of patients with 
preserved systolic function (ejection fraction (EF) >45-50 %) seems to be similar to those with 
decreased systolic function. (Tsuyuki et al., 2001)(Bhatia et al., 2006)(Dickstein et al., 2008) Pure 
diastolic HF occurs in elderly patients, predominantly in women, and is mostly associated with 
preexisting LVH systemic hypertension and preserved EF. (Francis, 2001)(for review see (Franklin and 
Aurigemma, 2005)) 
Surveys have established that hypertensive HF patients requiring care are older, with a mean age 
between 70 and 75 years, commonly female and have a greater number of concomitant diseases, 
making them more susceptible to decompensation, more difficult to treat and more prone to 
recurrent events. (for review see (Lee, 2004)) Appropriate strategies to effectively fight the 
development of HF during its asymptomatic stages, or at least when early structural and functional 
cardiac abnormalities have been identified, need to be investigated in individuals with hypertension 
12 
 
or who display a ‘high’ cardiovascular risk profile as recommended by current guidelines on 
hypertension and HF. (Tocci, 2008) Even though over the past 20 years, there have been major 
advances and declining mortality due to novel ways of treating HF with angiotensin-converting-
enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), aldosterone antagonists, β-
blockers, diuretics and cardiac resynchronization therapy, this disease is still associated with an 
annual mortality rate of 10 %. (Dickstein et al.,2008)(for review see (Neubauer, 2007))  
The increasing understanding of cellular and molecular pathways has opened novel types of 
approaches and revealed new targets for the treatment of diseases. Cardioprotection is one novel 
therapeutic approach for the treatment of cardiovascular diseases, especially HF, i.e. targeting the 
molecular pathways associated with the progression of the disease. Cardioprotective salvage 
pathways include sustained mitochondrial function, corrected cardiac energy metabolism, improved 
myocyte contractility, suppressed local renin-angiotensin-aldosterone system (RAAS), reduced 
apoptosis and decelerated cellular senescence. The exact molecular mechanisms of hypertensive HF 
still remain unclear; therefore studying the signaling pathways known or suspected to be involved in 
this detrimental process is a prerequisite before one can develop the novel treatments to stop, delay 
or even reverse progression of established disease. (Slama et al. , 2002) (for review see (Gradman 
and Alfayoumi, 2006)(Varagic and Frohlich, 2002)(Murray et al., 2007)(Gradman and Wilson, 2009))  
This study aimed at characterizing the molecular pathways associated with angiotensin II (Ang II) 
overactivity. Rat models of hypertension-induced HF were used to examine cardioprotective effects 
and mechanisms of compounds such as the Ang II receptor antagonist valsartan, the calcium 
sensitizer levosimendan and the silent mating type information regulation 2 homolog 1 (SIRT1) 
activator resveratrol, all of which may exert beneficial actions. 
13 
 
2. REVIEW OF THE LITERATURE 
2.1 Hypertension as a risk factor for cardiovascular disease  
Elevated blood pressure (BP) is known to correlate with increased cardiovascular risk. A higher BP 
means a higher risk of cardiovascular diseases (CVD) such as stroke, MI, renal disease which 
eventually can lead to hypertension-induced HF. Due to its life-preserving role, BP must be tightly 
regulated to maintain a constant perfusion of all organs. (for review see (Lifton et al., 2001)) An 
increment of as little as 20/10 mmHg starting from BP level of 115 mmHg results in an increased risk 
of CVD. (for review see (Landmesser and Drexler, 2007) The increase in systolic blood pressure (SBP) 
develops gradually and often concomitantly with other diseases such as dyslipidemia, insulin 
resistance, and abdominal obesity. (for review see (Carretero, 2000)) SBP elevation results in a 
hypertrophic reponse in the arterial smooth muscle layer, decreasing the diameter of the vessel 
lumen. A consequent increase in afterload contributes to cardiac muscle overgrowth as an 
adaptation, since the heart needs to pump against a higher resistance. These compensatory 
mechanisms become maladaptive, increasing the risk of other target organ damage such as in the 
vascular endothelium, kidney and brain, and thus cardiovascular events. (McEniery et al., 2006)(for 
review see (Gradman and Alfayoumi, 2006)(Landmesser and Drexler, 2007)(Gradman and Wilson, 
2009))  
The exact pathogenetic pathways of essential hypertension remain largely unknown and the detailed 
mechanisms have proved elusive. To date, a significant involvement in this process has been assigned 
mostly to genetic, environmental and demographic factors. Essential hypertension is shown to be a 
polygenetic disorder with contribution from variety of risk factors (25-65 % of the total risk). Genes 
accounting for the onset of hypertension are those predisposing to its progression especially, if the 
dietary regimen, such as high salt, low potassium or low calcium intake, is imbalanced. (McEniery et 
al., 2006) (for review see (Gradman and Alfayoumi, 2006)(Landmesser and Drexler, 2007)) In addition 
to genetic factors, excessive alcohol intake, salt intake (in salt-sensitive patients), aging, sedentary 
lifestyle, stress, low potassium and calcium intake predispose towards an increase in BP and in that 
way to CVD. (Carretero, 2000)  
2.1.1 Definition and classification of hypertension 
BP is defined as force exerted upon vessel wall by circulating blood. When high BP appears to be due 
to reasons other than secondary causes such as renovascular disease, renal failure, 
pheochromocytoma, aldosteronism, essential or primary hypertension is used. (Mancia et al., 2007)  
14 
 
The evaluation of hypertension is based on repeated BP measurements. (Mancia et al., 2007)  
Depending on the advancement of the condition, different categories can be assigned to the patient. 
Prehypertension describes the patient at a high risk of developing hypertension. These individuals 
are encouraged to change the lifestyle and diet to reduce the risk of hypertension in the future. 
Further stages in the classification of hypertension, defining systolic and diastolic increase in BP (SBP 
and DBP respectively) for adults are shown in Table 1. The treatment goal for individuals with 
hypertension is <140/85 mm Hg.  (Finnish Current Care Guidelines 2009) 
 
BP classification SBP  
(mmHg) 
DBP 
(mmHg) 
Optimal 
Normal 
Pre-hypertension 
            < 120                   and              < 80 
            < 130                   and              < 85 
            130-139              and              85-89 
Slightly elevated 
Moderately elevated 
Significantly elevated 
Hypertensive crisis 
            140-149               or                90-99 
            160-179               or               100-109 
            ≥ 180                    or                ≥ 110 
            ≥ 200                    or                ≥ 130 
 
Table 1. A classification system for hypertension for adults. (Finnish Current Care Guidelines 2009) 
 
2.1.2. Importance of dietary salt as key risk factor for hypertension  
The link between salt-sensitivity and BP interactions depends on genetic and environmental factors. 
Genetic factors determine the extent of the BP increase or decrease required to restore and maintain 
the salt and water balance, indicating that the BP fluctuations of some individuals may be sensitive or 
resistant to a high salt intake. (for review see (Karppanen, 2006)(Ruilope et al., 2001)) Dietary salt 
intake is a major contributor to the development of high BP, and even a modest decrease in dietary 
Na+ can lower BP. Humans are genetically adapted to consume 0.25 g of salt daily, however 
nowadays the average daily consumption equals 3-4 g daily. (for review see (Karppanen et al., 
2005)(Karppanen, 2006)) The salt excreting mechanisms of the kidney, which are evolutionarily 
adapted to handle lower amounts of Na+, become quickly saturated and the kidney is not able to 
excrete the excess NaCl. This leads to elevated BP, which is an adaptive mechanism allowing the 
kidney to secrete more salt by using pressure-natriuresis. The magnitude of the BP increase, which is 
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needed to eliminate a given amount of salt and water, depends strongly on the sodium-handling 
mechanisms of the kidneys. (for review see (Karppanen, 2006)(Ruilope et al., 2001)) The 
development of sodium deficiency and decreased extracellular fluid volume during a prolonged 
period of very small sodium intake or losses due to gastrointestinal causes, sweating, or blood loss, 
can be effectively prevented by decreasing the BP. By lowering BP, the body is able to prevent renal 
sodium and fluid excretion completely. On the other hand, in the case of high salt intake the body, is 
able to effectively prevent salt and fluid accumulation by raising the BP to such an extent that 
pressure-induced increase in salt and water excretions matches the intakes. (for review see 
(Karppanen, 2006)) Interestingly, in the presence of normal genetic variations in salt-handling pumps 
and channels, the excretion of excess sodium is markedly improved by increased intakes of 
potassium, calcium, and magnesium. Hence, a given amount of excess salt and water can be excreted 
in at a lower BP than needed with a low intake of the above mineral nutrients. (for review see 
(Karppanen, 2006))  
2.1.3. Subclinical target organ damage in hypertension 
2.1.3.1 Endothelial dysfunction and alterations in the vascular wall 
Hypertension is associated with abnormal endothelial function in the peripheral, coronary and renal 
circulation. Endothelial dysfunction is both a consequence of hypertension, and a factor predisposing 
towards hypertension. Endothelial dysfunction has been implicated in the pathophysiology of macro- 
and microvascular beds. Thus, it is directly linked to arterial stiffness, coronary atherosclerosis and 
renal dysfunction in hypertension. (Simko and Pechanova, 2010)(for review see (Landmesser and 
Drexler,  2007))  
Endothelium-derived nitric oxide (NO) relaxes blood vessels and thus regulates vascular tone and 
structure. It prevents platelet aggregation and adhesion, limits oxidation of low-density lipoprotein 
(LDL) cholesterol, inhibits the proliferation of vascular smooth muscle cells, and decreases the 
expression of pro-inflammatory genes that promote atherogenesis. (for review see (Fostermann et 
al., 2010)(Pechanova and Simko, 2009)(Landmesser and Drexler, 2007)) NO is synthetised by 
endothelial nitric oxide synthase (eNOS) in the vasculature in the presence of L-arginine. Impairment 
in NO production leads to changes in BP, decreased shear stress and pulsatile stretch, thrombosis, 
and atherosclerosis. These changes evoke also disorganization in the structure of vasculature such as 
vascular smooth muscle cell hypertrophy. (for review see (Landmesser and Drexler, 2007)) Increased 
reactive oxygen species (ROS) concentrations are known to reduce the amount of bioactive NO by 
chemical inactivation to form toxic peroxynitrite, which in turn can “uncouple” eNOS to become a 
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dysfunctional superoxide-generating enzyme that contributes to the vascular oxidative stress. (for 
review see (Fostermann et al., 2010)(Pechanova and Simko, 2009)) 
The endothelium is known to produce not only vasodilating NO, but also vasoconstricting factors. 
These include prostanoids, prostacyclins, acetylcholine and bradykinin, which play a crucial role in 
the pathogenesis of vessel damage, i.e. they are involved in the processes leading to cardiovascular 
diseases including HF when in abundance. Of these factors, endothelin-1 seems to be one of the 
most powerful force. Endothelin is secreted in a paracrine manner in the abluminal direction. It 
facilitates vasoconstriction hence elevating BP. This increase in BP takes place in the vasculature of 
smooth-muscle cells with no inevitable alteration in the systemic circulation. (Spanikova et al., 
2008)(Simko and Pechanova, 2010)(for review see (Oparil et al., 2003) Tumor necrosis factor-α (TNF-
α) in turn, as well as interleukins mediates pro-inflammatory responses in the endothelium. (Zhang et 
al., 2010) (for review see (Boos and Lip, 2006))  
Peripheral vascular resistance is elevated in hypertension, contributes to remodeling of vessels and 
to high BP and is associated with target organ damage. (Luo et al., 2010)(for review see (Oparil et al., 
2003)) Vascular remodeling comprises of adaptive and/or maladaptive changes in the mechanical 
properties of vasculature. (Kwon et al., 2006)(for review see (Sonoyama et al., 2007)) These kinds of 
changes may be classified as vessel enlargement (outward remodeling), diminution (inward 
remodeling), alternatively as adaptive, or maladaptive. (for review see (Herity et al., 1999)) In 
eutrophic inward remodeling, the diameter of the small arteries lumen decreases and wall thickness 
increases with no changes in cross-sectional areas. (for review see (Sonoyama et al., 2007)) A 
disturbed myogenic reflex or further elevated pressure may disrupt the autoregulatory adaptive 
ability of the vessel. When the vessel wall pressure stress is further increased, eutrophic remodeling 
is replaced by hypertrophic outward remodeling with reduced ability to contract, namely the 
myogenic reflex. If this reflex is non-functional or if accelerated pressure overwhelms the blood 
vessel’s ability to autoregulate, then it will be unable to withstand the increased wall stress and it 
replaces eutrophic inward remodeling with hypertrophy. (for review see (Sonoyama et al., 2007))  
Vascular remodeling may also have direct consequences on the heart. Hypertension induced aortic 
stiffness accelerates aortic pulse wave velocity, which in turn results in a premature wave return in 
systole. This increases LV afterload and central pulse pressure contributing to cardiac hypertrophy. A 
decrease in diastolic pressure occurs in parallel, as a result of the concomitant decrease in diastolic 
BP, reducing coronary perfusion. (for review see (Nagashima and Kasanuki, 2003)(Gradman and 
Alfayoumi,  2006)(Gradman and Wilson, 2009)(Raman, 2010))  
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2.1.3.2 Hypertrophy and cardiac remodeling 
The main structural adjustment of the heart to pressure overload is LVH. Cardiac hypertrophy is 
defined as an abnormal increase in heart mass, resulting in increased wall thickness with 
compromised chamber volume. (for review see (Nadar et al., 2006)(Yip et al., 2009)) Elevated SBP, 
volume overload and prolonged ejection time, at the expense of reduction of diastole duration and 
myocardial relaxation, lead to LVH. (for review see (Yip et al., 2009)) LVH predisposes towards 
coronary heart disease, stroke, cardiac arrhythmias, myocardial ischemia, sudden death, carotid 
atherosclerotic plaques, and ultimately HF. (for review see (Yip et al., 2009)(Frohlich, 1999)(Phillips et 
al., 1998))    
Cardiac remodeling is associated with the growth and alterations of cardiac myocytes and interstitial 
matrix, including accumulation of fibroblasts and macromolecules such as collagen, elastin and 
fibronectin to the extracellular space. (for review see (Finckenberg and Mervaala, 2010)) Loss of 
myofilaments and myocyte apoptosis are also involved. These changes are accompanied by 
abnormalities in intracellular calcium handling, initiation of inflammatory processes, and triggring of 
complex changes in cardiac gene expression encoding ion channels, growth factors and metabolic 
enzymes. (for review see (Mancia et al., 2007)(Meredith and Ostergren, 2006)(Yip et al., 2009) These 
detrimental alterations lead to a disproportional growth in the cardiac muscle. (for review see (Yip et 
al., 2009)) They facilitate diastolic dysfunction, which in turn promotes the progression of systolic 
dysfunction. (Mancia et al., 2007)(for review see (Moncrieff, 2004)(Meredith and Ostergren, 2006))  
As the cardiac remodeling progresses, various types of LVH develop over time. Three major types of 
LVH are known. Concentric remodeling, in pressure overload conditions, is characterized by 
sarcomeres which become organized in parallel, adding to the cardiomyocyte thickness and non-
dilated thick walled left ventricle, which increases more than the LV cavity volume. This remodeling is 
associated with a normal ejection fraction and unchanged endocardial stress-shortening relationship. 
(for review see (Yip et al., 2009) In eccentric remodeling, which is related to volume overload, the 
sarcomeres become organized in series to promote myocyte lengthening, which results in a 
proportional increase in LV mass and volume, resulting in ventricular dilation with relatively normal 
wall thickness but reduced LV systolic function. (for review see (Mancia et al., 2007)(Yip et al., 2009)) 
MI which combines both of these remodeling types can be considered as the third type of LVH. (for 
review see (Yip et al., 2009))  
Non-hemodynamic factors, such as adrenergic, RAAS and endothelin signaling, are known to activate 
important pathways, causing downregulation of myocardial β-receptors, inhibition of sarcolemmal 
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calcium release channels and exaggerated activation of extracellular matrix metalloproteinases 
(MMPs). (for review see (Mancia et al., 2007)(Gradman and Alfayoumi,  2006)(Subramaniam and Lip, 
2009)) Dysregulation of MMPs and their inhibitors (the tissue inhibitors of metalloproteinases, 
TIMPS) is typical for LVH facilitating the degradation of normal type collagens, which are then 
replaced by fibrous intestinal deposits of incorrectly crosslinked collagens. This promotes dilatation 
of the ventricle. In addition, the digestion of extrecellular matrix components by MMPs causes a 
reactive increase in the production of other factors, including transforming growth factor β (TGF-β), 
insulin-like growth factor and fibroblast growth factor. (for review see (Diamond and Phillips, 2005)) 
The increased wall tension evolves into cardiac hypertrophy under the influence of sequencing 
pathophysiological pathways. These pathways involve intracellular calcium release, as an early 
response to myocyte stretch and humoral stimuli such as Ang II, phenylephrine and endothelin. The 
increase in intracellular calcium results in activation of the phosphatase calcineurin, which 
dephosphorylates a transcription factor, nuclear factor of activated T cell (NFAT3). This results in 
NFAT3 translocation to the nucleus to initiate transcription of genes that lead to myocyte 
hypertrophy, such as β-myosin heavy chain and β-skeletal actin. (for review see (Diamond and 
Phillips, 2005)) Physiological hypertrophy of the heart is generally associated with the induction of α-
myosin heavy chains (MHC) expression; however, during pathologic pressure and volume overload 
hypertrophy, β-MHC is increased at the expense of α-MHC, demonstrating adenosine triphosphate 
(ATP) management deprivation. (Gupta, 2007) This shift in the myosin- isoform arrangement as well 
as cross-bridging cycling alterations in the sarcomere plays a significant role in controlling the 
shortening velocity of cardiac muscle fibers. (Gupta, 2007) Other pathways upregulated genes (such 
as phospholamdan) and pathways interacting with the calcineurin–NFAT pathway to regulate cardiac 
myocyte growth, like the mitogen-activated protein kinase (MAPK) pathway. (Rysä et al., 2005)(Rysä 
et al., 2006)(for review see (Diamond and Phillips, 2005)) Other pathways are known to interact with 
calcineurin-NFAT pathway and thus regulate cardiac myocytes growth. The MAPK pathway regulates 
calcineurin via the c-jun N-terminal kinases (JNKs) and extracellular signal-regulated kinases (ERKs). 
Targeting these pathways occurs to promote LV mass regression. (for review see (Diamond and 
Phillips, 2005)) 
2.1.3.3 Kidney dysfunction 
The renal system is responsible for maintaining fluid and electrolyte balance, and therefore playing a 
crucial role in the development of cardiovascular diseases (CVDs). On average, 20 % of the cardiac 
output goes to the kidneys. (for review see (Rea, 2008)) The presence of mild renal insufficiency in 
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hypertensive subjects is accompanied by higher initial levels of both SBP and DBP. (for review see 
(Ruilope et al., 2001)) Elevated systemic and increased glomerular BP both contribute to 
nephropathies. (for review see (Cohuet and Struijker-Boudier, 2006)) Hydrostatic and oncotic 
pressure gradients and permeability of the glomerular basement membrane impact on the 
glomerular filtration rate (GFR). Neurohumoral mechanisms such as RAAS, anti-diuretic vasopressin 
and endothelin have a vasoconstrictive role in the kidney. Sympathetic nervous system (SNS) 
activation decreased NO levels and the resulting increase in oxidative stress causes a constriction of 
afferent and efferent arterioles, decreasing renal blood flow and GFR. The vascular damage is 
followed by vascular stiffening, intense neuronal activation, venous congestion, reduced blood flow 
facilitating the endothelium and media damage; thrombosis, inflammation, hemorrhage and edema. 
It is crucial that all the regulatory systems in the kidney remain balanced, including the continuous 
monitoring of the sodium concentration in the distal tubule. These regulatory systems maintain renal 
hemodynamics and correct GFR and they are controlled by tubuloglomerular feedback loop within 
the juxtaglomerular apparatus. (for review see (Rea, 2008)) 
Renal damage mostly can be traced to renal arterioral thickening, fibrinoid deposition in the 
glomeruli and proteinuria (for review see (Cohuet and Struijker-Boudier, 2006)) Microalbuminuria, or 
the development of overt proteinuria progresses in parallel with the development of hypertension. 
There is a concomitant increase in serum creatinine concentration or a decrease in creatinine 
clearance. Both elevated serum creatinine levels and a decrease in GFR (creatinine clearance, 30-90 
ml/min) and elevated urinary excretion of albumin below crucial limits i.e. (microalbuminuria, 30 to 
300 mg/day) or above (macroalbuminuria, 300 mg/day), serve as good markers of the development 
of kidney dysfunction. (for review see (Ruilope et al., 2001)(Johnson, 2008)) Moreover, additional 
electrolyte imbalances occur; hyponatremia, hypomagnesemia, and hypokalemia in parallel with 
increased blood urea nitrogen (BUN). (for review see (Francis, 2001)) 
2.1.4 Hypertension-induced target organ damage 
2.1.4.1 Stroke 
Cerebrovascular disease is one of the most common consequences of hypertension. This may result 
in haemorrhagic and ischemic strokes, as well as vascular dementia. (for review see (Aronow and 
Frishman, 2004)(Veglio, 2009)) Stroke is associated with 9 % mortality worldwide and with 2-4 % of 
total health care expences. There are several stroke-related risk factors e.g. hypertension, diabetes, 
and smoking. (for review see (Donnan et al., 2008))  A quarter of all stroke patients have a history of 
some kind of symptomatic coronary event. One of the major risk factor is atrial fibrillation, 
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contributing to nearly 10 % of all ischemic strokes. (for review see (Bernstein, 2010)(Armario and de 
la Sierra A, 2009))  
Strokes can be divided into haemorrhagic (intracerebral haemorrhage) and ischemic. The 
management of stroke is type-dependent. (for review see (Donnan et al., 2008))  Ischaemic strokes 
account for 80 % of all strokes. The mechanism involves vessel occlusion, impaired cellular perfusion, 
functional cerebral impairments creating an area called the penumbra. The penumbra is associated 
with imbalances in energy and ion homeostasis, the presence of free radicals, necrosis, apoptosis and 
onset of inflammatory processes. These cascades in the penumbra can be arrested and thus cells can 
be saved. However the infarct core itself consists of tissue which has been fatally damaged. (for 
review see (Donnan et al., 2008)) Heamorrhigic strokes are commonly associated with hypertension 
and the mechanism is directly related to hypertensive small vessel disease. Systemic hypertension 
predisposes to aneurysm, blood-filled dilation. When the size of the aneurysm increases, the risk of 
its rupture is also increased, leading severe complications or even death. (for review see (Donnan et 
al., 2008))   
The prognosis for patients with stroke is poor; approximately a quarter of stroke patients will die, a 
third by six months, and a half by a year. (for review see (Donnan et al., 2008)) Antihypertensive 
therapy can reduce stroke events by 40 % and the recurrence of stroke by 28 %. (for review see 
(Aronow and Frishman, 2004)(Veglio, 2009)) In particular, rapid and aggressive management for 
acure stroke such as fibrinolytic agents may be needed to reduce mortality and improve patient 
recovery. Recombinant tissue plasminogen activator must be injected urgently within 3-4.5 hours 
after onset of acute stroke. (Otwell et al., 2010) (for review see (Goldemund and Mikulik, 2010))  
2.1.4.2 Coronary heart disease  
Atherosclerosis is the process predominantly involved in vessel diseases. The predisposition to 
coronary heart disease is influenced by both- genetic and environmental factors. The heritability of 
atherosclerosis exceeds 50 % and is subjected to the presence of complex factors such as lipoprotein 
levels, body fat and others. (for review see (Lusis, 2000)) In addition to hypertension, dyslipidemia 
and cigarette smoking contribute to its development. (for review see (Veglio, 2009)) The 
atherosclerotic process comprises vessel remodeling including coronary arteries comprising also 
inflammatory responses. (for review see (Ross, 1999)) First, there is a compensatory enlargement of 
the cross-sectional areas of the vessels and changes in the structure and functions. The 
atherosclerotic plaque develops and occupies 30 % to 40 % of the vessel space. (for review see 
Palluzzoli et al., 2010)(Francis, 2001)) This vascular stiffness causes major hemodynamic alterations, 
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these being associated with arterial pulse widening and increases in cyclic arterial flow. The 
ventricular-arterial stiffening results in changes in cardiovascular reserve, BP variations, diastolic 
dysfunction, altered coronary and peripheral flow regulation, and mechanical signaling as well as 
endothelial dysfunction. These changes are common in subjects having cardiac hypertrophy with 
increased end-systolic chamber stiffness progressed into HF with preserved ejection fraction. 
(Kawaguchi et al., 2003)(for review see (Chen, 1998)) 
The progression of atherosclerosis includes disruption of the endothelium, which in turn predisposes 
lipids and fibrous elements to combine, to form complicated plaques and accumulate in the large 
arteries. (for review see (Veglio, 2009)(Lusis, 2000)) Plaques are mostly found in large vessel 
bifurcations and bends where the blood flow is impaired. (for review see (Veglio, 2009) 
Subendothelial aggregation of LDL cholesterol, which on the contrary to high-density lipoprotein 
(HDL) is strongly promoting atherosclerosis, accumulates inside congested macrophages (foam cells). 
Subsequently, the fatty streaks formed are precursors of more advanced fibrous lesions, such as 
smooth muscle cells and lipid-rich necrotic cells. More extensive alterations may occur e.g. 
calcification, luminal surface ulceration and hemorrhage from small vessels, which may grow into the 
lesion from the media of the blood vessel wall. This change may even result in an interruption the 
block of blood flow, leading to thrombus of blood clot and in the end to infarction, HF or stroke. 
(Lehtonen-Smeds et al., 2005)(for review see (Lusis, 2000)(Kovanen and Pentikainen, 2003)) 
Concomitant inflammation triggered by oxidized LDL, is associated with the recruitment monocytes 
and lymphocytes to the artery wall. Oxidized LDL reduces NO production, thus causing 
vasoconstriction. Haemodynamic forces, sex, hormones and infections can also regulate the 
inflammatory process, which further promotes vascular stiffness. (for review see (Lusis, 2000))  
2.1.4.3 Myocardial infarction and ischemic heart disease 
MI is defined as a necrotic locus in the heart. This area has low tissue perfusion due to symptomatic 
cardiac cell death. (Zornoff, 2009)) Commonly the rupture of atherosclerotic plaque in the wall of the 
coronary artery leads to the interruption of the blood supply to the heart. The triggering event for MI 
is the disruption of a sufficiently large atherosclerotic coronary plaque with the consequent 
production of a thrombus (blood clot). This onset may start due to internal circadian, external 
physical or emotional factors. (for review see (Hammoudeh and Alhaddad, 2009)) Cardiac 
arrhythmias such as tachycardia can enhance the formation of an atherosclerotic plaque and later its 
disruption. (for review see (Orso et al., 2009) Coronary arteries undergo compensatory outward 
remodeling in relation to the plaque area over the years. Therefore the development of MI may be 
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clinically silent for a very long time. Ultimately MI may lead to ischemia and its consequences i.e. lack 
of oxygen in the myocardium and metabolic dysregulation. (Otwell et al., 2010) (for review see 
(Misra et al., 2009) 
Infarcted myocardial muscle displays an increased stiffness independently of the volume due to the 
development of myocardial contracture, interstitial edema, fibrocellular infiltration and scar. In case 
of large infarcts, LV remodeling and dilation progress further. If these detrimental changes continue 
to develop, the failure of relaxation intensifies and will be accompanied by concentric hypertrophy 
resulting in post-infarct remodeling. Tachycardia is capable of reducing the duration of diastole, 
therefore raising ventricular volume; bradycardia in turn has the opposite effect but both conditions 
worsen the ischemic state. Successful treatment of ischemia improves diastolic relaxation and lowers 
both diastolic and pulmonary venous pressures, thereby reducing dyspnea. (Braunwald et al., 2008) 
(for review see (Gajarsa and Kloner, 2010) 
2.1.4.4 Hypertension-induced heart failure 
HF represents the final common pathway of many different cardiac diseases of different etiologies as 
described earlier. (Tocci, 2008)(for review see (Dickstein, 2005)) When the ventricle becomes 
hypertrophied and stiffened, it fills abnormally and fails to relax completely. These chronic changes 
predispose the individual to diastolic dysfunction but these may remain asymptomatic, until they 
ultimately progress into symptomatic HF. At first a shift towards increased diastolic pressure-volume 
overload enhances increased end-diastolic pressure, left atrial and pulmo-capillary pressure and 
greater stroke volume (for review see (Mandinov et al., 2000)(Meredith and Ostergren, 2006)) but 
with time, even this mechanism starts to fail. Then the LV filling worsens even more, resulting in 
inadequate filling even though elevation in diastolic pressure. This decreases end-diastolic volume, 
which in turn depresses stroke volume (for review see (Mandinov et al., 2000) leading to pulmonary 
congestion. Furthermore, due to the continuous accumulation of extracellular matrix, cardiac 
stiffness and vascular resistance, diastolic dysfunction becomes worse and evolves into overt systolic 
reduction, where cardiac output is decreased. (for review see (Mandinov et al., 2000)(Meredith and 
Ostergren, 2006) Primarily systolic function of heart such as left ventricular ejection fraction (LVEF) 
and left ventricular fractional shortening (LVFS) are sustained in diastolic HF, nonetheless it develops 
further into systolic HF with reduction in systolic function of the heart and concomitant increase in 
ventricular volume. (for review see (Kitzman et al., 2002)(Kostis, 2003)(Zile and Brutsaert, 2002)) The 
development of hypertension-induced HF in depicted in Figure 1. 
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Figure 1. The development of diastolic HF concomitant with systolic HF. As the disease progresses 
and congestive symptoms become more apparent, thus result can be sudden cardiac death or end-
stage failure. Modified from (Mandinov et al., 2000)  
 
The compensatory mechanisms in heart and kidney are associated with overactivity of SNS and 
overstimulation of RAAS. These systems provide inotropic support to the failing heart, increasing 
stroke volume and peripheral vasoconstriction in attempts to maintain mean arterial perfusion 
pressure. However, these alerations are deleterious to cardiocirculatory homeostasis during the late 
stages of the disease. (for review see (Palazzuoli, 2010)) 
Acute decompensated HF may be challenging to diagnose. (Lee, 2004) The clinical signs vary 
depending whether there is pulmonary congestion, organ perfusion, or the presence of coronary 
disease, fluid retention and systemic pressure. (for review see (Palazzuoli, 2010)) The evaluation of 
the level of congestion and tissue perfusion thus the disease appear to be the most appropriate ways 
to achieve the correct diagnosis and treatment. (Lee et al., 2004)  
The symptoms and signs of HF include predominantly: 
• HF with SBP greater than 140 mmHg (50 %); 
• HF with SBP 90 mmHg to 140 mmHg (48 %) 
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• HF with SBP less than 90 mmHg (2 %) 
• Cardiogenic shock (< 1 %) 
• Dyspnea (90 %) 
• Pulmonary congestion (74 %) 
• Pulmonary edema (< 3 %). (Lee et al., 2004)  
HF is mostly clinically characterized by fluid overload due to filling pressures and paroxysmal 
nocturnal dyspnea and orthopnea (shortness of breath) with apparent fatigue and cough. The 
symptoms best indicating HF are a distended internal jugular vein, tachycardia, and displaced apical 
impulse. In addition swelling in ankles, legs and abdomen area (ascites) occur being a sign of HF. 
(Dickstein et al., 2008)(Lee et al., 2004)(for review see (Francis, 2001))  
Elevated levels of natriuretic peptides, namely brain natriuretic peptide (BNP) and N-terminal pro-
BNP, can serve as diagnostic tools to differentiate HF from non-heart failure- related symptoms. (for 
review see (Onwuanyi and Taylor, 2007)(Francis, 2001)(Meredith and Ostergren, 2006)) The BNP is 
produced by the heart ventricles in response to mechanical overload and increased wall stretch, and 
thus elevated levels of BNP can serve as a good indicator of HF. (for review see (Vuolteenaho et al., 
2005)) There are results that BNP reflects the remodelling process in hypertension. (Uusimaa et al., 
2004)  
Correct and early diagnosis and choice of treatment strategy are still challenges for scientists and 
clinicians, both partly because there is no comprehensive understanding of the mechanisms 
contributing to HF development as well as the unsatisfactory availability of drug regimens. 
2.1.4.5 Kidney failure 
Kidney function is also greatly disturbed and its dysfunctions are driven by the RAAS and the SNS. (for 
review see (Schrier and Fassett, 1998)) The efferent arteriole of the kidney constricts at the low 
blood flow levels and the kidney attempts to re-absorb more salt and water, but it excretes more 
potassium in attempt to maintain proper tissue perfusion. This triggers peripheral edema and 
imbalanced electrolyte homeostasis. Afferent arteriolar vasodilatory hormones such as 
prostaglandins and natriuretic peptides, which initially are able to balance glomerular efferent 
vasoconstricting mechanisms, later fail to maintain renal blood flow. The GFR is usually adequate in 
the early stages of HF. However due to the decreases in cardiac output and renal blood flow, it fails 
to remain stable. (for review see (Francis, 2001))  
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Once there is the presence of renal injury or inflammation a vicious circle ensues to enhance 
detrimental processes. Not only vasoconstriction (renal artery, efferent and afferent arterioles) and 
reduced total renal and glomerular blood flow, but there is also a reduction in the number of 
nephrons processes. The remaining nephrons exhibit glomerular capillary hypertension accompanied 
by hyperfiltration proteins and other molecules due to increased permeability of the glomerular 
capillary wall, a decrease in the sodium filtration rate, which ultimately will lead to hyaline 
deposition, fibroplastic intimal thickening of small arteries, glomerulosclerosis, tubular damage, 
inflammation and tissue scarring. (for review see (Frohlich, 2001)(Cohuet and Struijker-Boudier, 
2006)(Ruilope et al., 2001))  
2.2. Pathophysiology of hypertension-induced heart failure 
Transition from cardiac hypertrophy to cardiac decompensation is an overt sign of HF. Extrinsic and 
intrinsic stimuli providing an adaptive response in cardiac hypertrophy start to fail in the 
maintenance of cardiac output. Over time this decompensation in the heart leads to cardiac failure. 
(for review see (Lorell, 2000)) At this point the heart has an elevated left ventricular mass with 
extensive fibrosis and significantly impaired contractility. (for review see (Kitzman et al., 
2002)(Kostis, 2003)(Zile and Brutsaert, 2002)) These maladaptive changes resulting in diastolic and 
followed by systolic HF are driven primarily by neurohumoral stimulation. The low blood supply 
triggers responses that had developed in order to regulate BP, blood flow and organ perfusion, 
including RAAS and sympathetic activation. Both of these systems are involved in induction of 
detrimental molecular pathways. The important molecular pathways associated with HF are 
impairments in cardiac calcium handling, mitochondrial dysfunction and deprivation in energy 
utilization, generation of ROS, induction of cell death pathways, and cellular senescence. (for review 
see (Finckenberg and Mervaala, 2010))  
2.2.1. Neurohumoral activation 
2.2.1.1 Renin-Angiotensin-Aldosterone System 
RAAS regulates sodium balance, extracellular fluid volume, vascular resistance, and, ultimately, 
arterial BP. (for review see (Harrison-Bernard et al., 2009)(Danilczyk, 2006)) It has been proposed 
that the RAAS has evolved in order to respond to changes in the level of blood volume and salt 
intake, which may occur under natural conditions. (for review see (Karppanen, 2006)) Its main 
effector, Ang II is produced by enzymatic activity of renin. Renin release is stimulated by three 
mechanisms: 1) intrarenal baroreceptors within the afferent arteriole, 2) alterations in the delivery of 
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sodium chloride to the macula densa cells, and 3) the influence of sympathetic nerves in the 
arterioles of the juxtaglomerular apparatus. (for review see (Harrison-Bernard et al., 2009)) The RAAS 
cascade is presented in the Figure 2. 
 
 
 
Figure 2. Novel insights into RAAS system and many novel components. Modified from (Bader and 
Ganten, 2008) 
 
Renin cleaves Ang I from angiotensinogen (Ao). Ang I is then converted to Ang II by ACE. ACE is a 
circulating enzyme found in the endothelial cells of lungs, vascular endothelium, and cell membranes 
of the kidney, heart, and brain. ACE also degrades bradykinin into inactive fragments, reducing the 
serum levels of this endogenous vasodilator. (for review see (Cassis et al., 2010)) Ang II is not only 
generated in the circulation but also locally in several organs and tissues including kidney, vessels, 
heart, adrenal gland, eye, testis, and brain. The local RAAS amplifies the actions of circulating Ang II 
with important implications for physiology and pathophysiology of cardiovascular diseases (for 
review see (Bader and Ganten, 2008)) It is well known that all components required for Ang II 
production are available in the heart, and cardiac Ang II formation seems to be regulated 
independently of circulating RAAS. (for review see (Ferreira et al., 2008)) Ang II causes an increase in 
systemic and local BP via its vasoconstrictive effect. It influences renal tubuli to retain sodium and 
water through the hemodynamic regulation of renal blood flow and glomerular filtration rate, 
tubular epithelial cell sodium chloride and water transport mechanisms. It also stimulates 
aldosterone release from adrenal gland. (for review see (Harrison-Bernard et al., 2009)) Since renin 
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secretion followed by Ang II production helps to maintain the correct level of BP, there is a feedback 
control mechanism, which in response to elevated BP suppresses plasma renin activity almost 
completely. Hence in hypertensive patients low plasma renin levels may be a predictive factor for 
cardiovascular (stroke, heart attack, HF) and their renal sequelae, and often correlate with a high 
sodium intake. In contrast, a low sodium intake/excretion correlates with reduced incident of heart 
disease and strokes. (Schmieder, 1996)(for review see (Cohen, 2007)) Ang II, known to play a 
prominent role in the transition of cardiac hypertrophy to HF, is related to a progressive impairment 
of ventricular function, as well as myocardial fibrosis in humans; however its mechanisms still remain 
to be resolved. It impairs mechanical and humoral regulation in HF, increasing cardiac wall tension 
and sympathetic hyperactivity. Sympathetic activity, by activating β-adrenergic receptors (β-AR), 
stimulates renin and Ao synthesis in fibroblasts and Ao synthesis in cardiac myocytes. (for review see 
(Ferreira et al., 2008))  
Ang II exerts its effects via G-protein-coupled receptors type1 (AT1) and type2 (AT2) in many 
cardiovascular and other tissues. The majority of the cardiac and renal actions of Ang II are mediated 
by the AT1 receptor, including vascular smooth muscle contraction, aldosterone secretion, dipsogenic 
responses, adrenergic stimulation, renal sodium reabsorption, and pressor and chronotropic 
responses. (for review see (Danilczyk, 2006)(Bader and Ganten, 2008)) AT1 serves also as a mediator 
of normal aging processes by stimulating both cytosolic and mitochondrial ROS increasing oxidative 
stress damage to mitochondria. (for review see (Cassis et al., 2010)) It has been also demonstrated 
that disruption of the gene encoding AT1A receptor subtype can prolong lifespan in mice. (Benigni et 
al., 2009) The AT2 receptor in turn antagonizes many effects of AT1. (for review see (Cassis et al., 
2010)) Binding of Ang II to the AT2 receptor evokes vasorelaxation that is largely mediated by 
bradykinin and NO. (for review see (Danilczyk, 2006)) These agents reduce resistance artery 
remodeling, promote cardiovascular protection against ischemia-reperfusion injury and acute MI, 
inhibit cardiac fibrosis, and protect the kidney from ischemic injury. (for review see (Cassis et al., 
2010))  
Aldosterone triggers sodium and fluid retention resulting in increases in intravascular volume and 
suppression of endothelial function. In addition, aldosterone, similarily to Ang II, exerts non-
hemodynamic effects. They comprise direct pro-inflammatory and pro-fibrotic effects of vascular 
bed, kidneys and heart, thus contributing to target-organ damage, followed by the development of 
cardiovascular events. In subjects with hypertension or HF, the plasma aldosterone level correlates 
negatively with systemic arterial compliance as calculated from intra-arterial BP and cardiac output. 
(for review see (Gaddam et al, 2009)(Cassis et al., 2010)(Harrison-Bernard et al., 2009))  
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In addition to the classical RAAS components, several new participants have been discovered lately; a 
homolog of ACE- ACE2, which degrades Ang II to Ang-(1-7). The Mas proto-oncogene is a receptor for 
this peptide and the ACE2-Ang-(1-7)-Mas axis can counter-regulate the above mentioned 
cardiovascular actions of the classical RAAS. Furthermore, a protein which binds and activates renin 
and prorenin in tissues, the (pro)renin receptor or (P)RR has been discovered. The physiological role 
of these new RAAS components is not totally clear. (for review see (Bader and Ganten, 2008))  
2.2.1.2 Sympathetic nervous system 
Sympathetic hyperactivity is a hallmark of the early stages of hypertension and HF. It has been 
associated with higher cardiovascular risk and target-organ damage in heart, blood vessels and 
kidneys. (Ferreira et al., 2008) (for review see (Malpas, 2010)(Charkoudian and Rabbitts, 2009)) SNS 
causes a plethora of cardiovascular actions: increased heart rate (HR) (positive chronotropism), 
elevated cardiac contractility (positive inotropism), increases in the rate of relaxation (positive 
lusitropism), and impulse conduction through the atrioventricular node (positive dromotropism). (for 
review see (Triposkiadis et al., 2009)(Charkoudian and Rabbitts, 2009) SNS is a critical component of 
neurohumoral response observed in HF. In the early stages of the syndrome, an intrinsic decrease in 
myocardial function leads to an increase in sympathetic activity. Altered cardiac structure, increased 
cardiac output, stroke volume and peripheral vasoconstriction are at first effective compensatory 
mechanisms to maintain arterial perfusion pressure overload. However over time they fail, 
eventually leading to failure of the myocardial muscle. (Mancia et al., 2007) Chronic exposure of the 
heart to elevated levels of catecholamines released from sympathetic nerve terminals and the 
adrenal gland may evoke further pathological changes in the heart. These can result in continued 
elevation of sympathetic tone and a progressive deterioration in cardiac structure and function, 
leading to hypoxia, increased sarcolemmal permeability, calcium overload, oxidative damage, fibrosis 
and apoptosis. (For review see (Triposkiadis et al., 2009)) Moreover, cardiovascular reflexes are 
disturbed: inhibited aortic arch, carotid, cardiopulmonary baroreflexes, as well as 
sympathoexcitatory reflexes, such as augmented cardiac sympathetic afferent reflexes and arterial 
chemoreflexes. (Chan, 2010)(Ferreira et al., 2008) The increased sympathetic signaling in conjunction 
of RAAS worsens the pathological effects on the cardiovascular system. It has been claimed that Ang 
II activates central sympathetic outflow and norepinephrine secretion from adrenergic nerve 
terminals and reduces adrenergic receptor responsiveness. (for review see (Grassi, 1998))  
The effects of SNS are mediated in many sites e.g. sinoatrial node, myocardium and peripheral 
vasculature via the β1 and β2 beta-adrenergic receptors (ARs). In the failing heart, the elevated level 
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of noradrenaline downregulates β-adrenergic receptors, mostly β1-AR, and causing uncoupling of the 
β2-subtype. The imbalanced β1/β2-AR ratio results in impairment of the myocardial contractile 
response as well as structural changes involved in the transition from compensated cardiac 
hypertrophy to decompensated HF. (for review see (Triposkiadis et al., 2009)(Charkoudian and 
Rabbitts, 2009)) In the human heart, activation of β1- and β2-ARs is the most powerful physiologic 
mechanism to increase cardiac in the short term performance. The human heart also expresses α1A- 
and α1B-ARs, but at lower levels. (for review see (Triposkiadis et al., 2009)) It is unknown whether 
cardiac α1-ARs play any significant role under physiological conditions. Moreover, the α1-ARs heavily 
populate the major arteries (including the aorta, pulmonary arteries, mesenteric vessels, and 
coronary arteries) and activation of these receptors by noradrenaline (NA) and adrenaline (ADR) and 
the resulting vasoconstriction is a major contributor to the regulation of blood flow. α1-ARs may 
function in a compensatory fashion to maintain cardiac inotropy in the heart and are involved in both 
developmental cardiomyocyte growth as well as pathological hypertrophy. In the presence of 
pressure overload or in cases of MI, activation of α1-ARs also appears to produce important pro-
survival effects at the level of the cardiomyocyte and helps to protect against maladaptive cardiac 
remodeling and decompensation to HF. There is recent evidence to suggest that α2-AR deficiency can 
be associated with elevated catecholamine levels, cardiac hypertrophy, fibrosis, and eventually HF. 
(for review see (Triposkiadis et al., 2009))  
The exposure to high levels of circulating catecholamines has been reported to be toxic to cardiac 
myocytes, leading to myofibrillar degradation and increased cardiac collagen volume fraction 
mediated by β-AR stimulation. The deleterious cardiac effects of sympathetic overactivity seem to be 
related mainly to the activation of β1-AR pathway. (for review see (Brum et al., 2006)  
The role of β3-AR is still unclear, however they have been postulated to be inactive under 
physiological conditions or to exert a negative inotropic effect due to increased NO production and 
inhibition of calcium transients. (for review see (Triposkiadis et al., 2009))  β-adrenergic effects are 
mediated via protein kinase A (PKA) related pathways. (for review see (Triposkiadis et al., 
2009)(Charkoudian and Rabbitts, 2009))  
In kidneys, activation of the SNS causes vasoconstriction, decreasing renal blood flow and reducing 
the glomerular filtration rate, increasing the risk of renal ischemia.  Sympathetic nervous activity 
prevents the kidney from excreting sodium. (for review see (Rea, 2008))  
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2.2.2. Derangement in cardiac excitation-contraction coupling 
Calcium plays a vital role in coupling the depolarization process in the cell membrane to muscle cell 
contraction. This process is called the excitation-contraction coupling (EC-coupling) and it is 
responsible for the contractile force of each cardiomyocyte and in the end for all cardiac muscle. (for 
review see (Birkeland et al., 2005)) Calcium ions enter cardiac myocyte cells via L-type calcium 
channels and these channels are known to contribute to electrical and contractile heart function. 
They regulate the duration of the action potential, enabling calcium to enter the cardiomyocytes, to 
trigger contraction, and regulate growth-related signaling in the heart. (for review see (Satin and 
Schroder, 2009)) The presence of intracellular Ca2+ causes myosin, a motor protein present in the 
sarcomere, to bind to actin filament consuming ATP, resulting in sarcomer shortening. During 
relaxation, tropomyosin covers the binding sites for myosin on actin. In addition to the tropomyosin 
filament, the troponin complex, which consists of troponin-I, -T and -C, is found in the sarcomere. In 
the presence of Ca2+, which binds to troponin-C, the troponin complex will move tropomyosin so that 
the myosin heads can bind to the actin filament, and the sarcomere can contract. When the Ca2+ 
concentration in the cytosol declines, tropomyosin again covers the binding sites for myosin on actin, 
and the contraction terminates. Inside the cell Ca2+ is stored in the sarcoplasmic reticulum (SR). The 
contraction is initiated by the opening of ryanodine receptors (RyRs) on the SR. Ca2+ removal from 
cytosol to SR by plasma membrane Ca2+ ATPases (PMCAs),  SERCA, and out of the cell by Na+/Ca2+-
exchanger (NCX), causes relaxation. (for review see (Birkeland et al., 2005)) The calcium interplay is 
depicted in Figure 3. 
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Figure 3. Regulation of calcium interactions in cardiac action. DHPR, denotes dihydropyridine 
receptor (L-type Ca2+ channel); CICR- Ca2+-induced Ca2+ release mechanism; RyR, denotes ryanodine 
receptor; SERCA2a- sarco-endoplasmic Ca2+-ATPase; TnC- troponin C; TnI- troponin I; TnT- troponin T; 
TM- tropomyosin. Modified from (Endoh, 2008) 
 
In HF, the heart is not capable of pumping enough blood to satisfy the needs of the metabolic tissues, 
without increasing left ventricular filling pressure. Systolic dysfunction may be due to too few 
cardiomyocytes, or to reduced contractile function of the cardiomyocytes. In the latter situation the 
myocardial function is impaired and this condition is called myocardial failure. The pathophysiological 
mechanisms behind myocardial failure are not known, but it is believed that there may be a defect in 
L-type Ca2+ current and EC-coupling. Many of the changes at the molecular level represent a 
transition to the fetal phenotype. At the functional level, altered EC-coupling has been demonstrated 
in cardiomyocytes. (for review see (Birkeland et al., 2005)(Endoh, 2008)) 
The cardiac isoform of the SERCA2a is a Ca2+ pump powered by ATP hydrolysis. SERCA2a transfers 
Ca2+ from the cytosol of the cardiomyocyte to the lumen of the sarcoplasmic reticulum during muscle 
relaxation, and thus plays a key role in cardiomyocyte Ca2+ regulation. In both experimental models 
and human HF, SERCA2a expression is significantly decreased, which leads to abnormal Ca2+ handling 
and an impaired contractile state. A large number of studies in isolated cardiac myocytes and in small 
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and large animal models of HF have revealed restoration of SERCA2a expression by gene transfer can 
correct the contractile abnormalities and improve energetics and electrical remodeling. (for review 
see (Lipskala et al., 2010)) Beyond its role in contractile abnormalities in HF, SERCA2a overexpression 
has beneficial effects in a host of other cardiovascular diseases. (for review see (Kawase, 2008)) 
Similarly the RyR Ca2+-channel, which controls the SR Ca2+-release, has been shown to have an 
important role in HF and cardiac hypertrophy. The levels or activity of these key Ca-handling proteins 
are known to be altered in cardiomyopathies, and these changes have been linked to the 
deteriorations in cardiac function and deranged. Furthermore, genetic variants in these SR Ca-cycling 
proteins have been identified, which may predispose to HF or fatal arrhythmias. (for review see 
(Kranias, 2007))  
2.2.3 Reactive oxygen species  
Reactive oxygen species (ROS) is a collective term that describes O2- derived free radicals such as 
superoxide anion (O2
•-), hydroxyl (HO•), peroxyl (RO2
•), and alkoxyl (RO•) radicals, as well as O2-
derived non-radical species such as hydrogen peroxide (H2O2). (Dai and Rabinovitch, 2009)(for review 
see (Circu and Aw, 2010)) A small amount of ROS is vital for the organisms since these agents are 
involved in many physiological processes such as cell-cell communication, cell respiration and energy 
production; phagocyte derived engulfment and digestion alien particles (anti-inflammatory 
properties), mediation ROS-signaling pathways, programmed cell death-apoptosis, necrosis as well as 
aging. (for review see (Pourova et al., 2010)(Puzanowska-Tarasiewicz et al., 2009)) They are therefore 
involved in the development of cardiovascular diseases, hypertension, atherosclerosis and HF. (for 
review see (Pourova et al., 2010)) 
Oxidative stress is involved in cardiac remodeling in patients with chronic HF, and increasing 
oxidative damage may be a marker of worsening functional capacity within this disease. These 
changes have been shown to be in line with enhanced neurohumoral activity in HF. (Rodanovic et al., 
2008) ROS display high reactivity with lipids, proteins and nucleic acids. Different cell types including 
vascular endothelial, vascular smooth muscle, fibroblast and tubular epithelial cells are being 
damaged. This happens not only due to generation of both NO and the reduced form of nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase-derived superoxide in the cytosol, but  also to 
stimulation by Ang II, which triggers eNOS uncoupling, switching from NO to superoxide production. 
(for review see (Cassis et al., 2010)) These events contribute vasoconstriction and increased cardiac 
loading. (for review see (Seddon et al., 2007))  Oxygen deprivation resulting from stress conditions 
and which can be accompanied by ROS formation is characterized as an oxidative stress response. 
(Wang et al., 2008)(for review see (Marin-Garcia, 2008))   
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Two main physiological sources regulate oxidative response in the cell; NADPH oxidases (Noxes) and 
mitochondria as a major intracellular source of ROS. Moreover ROS is produced by enzymes such as 
xanthine oxidase, cyclooxygenases, lipoxygenases, myeloperoxidases, haem oxygenases, as well as 
cytochrome P450-type enzymes. (for review see (Pourova et al., 2010)(Circu and Aw, 2010)(Dai and 
Rabinovitch, 2009)) Excessive production of NO is associated with peroxynitrite (ONOO-) production. 
Thus particularly cytotoxic factor is created from the diffusion-controlled reaction between NO and a 
superoxide anion. It serves as a key element in resolving the contrasting roles of NO in physiology 
and pathology. (for review see (Pacher et al., 2007))  
The cell ROS defence system includes glutathione (GSH), vitamins C and E, enzymes such as 
superoxide dismutase (SOD), manganese superoxide dismutase (MnSOD), catalase and peroxidases. 
(for review see (Pourova et al., 2010)(Dai and Rabinovitch, 2009)) The potent mechanisms of ROS 
signaling are presented in Figure 4. 
 
 
 
Figure 4. A graph demonstrating involvement of reactive oxygen and nitrogen species in defects 
insubcellular organelle, involved in cardiovascular dysfunctions. Modified from (Dhalla, 2000) and 
(Seddon et al., 2007) 
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2.2.4. Altered myocardial energetics and mitochondrial dysfunction 
2.2.4.1 Myocardial energetics 
Deprivation of cardiac energy utilization makes a significant contribution to HF. The heart consumes 
more energy than any other organ, and it cycles about 6 kg of ATP every day, 20 to 30 times of its 
own weight. (for review see (Neubauer, 2007)) The normal, healthy adult heart utilizes diverse 
substrates as fuels; lactate, amino acids, ketones, and notably free fatty acids (FFA) (60-90 %) and 
glucose (Turer, 2009) to generate ATP for cardiac performance. The source of the fuel depends on 
physiological/patophysiological conditions. This work of the actin-myosin interaction of myofibrils 
comprises contraction (pump function), Ca2+ uptake into the sarcoplasmic reticulum, and 
maintenance of the sarcolemmal ion gradients. (for review see (Huss, 2004)) As the heart has a 
limited storage capacity of substrates, the balance between energy demand and energy supply must 
be maintained, (for review see (Huss and Kelly, 2005)) even with large increases in cardiac output as 
during intense exercise. (for review see (Stanley et al., 2005)) In non-ischemic conditions, ATP 
production originates from mitochondrial oxidative phosphorylation (95 %). The FFA β-oxidation 
pathway, the citric acid cycle, and with a minor contribution from the pyruvate dehydrogenase 
reaction and glycolysis which result in generation of the reduced form of nicotinamide adenine 
dinucleotide (NADH) and the reduced form of flavin adenine dinucleotide (FADH2) to create a proton 
gradient in the electron transportation chain, the reaction coupled with ATP production. (for review 
see (Huss, 2004)) Mitochondrial creatine kinase catalyzes the transfer of the high-energy phosphate 
bond in ATP to creatine to form phosphocreatine and ADP. Phosphocreatine rapidly diffuses from the 
mitochondria to the myofibrils, where myofibrillar creatine kinase catalyzes the reformation of ATP 
from phosphocreatine. The free creatine, formed by the removal of phosphate from 
phosphocreatine, diffuses back to the mitochondria. An important function of the creatine kinase 
system is to act as an energy buffer. (for review see (Neubauer, 2007))  
Much of the metabolic regulation of these processes is directly linked to the expression of genes 
controlling the utilization of cellular FFAs; switch from glucose to FFAs in newborns occurs under O2 
availability and dietary fat consumption. In contrast, in pressure- or volume overload–induced 
hypertrophy, the mitochondrial oxidative capacity is reduced, enhancing cardiac glucose metabolism, 
resembling the fetal metabolic pattern. (for review see (Huss, 2004)) During the development of 
cardiac hypertrophy and in the failing heart, the chief myocardial energy source switches from fatty 
acid beta-oxidation to glycolysis: a reversion to the fetal energy substrate preference pattern. For 
review see (Barger et al., 1999) Impairments in HF-related energy metabolism occur in all three core 
points: substrate utilization (cellular uptake and breakdown), oxidative phosphorylation, and high-
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energy phosphate metabolism. (for review see (Neubauer, 2007)) Schematic pathways related to 
energy utilization are depicted in Figure 5. 
 
 
 
Figure 5. Cardiac energy utilization. Substrate utilization- beta-oxidation and glycolysis resulting in 
formation of CoA, which is fed later into the Krebs cycle, which in turn produces nicotinamide 
adenine dinucleotide phosphate (NADP) and CO2; Oxidative phosphorylation and production energy 
via respiratory chain and electrons transfer from NADH to oxygen. The emerging gradient provides 
ATP synthase by phosphorylation of adenosine diphosphate (ADP), and in case of uncoupling 
proteins-heat rather than ATP; Energy transfer and utilization, the transport of energy and usage by 
myofibrillar ATPase and other reactions (sarcolemmal/ sarcoplasmic reticulum ion pumps). ATP 
transfer is obtained by the creatine kinase energy shuttle. Creatine, which is not produced in the 
heart, is taken up by the creatine transporter. Modified from (Neubauer, 2007)  
 
When the energy demand exceeds the energy supply, the phosphocreatine level falls, keeping ATP at 
a normal level. The reduced phosphocreatine/ATP ratio limits cardiac performance during metabolic 
stress conditions and can be one way to predict early stage of HF. (for review see (Neubauer,  
36 
 
1997)(Neubauer, 2007)) The free ADP level is elevated, which in turn inhibit the function of many 
intracellular enzymes, causing failure of the heart's contractile mechanism. Thus, a metabolic 
derangement in the cardiac myocyte can occur when phosphocreatine levels fall and free ADP levels 
rise, even though ATP levels remain unchanged. (for review see (Neubauer, 2007))  
In HF both changes in glycolytic and mitochondrial enzyme expression occur, as well as alterations in 
nuclear and mitochondrial transcription rates which are known to be crucial in the metabolic 
profiling. (for review see (Stanley et al., 2005)) The peroxisome proliferator-activated receptors 
(PPAR) family of nuclear receptor transcription factors has been shown to regulate cardiac fuel 
metabolism at the gene expression level. The three PPAR family members (α, β/δ and γ) serve as 
transducers of developmental, physiological, and dietary cues that influence cardiac fatty acid and 
glucose metabolism. (for review see (Madrazo and Kelly, 2008)) In cardiac hypertrophy the 
expression of PPAR(α) is decreased in proportion to the depression of fatty acid utilization. For this 
reason, the down-regulation of PPAR(α) is thought to be the main mechanism underlying the switch 
in substrate utilization from fatty acids to glucose. This switch is a typical characteristic of the 
hypertrophied heart.  A nuclear-receptor coactivator, PPAR(γ) coactivator-1 (also known as PCG-
1(α)), is a master regulator of metabolic function in mitochondria since it can activate several genes 
that are responsible for fatty acid uptake and oxidation and for oxidative phosphorylation. These 
genes include PPAR(α) and PPAR(β) and nuclear respiratory factors 1 and 2 (NRF-1 and NRF-2). There 
are experimental studies revealing that the inhibition of PCG-1(α), probably as a direct consequence 
of high plasma catecholamine levels, leads to down-regulation of mitochondrial gene expression. In 
this way, it contributes to the impairment of oxidative phosphorylation in the failing heart. The 
development of HF is accelerated by PCG-1(α) deficiency, suggesting that this coactivator may have a 
cardioprotective function. (for review see (Neubauer, 2007)) 
Genetically manipulated mice with selective knockout of genetic components have been created to 
study altered energetic profiles in HF. The deletion of a variety of genes that encode specific 
metabolic components related to substrate utilization, oxidative phosphorylation, and high-energy 
phosphates has evoked a loss of contractile reserve, overt HF, cardiac hypertrophy, 
tachyarrhythmias, or even bradyarrhythmias. These genetic studies show that a fully integrated 
metabolic machine is important for normal cardiac function and that selective deficiency of 
components of energy metabolism can cause early or advanced HF. (for review see (Neubauer,  
2007))  
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2.2.4.2 Mitochondrial biogenesis  
Mitochondrial biogenesis is a process of growth and division of pre-existing mitochondria. 
Mitochondria are organelles derived from α-proteobacteria, which during the process of 
endosymbiosis became established in the host cells. They have their own genome and 
autoreplication capacity. Mitochondrial proteins are encoded by both the nuclear and mitochondrial 
genomes. (for review see (Rimbaud, 2009)(Ventura-Clapier, 2008)) Owing to the dynamic properties 
of fusion and fission, controlled by GTPases and mitofusins, and translocations, mitochondria are 
able to divide and organize during the biogenesis process, including accompanied size, number, mass 
variations, as well as ensuring proliferation of mitochondrial membrane. Mitochondrial biogenesis is 
enhanced in the presence of environmental stress factors- oxidative stress, exercise, cold exposure, 
caloric restriction, cell division/renewal and differentiation. (for review see (Ventura-Clapier, 2008))  
The continual cardiac contractile activity requires sustained energy production. Mitochondrial 
respiration accounts for 95 % of heart energy supply and depends on both dynamics and function of 
mitochondria. (for review see (Rimbaud, 2009)) and alterations in mitochondrial biogenesis can 
result in cardiac hypertrophy or failing heart. (for review see (Ventura-Clapier, 2008))   
Interactions between transcriptional in the mitochondrial and nuclear genome allows co-ordination 
of biogenesis. The transcriptional co-activator PGC-1α, a master regulator of mitochondrial 
biogenesis, is abundantly present in cardiac tissue and is activated in the energy demand state. PGC-
1α regulates mitochondrial biogenesis and controls mitochondrial content in the normal heart. 
During compensated hypertrophy, PGC-1α expression levels are maintained and mitochondrial 
biogenesis is increased in proportion to the increase in cell size. In HF, PGC-1α becomes down-
regulated and its oxidative capacity is reduced, leading to energy starvation and cardiac dysfunction. 
PGC-1α lacks DNA binding activity, but it undergoes an interplay with NRF-1 and NRF-2, increasing 
the transcriptional activities of these genes, and hence the respiration rate. (for review see (Ventura-
Clapier, 2008)) Nuclear encoded mitochondrial transcription factor A (Tfam) promoter possesses 
recognition sites for NRFs, thus ensuring that mitochondrial biogenesis is coordinated at the 
mitochondrial and nuclear levels.  (for review see (Ventura-Clapier, 2008)) In addition by binding and 
activating other promoters encoding nuclear genes, NRFs activate oxidative phosphorylation system 
(OXPHOS). (Garnier, 2003) PGC-1α also interacts with and co-activates PPARγ, encoding the major 
regulator of the fatty acid oxidation pathway, and enabling fatty acid oxidation (FAO) increase in 
parallel with mitochondrial biogenesis. The transcription factors PPARγ family is expressed in the 
heart, and plays a pre-dominant role in the regulation of mitochondrial FAO enzymes and transport 
proteins. (for review see (Ventura-Clapier, 2008))    
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Hypertrophied and failing heart is characterized by down-regulated FAO enzymes and other 
mitochondrial proteins, which result in cardiac inability to maintain normal heart function due to the 
down-regulation of the mitochondrial biogenesis transcriptional pathway. (for review see (Rimbaud, 
2009)(Ventura-Clapier, 2008)) There is also a decrease in oxidative capacity. 
Experiments conducted with PGC-1α knock-out mice demonstrated normal mitochondrial volume 
density in the heart, but blunted expression of mitochondrial genes.  When chronic haemodynamic 
overload had been produced, these mice developed accelerated cardiac dysfunction progressing to 
heart failure, suggesting that low PGC-1α level can be considered as a predisposing factor to HF. (for 
review see (Ventura-Clapier, 2008)) An in vivo rat model of chronic HF has exhibited down-regulation 
of PGC-1α, NRFs, Tfam, as well as impaired mitochondrial respiratory chain function as subunits 
cytochrome c oxidase 1 and 4 (cox1 and cox4), regulating mitochondrial capacity. (Garnier, 2003) 
Respiratory chain dysfunction is known to play a crucial role in a deprived mitochondrial ATP 
production rate. (Hansson et al., 2004) 
2.2.5 Apoptosis and ER stress 
Activation of cellular pathways of programmed cell death may lead to LVH, and cardiac dysfunction. 
(for review see (Ginzalez et al., 2006)) In cardiac failure, the heart is suffering from progressive 
myocyte loss. (for review see (Kang, 2000)(Kitsis, 2008)) In the adult, healthy heart, apoptosis has no 
physiological role, nonetheless it plays a crucial role in forming the cardiac valves and outflow track 
during cardiac development. (for review see (Dorn, 2009)) There are several death programs that can 
operate in a cell, necrosis, perhaps autophagy and perhaps the best understood- apoptosis, a kind of 
cell suicide process. (for review see (Kitsis, 2008)) Apoptosis is characterized by shrinkage of the cell 
membrane, condensation of nuclear chromatin, cellular fragmentation, and finally the engulfment of 
the apoptotic bodies by neighboring cells. (for review see (Kockx, 2000)) This process is mediated by 
two inter-connected pathways. (for review see (Kitsis, 2008)(Movassagh, 2008))  
In the extrinsic pathway, extracellular ligands bind to the tumor necrosis factor (TNF) superfamily, 
death receptors; Fas ligand (FasL), TNF-related apoptosis inducing ligand (TRAIL), TNF ligand 
superfamily member 10 (TNFSF10) or TNF-α. Binding to death receptors of extrinsic factors triggers 
apoptosis by receptor oligomerization and Fas Associated Death Domain (FADD)-containing protein 
and the initiating caspase 8, resulting in the formation of the death-inducible signaling complex 
(DISC). These reactions are followed by proteolytic degradation (caspase 8 and 10) of intracellular 
proteins and cleavage of nuclear DNA. The extrinsic pathway may directly result in apoptosis due to 
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activation of caspase 3 or may be associated with the intrinsic pathway. (for review see (Gerald et al., 
2009)(Movassagh, 2008))  
The intrinsic pathway is activated by nutrient shortage, survival factors, oxygen supply, oxidative 
stress, physical and chemical toxins, DNA damage and misfolded proteins. (for review see (Kitsis,  
2008)(Movassagh, 2008)) Outer mitochondrial membrane permeabilization (MOMP) occurs due to 
the formation of pores, which enhance the release of cytochrome c and intermembrane space 
proteins e.g. second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding 
protein (smac/Diablo). This in turn allows caspase activation which then causes structural and 
regulatory cytoplasmic and nuclear proteins to disintergrate. The process of cell apoptosis in this 
pathway is coordinated by pro- and antiapoptotic B-cell lymphoma 2 (Bcl-2) protein family members 
like Bak and Bax. (for review see (Parsons, 2010)) Bak and Bax, as well as p53 are pro-apoptotic 
factors that stimulate MOMP. P53 is known to trigger apoptosis directly by stimulating Bax or Bak or 
through binding to Bcl-2 and Bcl-xL. Bcl-2, Bcl-xL and induced myeloid leukemia cell differentiation 
protein (Mcl-1) prevent MOMP. (for review see (Movassagh, 2008)) Pro-apoptotic Bcl-2 induced in 
hypertrophied heart results in activation of the caspase cascade, impaired respiration and reduced 
ATP production. (for review see (Dorn, 2009)(van Empel, 2005)) 
The endoplasmic reticulum (ER) apoptotic pathway signaling starts by impairments Ca2+ signaling 
which disturb intracellular Ca2+ homeostasis and then there is impaired protein folding and glucose 
deprivation, which provoke ER stress thus trigerring apoptosis. (for review see (Okada, 2004)(van 
Empel, 2005)(Movassagh, 2008)) The ER stress response is an adaptive mechanism of cardiac 
myocytes to the prolonged need for excess protein synthesis of both structural and natriuretic 
peptides. (for review see (Toth et al., 2007)) The unfolded protein response (UPR) results in increased 
levels of G-protein coupled receptor 78 (GPR78)/binding immunoglobulin protein (BiP). (for review 
see (Brostrom and Brostrom, 2003)) This ER chaperone binds to unfolded proteins and regulates the 
activity of upstream proteins such as serine/threonine-protein kinase/endoribonuclease IRE1 (IRE1), 
protein kinase RNA-like endoplasmic reticulum kinase (PERK) and activating transcription factor 6 
(ATF6). (for review see (Tabas, 2010)) It can also bind to other chaperones of higher specificity such 
as GRP94, calnexin and calreticulin, in the folding of selected proteins. (Brostrom et al., 2001)(for 
review see (Brostrom and Brostrom, 2003)  
Virtually every myocardial disease is characterized by programmed cardiomyocyte death, resulting in 
pathological processes. (Jugdutt and Sawicki, 2004) HF for example is characterized by a significantly 
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elevated apoptosis level of myocytes in 0.08-0.25 % of patients with dilated cardiomyopathy 
compared to only 0.001-0.002 % of healthy patients. (for review see (Movassagh, 2008)) 
2.2.6 Autophagy 
Autophagy is a conserving process of degradation and recycling of cytoplasmic components, such as 
proteins and organelles, including selective elimination of damaged mitochondria as a cytoprotective 
mechanism, and maintenance of ER. As damaged mitochondria release pro-apoptotic factors such as 
cytochrome c, autophagy can prevent the activation of apoptosis. Constitutive cardiomyocyte 
autophagy is required for protein quality control and normal cellular structure and function under 
the basal state. The accumulation of abnormal proteins and organelles, especially mitochondria, may 
directly cause cardiac dysfunction. In the heart, autophagy is important for the turnover of organelles 
at low basal levels under normal conditions and it is upregulated in response to stresses such as 
ischemia/reperfusion and in cardiovascular diseases such as HF. The level of autophagy as well as 
triggering upstream signaling pathway determines whether either it has a protective or a detrimental 
function. (for review see (Nishida et al., 2009)) Autophagy has been observed in hypertrophied 
myocardium, failing myocardium caused by dilated cardiomyopathy by valvular disease and by 
ischemic heart disease, in patients with terminal HF. Nonetheless, the role of autophagy in cardiac 
hypertrophy remains to be elucidated. (for review see (Nishida et al., 2009)) 
Autophagy has a dual purpose. It is involved in cellular survival i.e. during ischemia or in nutrient-
deprived cells, or is a part of cell death at stages when progressive myocytes alterations are beyond 
repair. (for review see (Dhesi et al., 2010)(Nishida et al., 2009)) Multiple cross-linking signaling 
pathways are involved in mediating autophagy, apoptosis and necrosis, thus making them 
challenging to define and distinguish. (for review see (Dorn, 2010))  
Three forms of autophagy have been described to date; macroautophagy (most prevalent form), 
microautophagy and chaperon-mediated autophagy. Autophagy results from double-membrane 
autophagosome engulfing proteins and organelles. Subsequently, the autophagosome fuses with 
lysosomes forming the autolysosome. (for review see (Nishoda et al., 2009)  
One of the most important upstream regulatory pathways comprises class III phosphoinositide 3-
kinase (PI3K), which phosphorylates serine/threonine protein survival serine/threonine protein 
kinase Akt/PKB (provides mitochondrial protection) and thus activates the mammalian target of 
rapamycin (mTOR) protein kinases (a key regulator of cell growth and proliferation). Recently AMP- 
activated protein kinase (AMPK) pathway has been suggested to be involved in autophagy. (for 
review see (Wang et al., 2010)  
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Autophagy is controlled downstream by autophagy- related genes (Atgs), many of which are involved 
in autophagosome formation. Beclin1 (Atg6) and PI3K are needed for the vesicle (called isolation 
membrane) nucleation step of autophagy. (for review see (Nishida et al., 2009)) Formation of 
autophagosome is controlled by 2 conjugated systems; Atg12-Atg5 and the conjugation of 
phosphatidylethanolamine to Atg8 (microtubule-associated protein 1 light chain 3; LC3)-
phosphatidylethanolamine systems. (for review see (Nishida et al., 2008))) The conjugation leads to 
the conversion of the soluble form of LC3B (LC3-I) to the autophagic vesicle-associated form (LC3-II), 
which is used as a marker of autophagy. (for review see (Nishida et al., 2009)(Dhesi et al., 2010))  
In Atg5-deficient mice autophagy has been observed to be a protective mechanism in terms of 
pressure overload. In the failing heart, however this mechanism is believeded to be unable to 
undertake the repair during cardiomyocyte remodeling. (for review see (Nishida et al., 2009)) 
2.2.7 Cellular senescence  
Cellular senescence is the irreversible growth arrest process of mitotic cells. Accumulation of 
damaged DNA, telomere attrition and ultimately chromosomal damage can manifest itself as an 
increase in senescent cells in tissue and organs, followed by the dysfunctions. Accumulated pre-
mature senescent cells in the heart can be associated with the progressive heart degeneration, 
followed by the cardiac failure. (for review see (Bergmann et al., 2008)(Wong et al., 2010)(Dai and 
Rabinovitch, 2009))  
Various stressors are known to induce cellular senescence; RAAS, imbalanced ROS production, 
increased mitochondrial membrane permeability, followed by altered mitochondrial respiratory 
chain- derived oxidative stress, and impaired ATP production. (for review see (Dai and Rabinovitch, 
2009)(Juhaszova et al., 2005)(Sawyer, 2000)) Imbalanced calcium handling proteins, connected to 
altered β-adrenergic signaling, is linked to decline in SERCA2a, and the compensatory increase in NCX 
proteins impair Ca2+ intracellular transients. (Janczewski et al., 2002)(for review see (Josephson et al., 
2002)(Juhaszova et al., 2005)) These mechanisms orchestrate the decrease in the force of 
myofilaments, prolonged relaxation and contraction of heart muscle, predisposing it to cellular 
senscence. (for review see (Dai and Rabinovitch, 2010)) 
Cellular senescence can be triggered by various mechanisms such as telomere-shortening (replicative 
senescence), p16INK4a expression (telomere-independent senescence), oxidative stress/DNA 
damaging agents (stress-induced premature senescence) and activated oncogenes such as Ras 
(oncogene-induced senescence). The role of each of these mechanisms in inducing cellular 
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senescence in tissues remains to be elusive. (Krishnamurthy et al., 2004) (for review see (Bernhard 
and Laufer, 2008)) 
Furthermore senescent cells are characterized by elevated levels of cell cycle inhibitors like p21 and 
p16/INK4a and p53-pathway are upregulated. (for review see (Bernhard and Laufer, 2008)) p16Ink4a 
enhances and p19Arf attenuates the onset of cellular senescence and ageing in these tissues, 
however surprisingly in cultured cells p19Arf is known to be effector of senescence. (Baker et al., 
2008)) These 2 tumor suppressor molecules are encoded by the Ink4a/Arf locus. (Krishnamurthy et 
al., 2004) Expression of these principal aging mediators increases with age in both rodents and 
human tissues. (Baker et al., 2008) 
Mice lacking p16INK4a have an increased capacity for regeneration, whereas constitutive p16INK4a 
expression blocks endogenous regeneration. In addition, there is claimed to be an association 
between single nucleotide polymorphisms in the INK4a/ARF locus and early onset diabetes and 
vascular heart disease. (for review see (Sharpless and DePinho, 2007)) The p16INK4a expression 
tightly correlates with hypertensive tissue damage both in experimental models and human samples. 
Treatment prevents both organ damage and p16INK4a expression. (for review see (Bergmann et al., 
2008))  
2.2.8 Sirtuin- related pathways 
The sirtuins are a highly conserved family of nicotinamide adenine dinucleotide (NAD+) dependent 
histone deacetylases (HDACs) that removes acetyl groups from acetyl-lysine residues in histones and 
non-histone proteins such enzymes and transcription factors. Seven members of sirtuin family (1-7) 
have been described so far. (for review see (Finkel, 2009)(Schemies et al., 2009)) 
The silent mating type information regulation 2 homolog 1 (SIRT1), a nuclear protein, mediates 
lifespan extension (for review see (Alcendor, 2007)) and regulates numerous physiological and 
pathological processes (for review see (Lu et al., 2009)) like cardiovascular and metabolic diseases, 
diabetic nephropathy, metabolic diseases, aging, cancer and many other in experimental animal 
models. The cardioprotective effects of SIRT1 have been observed in HF, hypertension, inflammation 
and endothelial NO imbalance. (for review see (Zeng et al., 2009)(Li et al., 2009)(Schemies et al., 
2009)) 
In particular, the activity of SIRT1 has been associated with apoptosis, energy production, respiration, 
antioxidant defenses, as well as adaptation to environmental stresses by adapting cellular responses 
to the energetic state of the cell. These mitochondrial-related responses are crucial in cardiovascular 
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biology, highlighting the important functions of SIRT1 in regulating vascular growth, shape, and 
function; however SIRT1 mechanisms remain to be resolved. (for review see (Lu et al., 2009)(Gurani 
et al., 2010)) Recent studies have also elucidated new substrates for SIRT1 in metabolic regulation 
such as AMPK. (for review see (Tang and Chua, 2010))  
Various factors serve as SIRT1 substrates e.g. pro-apoptotic and carcinogenic p53, forkhead box class 
O which is involved in cell growth, proliferation, differentiation, and longevity, PGC-1α, 
transcriptional coactivator and metabolic regulator. (Vahtola et al., 2010)(for review see (Puigserver, 
2003)) SIRT1 is also known to induce NO signaling; eNOS, an enzyme that generates NO, is 
atheroprotective and promotes blood vessel relaxation. (for review see (Haigis, 2010)) SIRT1 
overexpression in transgenic mice has been found to be associated with its anti-aging properties and 
protection against oxidative stress, which may be a novel cardioprotective strategy against aging and 
certain types of cardiac stress, such as oxidative stress. (for review see (Chiao et al., 2008))  
In contrast, inhibition of SIRT1 reverses these cardioprotective actions. Its deactivation results in 
depletion of NO bioavailability, inhibits endothelium dependent vasorelaxation, causes induction of 
ROS and inflammation- mediated premature senescence of endothelial and smooth muscle cells and 
it can cause an imbalance in normal vascular function in the presence of ischemia. (for review see 
(Haigis, 2010))  
Even mild to moderate (up to 7.5-fold increase) expression of SIRT1 retards aging, delays or can 
prevent cardiac hypertrophy, apoptosis, fibrosis, cardiac dysfunction, expression of senescence 
markers, and induces resistance to oxidative stress. On the contrary to the situation after a 7.5-fold 
increase, a high level of SIRT1 (12.5-fold increase) induces cardiac remodeling and impairs cardiac 
functions. However, although high levels of SIRT1 increase oxidative stress, moderate expression of 
SIRT1 induces resistance to oxidative stress and apoptosis in transgenic Sirt1 mice. (Alcendor, 2007) 
SIRT1 is activated under caloric restriction, exercise, and by treatment with compounds such as 
resveratrol, and ican be nhibited by nicotinamide and sirtinol. (for review see (Haigis, 2010)) 
2.3 Management of hypertension-induced heart failure 
Lowering BP to the recommended guideline levels of 140/85 mmHg with utilizing antihypertensive 
medication could considerably reduce the morbidity and mortality of cardiovascular disease, 
including the incidence of myocardial ischemia and infarction, congestive HF, stroke, renal failure, 
and retinal damage. (for review see (Francis, 2001)) To date there are no specified guidelines how to 
treat HHF in particular, however these defined by European Society of Cardiology (ESC) consist of 
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treatment regimens also for HHF. Currently available therapies aim to prevent the development of 
HF, as well as to reverse already coexisting symptoms. Nonetheless due to incompletely understood 
mechanisms, the current available treatments still require further development and improvement in 
order to prevent and treat HF patient with more efficient outcomes. Most antihypertensive agents 
described by ESC belong to the following five major drug classes: diuretics, β-blockers, digoxin, 
hydralasine comined with isosorbide dinitrite and two drug classes that inhibit components of the 
RAAS. These drugs may efficiently control BP, but they do not reduce the risk of cardiovascular 
disease to the levels in normotensive individuals. (for review see (Rajko et al., 2007)) In conjunction 
with pharmacological treatment, and adherence to a diet regimen, exercise plays a crucial role in 
preventing cardiovascular events. 
2.3.1 Non-pharmacological treatment of hypertension-induced heart failure 
In addition to pharmacological treatment, self-education and understanding the etiology of the HF is 
crucial. Self-monitoring of BP is a practical approach of controlling the progress of the disease. 
Prevention of cardiac incidents consists of adoption of healthy lifestyles, such as a healthy low-salt 
diet, rich in fruits and vegetables and the avoidance of saturated fats and excessive alcohol 
consumption. Other efficient methods to prevent CVD are regular physical activity, rest and 
adequatel sleep. Only 20-60 % of patients with HF follow the pharmacological and non-
pharmacological treatments and recommendations. Therefore it will benefit these individuals if they 
are aware of their condition and the benefits of adherence to pharmacological treatments, as well as 
self-care management-related issues. (Dickstein et al., 2008)(Mancia et al., 2007)(Graham et al., 
2007)(for review see (He and MacGregor, 2007)) 
2.3.2 Current drug therapy for hypertension-induced heart failure 
2.3.2.1 Angiotensin-converting enzyme inhibitors (ACEIs) 
The mechanism of action in case of ACEIs is linked to inhibition of the Ang II-related effects. ACEIs are 
used primarily in the treatment of hypertension, though they are also sometimes used in patients 
with cardiac failure, renal disease or systemic sclerosis ACEIs can also be used to treat diabetic 
nephropathy and left ventricular hypertrophy. ACEIs are a group of drugs used in symptomatic HF 
with decreased systolic function, unless they are not tolerated or contraindicated. Their mechanism 
of action depends on ACE inhibition, preventing Ang II production; therefore ACEIs exert cardio- and 
renoprotective functions, also in diabetics. (Dickstein et al., 2008) These drugs reduce pre- and 
afterload in the heart, prevent ventricular remodeling, and even reverse atherogenic changes in the 
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vessel walls of patients with congestive HF, acute MI, or coronary artery disease. (for review see 
(Katragadda and Arora, 2010)) Potential adverse effects of ACEIs include renal function impairment, 
hyperkalaemia, symptomatic hypotension and cough. In those cases where ACEIs are not tolerated, 
AT1 receptor blockers (ARBs) should be used. (Dickstein et al., 2008) 
2.3.2.2 AT1 receptor antagonists 
ARBs block specifically Ang II binding to the AT1 receptor. Inhibitors antagonizing RAAS components 
seem to be efficient in regulating BP rates and reducing functional and structural abnormalities 
common in cardiovascular diseases. (for review see (Rajco et al., 2007)) ARBs are used in 
hypertensive patients, displaying LV hypertrophy, as well as in those with nephropathy with type 2 
diabetes. The group has seven representatives: candesartan, eprosartan, irbesartan, losartan, 
olmesartan, telmisartan, and valsartan. These drugs tend to be effective and well-tolerated. In 
patients with essential hypertension, ARBs are known to be as effective as ACEIs, however they do 
not produce bradykinin-mediated cough, a common side effect in patients treated with ACEIs. Due to 
their equivalence with ACEIs in the reduction of cardiac outcome, ARBs can be used in cases when 
ACEIs are contraindicated. (Mancia et al., 2007)(Graham et al., 2007)(for review see (Igic and Behnia,  
2007)) In addition, due to the development of tolerance ARBs can confer more beneficial effects than 
ACEIs in patients with a greater degree RAAS stimulation. (for review see (Ravandi and Teo, 2009)) 
The cardio- and vasoprotective effects of ARBs are not mediated only via their blood-pressure 
lowering- mediating properties. By blocking the effects of AT1 receptors, ARBs highly selectively 
reduce effects mediated by AT1 which are involved in cardiovascular disease. This mode of action 
prevents feedback inhibition of renin release leading to RAAS overstimulation, which would result in 
elevated Ang II levels. The ability of these drugs to block AT2 receptor activation, may possibly be 
another source of cardioprotective effects. 
Numerous clinical trials have proved the potency of ARBs in reducing blood pressure, promoting HF 
survival as well as improving left ventricular dysfunction, and inhibiting microalbuminuria. In diabetic 
patients these drugs can inhibit the appearance of diabetic nephropathy, and they offer protection 
against MI, atrial fibrillation, atherosclerosis, stroke and kidney damage. (for review see (Igic and 
Behnia, 2007)(Fitchett, 2007)(Siragy, 2010)) 
Since ACEIs, ARBs, and aldosterone antagonists can all increase potassium levels, this may represent 
a dangerous combination if used together. (for review see (Chavey, 2008)) As the ONTARGET study 
has demonstrated no greater benefits were obtained after combining ACE’s with ARB’s, however 
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worsened renal outcomes have been recorded. (for review see (Ravandi and Teo, 2009)(Perret-
Guillaume et al., 2009))  
2.3.2.3 Aldosterone antagonists 
Aldosterone antagonists are known to produce a reduction in remodeling of the vascular smooth 
muscle cells and myocytes and thus an improvement of endothelial cell dysfunction in heart failure. 
These changes slow down the progression of LV dysfunction and end-organ damage. In addition 
aldosterone receptor blockade improves heart rate variability in heart failure in humans due to 
restoration of the baroreceptor reflex. In mammals, aldosterone is the principal regulator of sodium 
and potassium homeostasis and hence is central to the control of extracellular fluid volume and BP. 
These effects improve vascular compliance and slow down the progression of left ventricular 
dysfunction and end-organ damage. Aldosterone receptor blockade also restores the baroreceptor 
reflex, improving heart rate variability in heart failure in humans. (for review see (Ovaert et al., 
2010))   
Aldosterone antagonists block the effects of aldosterone. They are often combined with ACEIs in 
patients with failing hearts. (for review see (Chavey, 2008)) As revealed in the RALE study, in addition 
to standard therapy, spironolactone by blocking aldosterone receptors significantly reduces the risk 
of progressive HF and sudden death from cardiac causes, contributing to decrease mortality rates. 
(Pitt et al., 1999)(Kulbertus, 1999) 
Aldosterone antagonists reverse aldosterone-mediated actions in kidney and heart, as well as in the 
vasculature such as sodium and water retention and potassium excretion. Aldosterone blockade 
produces potassium-sparing, causing hyperkalaemia, especially when combined with ACEIs, ARBs, 
and exogenous potassium (for review see (Chavey, 2008)) These actions are associated with adverse 
effects, such as impaired synthesis of the vasodilator NO; promotion of vasoconstriction, endothelial 
dysfunction, inflammation, and fibrosis in the vasculature; and ventricular hypertrophy, collagen 
deposition, fibrosis, and remodeling in the heart. (for review see (Struthers, 2004)) Spironolactone 
and eplerenone may induce hyperkalaemia, worsening renal function, and possible breast 
tenderness or enlargement. (Dickstein et al., 2008)(Mancia et al., 2007)(Graham et al., 2007) 
(Dickstein et al., 2008) 
2.3.2.4 β-Blockers  
Antagonism of β-receptors is known to cause anti-hypertensive effects due to exertion of their 
negative chronotropic and inotropic effects, resulting in reduced cardiac output. In addition β-
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blockers reduce renin release in kidney and reduce sympathetic activity SNS. (for review see 
(Goldsmith, 2004)) β-blockade is recommended in patients with HF caused by systolic dysfunction, 
except in those who are dyspneic at rest with signs of congestion or hemodynamic instability, or in 
those who cannot tolerate β-blockers. It has been recommended that β-blockers, such as carvedilol, 
metoprolol, bisoprolol should be added when patients are stable to diminish the progression of the 
disease. The β-blockade therapy is not recommended as a rescue therapy in decompensating 
patients. (Mancia et al., 2007)(Graham et al., 2007)(Dickstein et al., 2008) Similarly to ACEIs, β-
blockers improve ventricular function in patients with symptomatic HF with LVEF≤40 %. β-blockers 
are prescribed to the patients with mild to severe symptoms with asymptomatic left-ventricular 
systolic dysfunction after MI. With the special caution, they may also be administered to recently 
decompensated patients. . (Mancia et al., 2007)(Graham et al., 2007)(Dickstein et al., 2008)  
Indications for β-blockers are patients who have had a previous MI, acute coronary syndromes, 
congestive HF, ventricular arrhythmias, supraventricular tachyarrhythmias, diabetes mellitus, after 
coronary artery bypass graft surgery etc. Possible adverse effects consist of hypotension, worsening 
of HF and bradycardia. Adjustment of the dose or increasing the dose of the diuretics or 
discontinuation may be required. (Dickstein et al., 2008) 
Although the data related to β-blockers therapy in primary hypertension is controversial, the 
European Society of Hypertension guidelines state that diuretics, β-blockers, ACEIs, ARBs and calcium 
channel blockers do not significantly differ in their ability to lower BP and to exert cardiovascular 
protection in both elderly and younger patients. Nowadays novel β-blockers, carvedilol and nebivolol 
are believed to be effective at reducing cardiovascular events but nonetheless further clinical 
investigations are still required. (for review see (Aronow, 2010)) 
2.3.2.5 Diuretics 
Diuretics are classified as a group of drugs used in moderate to severe HF with clinical signs of 
congestion. (Dickstein et al., 2008) They are indicated for volume overload due to sodium and water 
retention. (for review see (Jhund et al., 2000)) Diuretics reduce blood volume, which in turn depletes 
the effective circulating volume and reduces cardiac output. (for review see (Francis, 2001))  
Diuretics however produce an ion imbalance such as potassium and magnesium wasting, therefore 
monitoring of electrolytes is very important. This group also elevates RAAS activity, hence must be 
combined either with ARBs or ACEIs. Most patients receive loop diuretics such as furosemide to 
obtain benecitial effects such as dilation of peripheral vessels, followed by a decrease in LV filling 
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pressure, reduced cardiac output and relieve symptoms of pulmonary congestion. (for review see 
(Jhund et al., 2000) (Somberg and Molnar, 2009)) 
Loop diuretics inhibit sodium reabsorption in the ascending tubule of the nephron, followed by water 
retention. Loop diuretics inhibit the Na+⁄2Cl-)⁄K+ cotransporter of the thick ascending loop of Henle, 
resulting in decreased sodium and chloride reabsorption from the urine and subsequent diuresis. 
Loop diuretics also induce the synthesis of prostaglandins, resulting in renal and peripheral vascular 
smooth muscle relaxation and venodilatation. (for review see (Jentzet et al., 2010)) Loop diuretics 
serve as a baseline therapy for HF and often being combined with ACE inhibitors, β-blockers, 
spironolactone, and digoxin, however they are associated with acute and chronic distal tubular 
compensation i.e. renal hypertrophy. Their mechanism of action is due to dilation of peripheral 
vessels, which produces a decrease in LV filling pressure. (for review see (Jhund et al., 2000)) 
Combining a loop diuretic with a thiazide diuretic increases potency by minimizing distal tubular 
compensation. (Mancia et al., 2007)(Graham et al., 2007)(Dickstein et al., 2008) (for review see 
(Chavey, 2008)) Thiazide diuretics inhibit sodium-chloride symporters at the distal portion of the 
ascending limb and in the early part of the distal tubule, thereby increasing the excretion of Na+, Cl-, 
and water across the renal tubular epithelium. Although they are less potent than loop diuretics, 
they have synergistic effects with loop diuretics via sequential segmental nephron blockade. 
Potassium-sparing diuretics in turn produces increases the secretion of water and Na+, and decreases 
in the excretion of K+, by competing for the aldosterone- sensitive Na+⁄K+ channel in the distal tubule 
of the nephron. Since sodium exchange in the distal tubule is low, potassium-sparing diuretics are 
generally relatively weak diuretics. (for review see (Felker, 2010)) 
2.3.2.6 Digoxin 
Digoxin, a cardiac glycoside, is known to act through inhibition of the sarcolemmal Na+-K+ ATPase 
pump, which in turn leads to increased intracellular Na+ that is then exchanged with Ca2+. This 
intracellular Ca2+ produces the inotropic effect of the drug. The beneficial hemodynamic effects of 
digoxin are attained and providing absence of any hypotension or tachycardia and with associated 
favorable effects on neurohormones including a decrease in the sympathetic drive and 
reninangiotensin- aldosterone activation and an increase in vagal stimulation. Few studies have 
assessed the effects of digoxin in patients with acute HF. Digoxin use is commonly in patients with 
chronic HF (approximately 50–65% of patients overall, range 55–91%). (for review see (Teerlink, 
2009)) Digoxin is also used in patients with atrial fibrillation and to correct sinus rhythm, however it 
does not reduce cardiovascular or all-cause mortality. (Dickstein et al., 2008)(for review see (Thadani, 
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2008)) Digoxin alone is not always sufficient though it does seem to alleviate the symptoms and 
decrease hospitalization rates in symptomatic patients and is a supplemental drug in addition to 
diuretics, ACE inhibitors, or β-blockers. There are reports of increased mortality among women with 
HF under digoxin. Therefore monitoring the correct dose and effects of digoxin is essential. 
Discontinuation of digoxin should be done with caution due to the possible clinical deterioration. 
(Dickstein et al., 2008)(for review see (Thadani, 2008)) It is important to stress that digoxin has no 
benefits in the conversion to sinus rhythm compared to placebo, although it has a rate-controlling 
effect (for review see (Khoo and Lip, 2009)) However, as long as providing toxicity is avoided, digoxin 
is remarkably free of side effects and improves quality of life in patients with atrial fibrillation. (for 
review see (Cleland and Cullington, 2009))  
2.3.2.7 Hydralazine and isosorbide dinitrate (H-ISDN) 
H-ISDN comprises of hydralasine, which is vascular smooth muscle relaxant and a vasodilator 
isosorbide dinitrite. This combination lowers BP, reduces cardiac filling pressures, increases cardiac 
output, reduces pulmonary vascular pressures, and improves in symptoms and exercise tolerance in 
patients with heart failure. Vasoconstriction and NO deficiency in the vasculature play a role in 
aggravating the symptoms of HF, especially in patients of African-American origin. (for review see 
(Thadani, 2008)) These patients are known to display lower bioavailability of NO and less RAAS 
activity than whites. (for review see (Vivian, 2006)) Therefore direct acting vasodilators such as H-
ISDN are used more frequently in blacks, when intolerance for ARB or ACEIs occurs in the treatment 
of HF. Their usage can decrease the number of hospitalized patients due to worsening of HF, they 
improve ventricular function and exercise capacity, and they may serve as additional therapy for 
patients receiving ACEI, ARB, or β-blocker, reducing the risk of death. (Dickstein et al., 2008) Possible 
adverse effects consist of symptomatic hypotension, which may disappear with time and therefore it 
may not require intervention, but there may be also muscle and joint pain, rash or fever. (Dickstein et 
al., 2008) Treatment with high doses of isosorbide dinitrate (ISDN) has been shown to increase 
symptom-free walking time, but tolerance to the hemodynamic effects of ISDN develops rapidly. 
Experimental data suggests that hydralazine, given concomitantly, attenuates the development of 
hemodynamic tolerance to ISDN and may increase the bioavailability of NO in the vasculature. (for 
review see (Thadani, 2008))(Dickstein et al., 2008) 
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2.3.3. Levosimendan 
Levosimendan (((-)-0-cyano-N-{4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-
yl]phenyl}methanecarbohydrazonoyl cyanide)) a novel inotropic compound used in hospitalized 
patients as intravenous infusions for the treatment of acute decompensated HF; however its long-
term effects are still largely unknown. Even though calcium sensitizers are not included in either 
European Society of Cardiology or American Heart Association guidelines as therapy for HF, these 
drugs may constitute an important part of the treatment of patients with failing hearts due to their 
peculiar ability to increase cardiac output without causing severe hypotension when compared to 
phosphodiesterase inhibitors (PDE III) such as milrinone. (for review see (Triposkiadis et al., 
2009)(Pollesello and Papp, 2007)) Inotropic agents, such as dobutamine and milrinone, that work 
through the β-receptor-cAMP-protein kinase A pathway, increase cardiac contractility at the expense 
of increased intracellular concentrations of calcium and cAMP. They increase myocardial oxygen 
demand and also induce myocardial ischemia or malignant ventricular tachyarrhythmias. Therefore 
they may cause to increased HR, hypotension, arrhythmias, and mortality. These adverse effects are 
inextricably linked to their inotropic mechanism of action. (for review see (Teerlink, 2009)(Fotbolcu 
and Duman, 2010)) 
Calcium sensitizers are a novel pharmacological group possessing inotropic properties. (for review 
see Fotbolcu and Duman, 2010) Levosimendan has been reported to increase myocardial 
contractility, improves hemodynamics and it also dilates peripheral and coronary vessels. (for review 
see (Antila et al., 2007)) Its mechanism of action is primarily due to binding in a calcium 
concentration dependent manner to the N-terminal domain of cardiac troponin C (TnC). This in turn 
facilitates inhibition of the effects of troponin I (TnI) effects and thus it can prolong the actin-myosin 
cross-bridging action. This positive inotropic effect is obtained without increasing the intracellular 
calcium concentration or significantly increased myocardial oxygen demand, seen with other 
inotropic agents. (for review see Fotbolcu and Duman, 2010)(for review see (et al., 2009)) In 
addition, levosimendan opens ATP-sensitive potassium channels (K+ATP) in vascular smooth muscle 
cells contributing thereby to vasodilatation, decreasing preload and afterload, improving coronary 
and systemic blood flow. Levosimendan opens also mitochondrial K+ATP channels, which are believed 
to mediate cardioprotective mechanism linked to the preconditioning in response to oxidative stress. 
(for review see (Fotbolcu and Duman, 2010)) Recently, levosimendan administered as a coronary 
bolus has been reported to counteract programmed cell death, specificly autophagy in anesthetized 
pigs with regional myocardial ischemia. (Grossini et al., 2010) The role of inhibition of PDE III still 
needs to be clarified. (for review see (Antila et al., 2007)) 
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Although levosimendan has a short half-life (about 1.5 hours) if given orally, its active metabolite OR-
1896 has a longer half-life, approximately 80 hours.  Due to the long half-life of the active metabolite, 
the effects last for up to 7 to 9 days after discontinuation of a 24-hour infusion of levosimendan. (for 
review see (Fotbolcu and Duman, 2010))  
There are several clinical observations indicating that levosimendan can improve hemodynamics 
even in patients with cardiogenic shock and sepsis-induced myocardial and pulmonary dysfunction. 
Future large-scale multicenter clinical trials are needed to clarify whether levosimendan can improve 
the overall outcome of patients with sepsis and septic shock. (for review see (Fotbolcu and Duman,  
2010))  
Levosimendan evokes fewer adverse effects (mostly nausea, dizziness, headache and hypotension) 
and lower risk of arrhythmias compared with traditional inotropics or inodilators. (for review see 
(Fotbolcu and Duman, 2010)(Parissis, 2009))  
Another calcium sensitizer, however with no vasodilation property, is pimobendan, approved only in 
Japan. It was found that pimobendan could reduce the Ca2+ level required for actin sliding in an in 
vitro motility assay using reconstituted thin filaments. Clinical data showed benefits on exercise 
capacity but also a trend toward increased mortality. (for review see (Anttila et al., 2007))  
2.4 Other potential therapies 
2.4.1 Resveratrol and SIRT1-mimetics 
Resveratrol (3,5,4'-trihydroxystilbene), a polyphenol obtained from grapes, and thus an ingredient of 
red wine, is synthesized by plants in response to attacks by fungi, bacteria, or other injurious 
substances. (for review see (Sadruddin and Arora, 2009)) Resveratrol mimicks the effects of calorie 
restriction by prolonging the lifespan and has been claimed to confer protection against 
cardiovascular disease. (for review see (Das, 2010)(Lippi et al., 2010)) Light to moderate red wine 
consumption is said to protect from atherosclerotic processes, atherogenesis, vessel occlusion and 
oxidative stress as well as to inhibit lipoproteins oxidation, macrophage cholesterol accumulation, 
foam-cell formation and to increase levels of HDL cholesterol thus enhancing cholesterol efflux from 
vessel walls. As a free radical scavenger and anti-oxidant, resveratrol, is responsible mainly for these 
effects and is known to mediate also the increase in NO availability hence improving structure and 
the function of the endothelium, decreasing blood viscosity. Resveratrol is also known to possess 
anti-thrombotic, fibrinolytic activity and to improve insulin sensitivity. (Sadruddin and Arora, 
2009)(for review see (Lippi et al., 2010)) It provides cardioprotection in association with catalase 
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activity upregulation and by balancing redox homeostasis in mammalian systems by regulating 
several antioxidant enzymes including glutathione peroxidase, glutathione-S-transferase and 
glutathione reductase. (Ungvari et al., 2009)(for review see (Das, 2010)) Resveratrol has been 
demonstrated to regulate process of apoptosis via Bax, p53 and TNF receptor associated factor. In 
addition, in earlier studies, resveratrol has been proposed to downregulate the expression of 
tumorigenic and pro-inflammatory nuclear factor NF-κB and it has displayed anti-inflammatory 
properties due to inhibition of cyclooxygenase-1 and -2 (COX1 and COX2) expression. (for review see 
(Das, 2010)) Moreover, resveratrol contributes to lifespan extension due to activation of the 
longevity gene SIRT1, (for review see (Sadruddin and Arora, 2009)) and by acting not only as an anti-
aging compound, (for review see (Das, 2010)) but also by suppressing AT1R expression via SIRT1 
activation in vivo and in vitro. (Miyazaki, 2008) Lately however it has been claimed that regulation of 
enzymes and molecular pathways involved in lifespan extension and disease protection are not 
necessarily connected to SIRT1 activation. (for review see (Das, 2010)) The AMPK- resveratrol 
regulated pathway may be also involved in PGC-1α activity, increased mitochondrial number, and 
improved motor function in obese mice. (for review see (Baur, 2010)) Nonetheless the same PGC-1α 
activation can be induced via a SIRT1-related pathway, evoking mitochondrial biogenesis. (Lagouge et 
al., 2006)(for review see Guarente, 2007)) In addition, several genes such as Sirt3, Sirt4, FoxO1, 
Foxo3a associated with cardioprotection are also induced by resveratrol. (for review see (Das, 2010))  
Other positive SIRT1 regulators, SRT1720, SRT501, SRT2104 are currently under investigation to 
determine whether or not they possess or not resveratrol- like effects. (for review see (Baur, 2010)) 
Isonicotinamide can relieve inhibition of Sir2 activity by competing with nicotinamide for binding in 
the same pocket within the enzyme. Since isonicotinamide cannot participate in the reverse reaction, 
the intermediate is stabilized and more likely to complete the deacetylation step. Isonicotinamide is 
therefore predicted to be an activator of sirtuins under normal physiological conditions. (for review 
see (Baur, 2010))  
Nicotinamide, produced by sirtuin enzymes, is a potent inhibitor of their activity. (for review see 
(Baur, 2010)) Nicotinamide has been claimed to be as a direct negative regulator of cellular Sir2 
function, an analog of SIRT1 in humans. (Jackson et al., 2003) Sir2 deacetylation reaction generates 
two products: O-acetyl-ADP-ribose and nicotinamide, a precursor of nicotinic acid and a form of 
niacin/vitamin B3. Physiological concentrations of nicotinamide noncompetitively inhibit both Sir2 
and SIRT1 by abolishing silencing heterochromatin and therefore shortening lifespan. The degree of 
inhibition by nicotinamide is equal to or better than the most effective known synthetic inhibitors of 
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this class of proteins. It has been reported that nicotinamide inhibits deacetylation by binding to a 
conserved pocket adjacent to NAD+, thereby blocking NAD+ hydrolysis. (Bitterman, 2002)   
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3. AIMS OF THE STUDY 
Hypertension-induced left ventricular hypertrophy represents an adaptive and compensatory 
response to increased workload and represents an independent risk factor of cardiovascular events. 
Biomechanical stress and neurohumoral activation are the most important triggers of pathologic 
hypertrophy and the transition of cardiac hypertrophy to HF.  The aim of this study was to investigate 
the molecular mechanisms and signalling pathways of hypertension-induced HF and, thus, to identify 
putative novel targets for drug development. In our experimental studies conducted in two different 
models of hypertension-induced heart failure special emphasis was placed on local renin-angiotensin 
system, cardiac metabolomics and calcium sensitizers. 
The specific objectives of this thesis were the following: 
I. To investigate by using tissue-based metabolomics approach and a hypertensive rat 
model with increased local RAAS activity (dTGR) whether Ang II alters cardiac substrate 
utilization and cardiac metabolomic profile. The effects of AT1 receptor antagonist 
treatment on cardiac metabolomic profile both in hypertensive and normotensive 
animals were also examined. 
II. To investigate whether resveratrol, a natural polyphenol derived from grapes, could 
prevent Ang II-induced cardiovascular damage. The possible mechanisms of action 
mediating the beneficial effects of oral resveratrol treatment were also examined.  
III. To examine whether oral levosimendan treatment could prevent Ang II-induced 
cardiovascular mortality and cardiac remodeling in dTGR. The influence of oral 
levosimendan treatment on cardiomyocyte hypertrophy, cardiomyocyte apoptotic 
signaling, inflammatory response, as well as myocardial expression of calcium-handling 
proteins was also examined.  
IV. To investigate whether oral treatment with levosimendan or valsartan can prevent 
cardiovascular mortality and hypertension-induced cardiac remodeling in Dahl/Rapp rats, 
a low-renin model of salt-sensitive hypertension and heart failure. The cardiovascular 
effects of the drug combination were also investigated.  
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4. MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Experimental animals 
The investigation conforms to the guide for the care and use of laboratory animals published by the 
US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The protocols were 
approved by the Animal Experimentation Committee of the University of Helsinki, Finland, and the 
Provincial State Office of Southern Finland. 
The double transgenic rats (dTGR) harboring human renin and human angiotensinogen genes were 
purchased from Biotechnology and Animal Breeding Division, Füllingsdorf, Switzerland, Sprague- 
Dawley (SD) rats- from Charles River, Dahl/Rapp SS rats- from Harlan. The animals had free access to 
chow; dTGR and SD to standard chow (SDS Special Diet Services), and Dahl/Rapp SS free access to 
high salt chow, which was produced by adding NaCl (8 %) (Honeywell Riedel-de-Haen) to commercial 
low salt diet (Na 0.3 %, K 0.8 %, Mg 0.2 %; Harlan).  Wistar rats (E17) for in vitro study were 
purchased from Harlan. 
4.1.2 Study design  
The study protocols were designed as showed in tables 2-7. 
 
Table 2. Design for in vivo study I. 
Study I (in vivo)     
Experimental 
group 
Rat strain Treatment Dose Follow-up period 
(weeks) 
dTGR dTGR   4 
dTGR+VAL dTGR Valsartan 
(in food) 
30 mg/kg 4 
SD SD   4 
SD+VAL SD Valsartan 
(in food) 
30 mg/kg 4 
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Table 3. Design for in vivo study II. 
Study II (in vivo)     
Experimental 
group 
Rat strain Treatment Dose Follow-up period 
(weeks) 
dTGR dTGR   4 
dTGR+Resv dTGR Resveratrol (by 
gavage) 
800 mg/kg 4 
dTGR+NAM dTGR Nicotinamide 
(i.p.) 
400 mg/kg 4 
SD SD   4 
 
Table 4. Design for in vitro study II.  
Study II (in vitro)     
Experimental 
group 
Cell line Treatment Concentration Incubation time 
(hours) 
Control Wistar rats (E17)   48 
Ang II Wistar rats (E17) Angiotensin II 100 nM 48 
Ang II + Los Wistar rats (E17) Angiotensin II 
Losartan 
100 nM 
10 μM 
48 
Ang II+PD 
123319 
Wistar rats (E17) Angiotensin II 
PD123319 
100 nM 
10 μM 
48 
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Table 5. Design for in vivo study III. 
Study III- 4 week 
follow-up (in 
vivo) 
    
Experimental 
group 
Rat strain Treatment Dose Follow-up period 
(weeks) 
dTGR dTGR   4 
dTGR+Levo dTGR Levosimendan  
(in drinking 
water) 
1 mg/kg 4 
SD SD   4 
SD+Levo SD Levosimendan  
(in drinking 
water) 
1 mg/kg 4 
 
Table 6. Design for in vivo survival study III.  
Study III (in vivo)     
Experimental 
group 
Rat strain Treatment Dose Follow-up period 
(weeks) 
dTGR dTGR   ∞ 
dTGR+Levo dTGR Levosimendan  
(in drinking 
water) 
1 mg/kg ∞ 
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Table 7. Design for in vivo study IV. 
Study IV (in 
vivo) 
     
Experimental 
group 
Rat strain Content of 
salt in a diet 
Treatment Dose Follow-up 
period 
(weeks) 
HS Dahl/Rapp SS  NaCl=8 %   8 
HS+Levo Dahl/Rapp SS  NaCl=8 % Levosimendan 
(in drinking 
water) 
1 mg/kg 8 
HS+Vals Dahl/Rapp SS  NaCl=8 % Valsartan 
(in food) 
30 mg/kg 8 
HS+Levo+Vals Dahl/Rapp SS  NaCl=8 % Levosimendan 
(in drinking 
water) 
Valsartan (in 
food) 
1 mg/kg 
 
30 mg/kg 
8 
LS Dahl/Rapp SS  NaCl=0.3 %   8 
 
4.2 Medicines and compounds used in experiments 
4.2.1 In vivo studies 
4.2.1.1 Valsartan 
Valsartan ((S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-
yl)phenyl]phenyl}methyl)pentanamido]butanoic acid) (a kind gift from Orion Pharma) was 
administered at the dose of 30 mg/kg either by mixing with food (study I and IV), or by gavage after 
diluting in hydroxymethylcellulose (study III). Fresh solutions were prepared daily. 
4.2.1.2 Resveratrol 
Resveratrol (trans-3,5,4 ′ -trihydroxystilbene, Orchid Chemicals & Pharmaceuticals Ltd.) was given as 
dissolved in hydroxymethylcellulose, at the dose of 800 mg/kg by gavage (Study II). Fresh solutions 
were prepared daily. 
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4.2.1.3 Nicotinamide 
Nicotinamide (NAM, 3-pyridinecarboxamide, Sigma-Aldrich, Germany; 400 mg/kg i.p.) was diluted in 
physiological saline (0,9 % NaCl) administered intraperitoneally (i.p.) at a dose of 400 mg/kg. Fresh 
solutions were prepared daily.  
4.2.1.4 Levosimendan 
Levosimendan ((-)-0-cyano-N-{4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-
yl]phenyl}methanecarbohydrazonoyl cyanide) (a kind gift from Orion Pharma) was given orally via 
drinking fluid to produce an approximate daily dosage of 1 mg/kg as in our previous rat experiments. 
(Louhelainen et al., 2007)(Louhelainen et al., 2009) Fresh levosimendan solutions were prepared 
daily (Study III and IV). Due to the dipsogenic effect of Ang II, (Fregly et al., 1992)(Fregly Rowland,  
1995) the water intake in dTGR is approximately 3-fold higher compared to SD rats. We therefore 
adjusted the levosimendan concentration in drinking fluid at three-fold higher concentration for SD 
rats (levosimendan concentration in drinking fluid 3 mg/L for dTGR and 10 mg/L for SD rats). 
 4.2.2 In vitro studies 
4.2.2.1 Angiotensin II 
Angiotensin II (Sigma-Aldrich) was used as a 100 nM water solution.  (Neuss, 1994) 
4.2.2.2 Losartan 
Losartan ((2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol) 
(Sigma-Aldrich), was used for cell incubation after dissolving in water at the concentration of 10 μM. 
(Gao et al., 2009) 
4.2.2.3 PD123319 
PD123319 (S-(+)-1-[(4-(Dimethylamino)-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-
tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid di(trifluoroacetate) salt hydrate) (Naito et al., 
2010)(Rabey et al., 2010) was used as 10 nM water solution of PD123319, as described previously 
(Okada, 2010) to treat neonatal rat cardiomyocytes. 
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4.3 Methods 
4.3.1 Blood pressure and heart rate measurement  
SBP and HR were measured using a tail-cuff blood pressure analyzer (Apollo-2AB Blood Pressure 
Analyzer, model 179-2AB, IITC Life Science). The measurements were taken in triplicates. 
4.3.2 Sample preparation 
Urine samples were collected over 24-hour period in metabolic cages for albumin measurement. 
Urine volumes and water intakes were measured gravimetrically. Rats were anesthetized with 
CO2/O2 (95 %/5 % AGA) and decapitated. Blood samples were collected for using 
ethylenediaminetetra-acetic acid (EDTA) as an anticoagulant. The hearts and kidneys were excised, 
washed with ice-cold saline, blotted dry, weighed, and snap-frozen in liquid nitrogen or isopentane (-
35 C). All of the samples were stored at -80 °C until assayed.  
4.3.3 Histology and cardiomyocyte cross-sectional area 
The heart and kidneys were fixed in 10 % buffered formalin solution for histological analysis. 
Transversal 5-μm-thick sections of the paraffin-embedded left ventricle were cut and stained with 
Masson’s trichrome or picrosirius red. The cross-sectional area was evaluated in a blinded fashion 
and was analyzed using the ISIimaging software (Image Solutions, Inc) as described earlier. (Vahtola 
et al., 2008) 
4.3.4 Myocardial and kidney morphology  
Tissue morphology was evaluated from hematoxylin eosin (H&E) stained cardiac and renal sections in 
a blinded fashion. The severity of observed lesions was graded with numerical values denoting to the 
degree of damage at the whole tissue level. The following system of severity grading according 
proliferative, degenerative, necrotic and inflammatory changes was used: (0, no abnormalities 
detected) 1, minimal; 2, mild; 3, moderate; 4, marked; or 5, severe. (Herbert et al., 2002)  
4.3.5 Echocardiography  
Transthoracic echocardiography (Toshiba Ultrasound) was performed on all rats under isoflurane 
anaesthesia (AGA) in a blinded fashion by the same technician during the last study week as 
described previously. (Vahtola et al., 2008) Parameters needed for the calculation of cardiac function 
and cardiac dimensions were measured from three systole-diastole cycles. A short-axis view of the 
left ventricle at the level of the papillary muscles was obtained by a two-dimensional imaging 
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method (Gibson method), using a 15-MHz linear transducer. Two-dimensionally guided M-mode 
recording through the anterior and posterior walls of the left ventricle was used to measure the left 
ventricle (LV) end-systolic (LVESD), and end-diastolic (LVEDD) dimensions. In addition, 
interventricular septum (IVS) and posterior wall (PW) thickness were measured. LV fractional 
shortening (FS) and ejection fraction (EF) were calculated from the M-mode LV dimensions using the 
following equations: 
FS (%) = {(LVEDD-LVESD) / LVEDD} x 100 
EF = SV/EDV 
SV = EDV – ESV 
EDV = 0.52 x (0.98 x (LVEDD/10) + 5.90) x (LVEDD/10)2 
ESV = 0.52 x (1.14 x (LVEDS/10) + 4.18) x (LVEDS/10)2 
LVEDD = Diameter of the short-axis left ventricle in end diastole. LVEDS = Diameter of the short-axis 
left ventricle in end systole. Diastolic dysfunction was assessed by measuring the isovolumic 
relaxation time (IVRT) using color Doppler imaging. IVRT was measured as the interval between the 
aortic closure click and the start of mitral flow. 
Diastolic dysfunction was assessed by measuring the isovolumic relaxation time (IVRT) using color 
Doppler imaging. IVRT was measured as the interval between the aortic closure click and the start of 
mitral flow. 
4.3.6 Western blotting 
Cardiac samples from the left ventricle were electrophoretically separated by 8 % SDS-PAGE (20 μg 
total protein of the whole cell lysate per lane). Each lane corresponded to one rat and all 4 groups 
were run on one gel. Proteins were transferred to a PVDF membrane (Immobilon-P®, Millipore) and 
blocked in 5 % non-fat milk-TBS-0.01 % Tween-20® buffer. The membranes were probed with the 
following primary antibodies; anti-Sir2alpha, 1/1000 (Upstate); anti-p53, 1/1000 (Chemicon); anti-
acetyl-p53 firma, 1/1000 (K373/K382) (Upstate), anti-Serca2a, 1/1000 (Abcam); anti-NCX, 1/5000 
(Immunodiagnostics); anti-LC3B, 1/500 (Cell Signalling Technology); anti-Bip, 1/1000 (Cell Signalling 
Technology). Tubulin was used as the loading control (Antialpha tubulin, 1/2000, 1/3000; Abcam). 
Horseradish peroxidase-conjugated anti-rabbit secondary antibody (Chemicon) was subjected to 
enhanced chemiluminescence solution (ECLplus, Amersham Biosciences). We quantified the relative 
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protein expression in separate samples from the membranes with Fluorescent Image Analyzer 
(FUJIFILM Corp). The measurements were repeated three times, and the data were presented as 
means ± standard error of the mean (SEM) of these experiments. 
4.3.7 Quantitative real-time RT-PCR 
Total cardiac mRNA was collected with Trizol® (Gibco, Invitrogen). 1 μg of isolated RNA was treated 
with DNAse1 (Deoxyribonuclease 1, Sigma Chemicals Co.) and reverse transcribed to cDNA by RT 
enzyme (reverse transcriptase-polymerase chain reaction)(Enhanced avian Hot Start RT-PCR kit 
(Sigma Chemicals Co or Im-Prom-II RT system, Promega). One μg of cDNA was subjected to 
quantitative real time PCR using the Lightcycler ® instrument (Roche Diagnostics) for detection of 
ANP, SIRT1,  monocyte chamoattractant protein 1 (MCP-1), PGC-1α, NRF-1, Tfam, cox4, Bax, α-MHC, 
β-MHC, p16INK4a, p19ARF, and ribosomal 18s. The samples were amplified using FastStart DNA Master 
SYBR Green 1 (Roche Diagnostics) according to the manufacturer’s protocol. The quantities of the 
PCR products were quantified with an external standard curve amplified from purified PCR products. 
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Table 8. RT-PCR primer sequences. 
 Forward Primer Reverse Primer Reference 
18S CATCCAAGGAAGGCAGCAG TTTTCGTCACTACCTCCCCG (Wellner et al., 
2005) 
ANP CCGATAGATTCTGCCCTCTTGA
A 
CCCGAAGCAGCTTGATCTTC (Heyen et al., 
2002) 
SIRT1 GCAGACGTGGTAATGT ACACTCTCCCCAGTAG  
PGC-1α GGTCCCCAGGCAGTAG CTCCATCATCCCGCAG Louhelainen et 
al., 2010 
NRF-1 GCTTGCGTCGTCTGGAT GCACCGTGTCGCTCAT Louhelainen et 
al., 2010 
Tfam AGACCTCGGTCAGCATATAACA GCGACGGATGAGATCACTT Louhelainen et 
al., 2010 
Cox4 TGGGAGTGTTGTGAAGAGTGA GCAGTGAAGCCGATGAAGAA
C 
 
Bax CGGCGAATTGGAGAGATG GGTCCCGAAGTAGGAG  
α-MHC CTGAAAACGGCAAGACGGT ACTTATAGGGGTTGACGGTG  
β-MHC GCCCGGCATGATTGCG TGGCGTCCGTCTCATACT  
p16INK4a AACACTTTCGGTCGTACCC GTCCTCGCAGTTCGAATC Bastide et al., 
2008 
p19ARF CAGGAGCATGGGTCGCAGGT GGTCGGGAGAGGGTGGTGGG Bastide et al., 
2008 
MCP-1 GCAGGTCTCTGTCACGCTTCT GGCTGAGACAGCACGTGGAT  
 
 
4.3.8 Gas chromatography coupled with time-of-flight mass spectrometry 
GC×GC-TOF/MS was used to detect intermediary metabolites from cardiac tissue. The instrument 
used was a GC×GC-TOF mass spectrometer (Pegasus 4D, Leco) with an autosampler (6890N GC and 
Combi PAL, Agilent Technologies). The metabolites were identified using an in-house reference 
compound library, as well as by searching the reference mass spectral library. Mass spectra from the 
GC×GC-TOF/MS analysis were searched against the Palisade Complete Mass Spectral Library, 600K 
Edition (Palisade Mass Spectrometry). (Oresic, 2009) 
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4.3.9 Respiratory chain functions 
The respiratory chain activities of complex I (reduced nicotinamide-adenine dinucleotide 
dehydrogenase), complex II (succinate dehydrogenase), and complex IV (cytochrome C oxidase) were 
quantitated by measuring the oxygen consumption polarographically with a Clark-type electrode 
(Instech). 
4.3.10 Cardiomyocyte cells studies 
Neonatal rat cardiomyocytes were isolated from hearts of the embryonic Wistar rats (E17). Rats were 
decapitated and hearts were quickly excised. Hearts were minced and enzymatically digested in a 
buffer containing 120 mM NaCl, 1 mM NaH2PO4 , 20 mM HEPES, 5.5 mM glucose, 5.4 mM KCl, 0.8 
mM MgSO4, 1 mg/ml collagenase IV (Worthington Biochemical Corp) and 2.5 % trypsin (Sigma-
Aldrich). Tissue was digested by incubating in a 37 °C water bath for 20 min and supernatant with 
cells was collected, centrifuged and re-suspended in fetal bovine serum (FBS). This cycle was 
repeated five times until all tissue was digested. After digestion, supernatant from digestion cycles 
was combined, centrifuged and resuspended in growth medium containing Dulbecco’s modified 
Eagle’s medium (DMEM), 5 % FBS and 10 % horse serum (all from Gibco). In order to remove non-
myocyte cells, the culture was plated on a cell culture dish for 90 min in growth medium and non-
adherent cells (mostly myocytes) were collected and plated on 0.2 % gelatin-coated 12-well plates 
for experiments. After 24 h, cells were washed and growth medium was replaced with a serum-free 
medium and incubated for another 24 h before treatments. The cell isolation method is the same as 
that described by Chlopčíková et al. (Chlopčíková et al., 2001) with the exception of the addition of 1 
mg/ml collagenase IV (Worthington) to the digestion buffer. Cells were treated with Ang II (100 nM, 
Sigma-Aldrich) alone and Ang II with angiotensin II type 1 receptor (AT1R) antagonist losartan (10 μM, 
Sigma-Aldrich) or with AT2R antagonist PD123319 (10μM, Sigma-Aldrich) for 48 h. After incubation, 
cells were collected with Laemmli sample buffer (Biorad) for analyzing SIRT1 protein level in cells. 
4.3.11 Electron microscopy 
Electron microscopy from samples taken from left ventricle. Fixation of mitochondria was performed 
by adding 1 % glutaraldehyde directly to the suspension. Samples were embedded, sectioned, and 
post-fixed with osmium tetroxide, dehydrated, and embedded in epoxy resin. Thin sections were 
stained with lead citrate and uranyl acetate. The sections were viewed in a Jeol 1200 transmission 
electron microscope at a magnification of ×10,000. 
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4.3.12 Biochemical determinations 
Serum creatinine and electrolytes as well as liver enzymes were measured by routine laboratory 
techniques. Serum aldosterone (Coat-a-Count Aldosterone RIA kit, DPC Biermann) was determined 
by radioimmunoassay according to the manufacturers’ instructions. Creatinine and electrolytes from 
plasma and urine as well as plasma lipids and liver enzymes were measured by routine techniques. 
Urinary albumin was measured by ELISA using rat albumin as the standard (Calltrend). Plasma 
samples were analyzed for levosimendan and OR-1896 by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). (Kivikko, 2003)(Lewis et al., 2008) 
4.3.13 Measurement of SIRT1 activity  
SIRT1 Fluorimetric Drug Discovery Kit (AK-555, Enzo Life Sciences Int.) was used to measure SIRT1 
activity. Human recombinant SIRT1 was incubated together with 25 μM Fluor de Lys-Sirt1, 
deacetylase substrate and 25 μM NAD+ (37 °C), in the absence (Control) or presence of resveratrol (2, 
10, 20, 40 and 100 μM) to produce deacetylated product. In the second step, treatment with 
Developer II/2 mM nicotinamide produced a fluorophore, which was detected on a fluorometric 
plate reader (Victor 2 Multilabel Counter, PerkinElmer, Ex. 355 nm, Em. 460 nm). 
4.3.14 Statistical analysis 
Data are presented as the mean ± SEM. Statistically significant differences in mean values were 
tested by analysis of variance (ANOVA) and the Tukey post hoc test or the Newman-Keul’s post-hoc 
test for comparison of multiple groups. Two-tailed Student’s t -test was used when comparing only 
two groups. The differences were considered significant when p<0.05. For cardiac metabolomic 
profiles, R statistical software (http://www.r-project.org/) was used for data analyses and 
visualization. The concentrations were compared using the Wilcoxon rank-sum test, with P values 
<0.05 considered significant. In order to take into consideration the problem of multiple 
comparisons, false discovery rate was estimated as the maximum q value in the set of significant 
differences for the metabolomic data set. False discovery rates were computed using the R package q 
value. The significance of the group differences was evaluated by the P value for the fixed-effect 
parameter estimate of group differences. The Kaplan-Meier test was used for survival analysis. The 
Log Rank test was used to compare survival distributions. The Pearson correlation co-efficients were 
calculated to measure the correlation between two variables. Linear regression curves were 
calculated by the partial least squares method. 
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5. RESULTS 
5.1 Survival (All studies) 
The dTGR rats develop fulminant hypertension and severe target-organ damage, with an increased 
mortality rate at the age of 7-9 weeks. During the 4 week follow-up period at about 8 weeks of age, 
the dTGR rats exhibited total mortality of 55-75 %, significantly more than the mortality rate of 
normotensive SD rats (Figure 6a). During this time period, valsartan and resveratrol completely 
prevented the excess mortaliy in dTGR (Study I and II), whereas levosimendan partially prevented 
Ang II-induced cardiovascular mortality in dTGR (survival rate 73 %) (Figure 6a, 6b and 6c 
respectively). In a separate survival study, a lifelong levosimendan treatment, when initiated at the 
age of 4 weeks, increased mean survival time in dTGR by 58 % (Study III). Nicotinamide did not affect 
the mortality rate in hypertensive dTGR (Study II). 
Cardiovascular mortality of untreated Dahl/Rapp SS rats was 30 % at postnatal weeks 13. All rats 
from valsartan, levosimendan, and the combination group as well as those from low-salt group 
survived the entire follow-up period (8 weeks) (Figure 6d). There was 1 death (7 %) in the 
levosimendan treated Dahl/Rapp rats consuming the high-salt diet.  
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Figure 6. Survival curves of dTGR and the effects of (a) valsartan (30 mg/kg), (b) resveratrol (800 
mg/kg) and nicotinamide (400 mg/kg), and (c) levosimendan (1 mg/kg) vs SD rats; and of (d) 
Dahl/Rapp SS rats on high salt diet (Dahl/Rapp HS) treated with levosimendan, valsartan and the 
combination of valsartan and levosimendan vs Dahl/Rapp rats (Dahl/Rapp LS). * denotes p<0.05 
compared to dTGR or Dahl/Rapp rats on high salt diet, ¤ denotes p<0.05 compared to 
dTGR+resveratrol, # denotes p<0.05 compared to SD. 
 
5.2 Blood pressure and heart rate (All studies) 
Overexpressed RAAS contributes to the development of fulminant hypertension in dTGR rats when 
compared to normotensive SD rats; 200 mmHg vs 97 mmHg (p<0.05, Study I), 200 mmHg vs 115 
mmHg (p<0.05, Study II), 205 mmHg vs 132 mmHg (p<0.05, Study III) (Figure 7a, 7b and 7c 
respectively). Both valsartan and resveratrol significantly decreased SBP (Study I and II). SBP in dTGR 
treated with nicotinamide remained at the level of dTGR i.e. at 215 mmHg (p<0.05, study II). 
Levosimendan did not produce any changes in SBP (Figure 7c), nor did it affect heart rate in dTGR 
(450 beats per minute (bpm)) (data not shown, Study III)). 
High-salt diet evoked fulminant hypertension in Dahl/Rapp SS rats; 228 mmHg vs 158 mmHg (p<0.05, 
Study IV) (Figure 7d). Levosimendan alone did not decrease systolic blood pressure, whereas 
valsartan reduced it moderately but significantly. The drug combination significantly reduced the 
development of hypertension to the level found in LS Dahl rats. At week 13, the heart rate was not 
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affected by the treatments during the 7-week follow-up period and i.e. it was at 448 bpm in high salt 
Dahl/Rapp SS (data not shown). 
 
 
Figure 7. Systolic blood pressure (SBP) development in dTGR treated with (a) valsartan, (b) 
resveratrol and nicotinamide, (c) levosimendan vs SD rats; and in (d) Dahl/Rapp rats on a high salt 
diet treated with levosimendan, valsartan and the combination of levosimendan and valsartan vs LS 
Dahl/Rapp. * denotes p<0.05 compared to dTGR or Dahl/Rapp HS, # denotes p< 0.05 compared to SD 
or high salt Dahl/Rapp rats + levosimendan, ¤ denotes p<0.05 compared to dTGR+resveratrol or 
HS+valsartan, §P<0.05 compared to HS+levosimendan+valsartan (See Figure 6 for doses). 
 
5.3 Cardiac functions (Study III and IV) 
RAAS induced deterioration of cardiac functions and LVH; however there was no difference in systolic 
function measured as ejection fraction or as fractional shortening between dTGR and SD rat strains 
at the age 8 weeks (Figure 8a and 8b). Levosimendan increased ejection fraction and fractional 
shortening, both in dTGR and SD rats (Study III). Color Doppler imaging revealed increased IVRT in 
dTGR as compared to SD rats, indicating impaired diastolic relaxation in dTGR. Levosimendan did not 
correct the Ang II-induced diastolic dysfunction in dTGR (IVRT 27.1±1.2 ms, p>0.05). 
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Seven weeks of high salt intake induced a slight increase in systolic function as measured via EF and 
FS at post-natal week 13 in Dahl/Rapp rats (Figure 8c and 8d). While valsartan decreased EF and FS 
variables, treatment with levosimendan or the combination did not significantly increase cardiac 
function at systole (Study IV). Diastolic function assessed as isovolumic relaxation time (IVRT) was 
prolonged in the high-salt group indicating diastolic dysfunction (Figure 7 e). Both levosimendan and 
the combination of the drugs significantly shortened IVRT comparably to low-salt rats. Valsartan did 
not correct diastolic dysfunction i.e. early diastolic filling to late diastolic filling (E/A ratio) remained 
unchanged (Figure 8f). 
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Figure 8. Systolic function assessed as (a) and (c) ejection fraction and (b) and (d) fractional 
shortening respectively in dTGR treated with levosimendan, vs SD rats, and in Dahl/Rapp rats treated 
with levosimendan, valsartan and duotherapy, vs LS Dahl/Rapp; diastolic function in Dahl/Rapp rats 
on high salt diet treated with levosimendan, valsartan and the combination of levosimendan and 
valsartan, assessed as (e) isovolumic relaxation time and (f) E/A waves compared to Dahl/Rapp LS. * 
denotes p<0.05 compared to dTGR or Dahl/Rapp HS, # denotes p<0.05 compared to 
dTGR+levosimendan or Dahl/Rapp HS + levosimendan, §P<0.05 compared to SD or Dahl/Rapp HS + 
levosimendan+valsartan, ¤ denotes p<0.05 compared to Dahl/Rapp HS +valsartan (See Figure 6 for 
doses). 
 
5.4 Cardiac hypertrophy and myocyte cross-sectional area (All studies) 
The dTGR rats demonstrated clearly elevated heart weight-to-body weight ratio compared with SD 
controls; 4.9 mg/g vs 3 mg/g (p<0.05, Study I and Study II), 5.2 mg/g vs 3.4 mg/g (p<0.05, Study III) 
(Figure 9a, 9b, 9c respectively). Treatment with valsartan and with resveratrol was able to 
significantly improve LVH (3.2 mg/g and 4.3 mg/g respectively), whereas neither levosimendan nor 
nicotinamide treatment influenced HW/BW ratio (5.0 mg/g and 4.7 mg/g respectively).  
Unmedicated Dahl/Rapp rats consuming the high-salt diet displayed pronounced cardiac hypertrophy 
expressed via the heart weight-to-body weight ratio, when compared with low-salt Dahl/Rapp (4.4 
mg/g vs 3 mg/g, p<0.05, Study IV) (Figure 9d). The combination of levosimendan and valsartan 
prevented cardiac hypertrophy more effectively than the monotherapies (3.2 mg/g, vs. 3.8 mg/g or 
3.7 mg/g, levosimendan and valsartan respectively). 
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Figure 9. Cardiac hypertrophy estimated as heart weight-to-body weight ratio in dTGR treated with 
(a) valsartan, (b) resveratrol and nicotinamide, (c) levosimendan vs SD rats, and in (d) Dahl/Rapp HS 
treated with levosimendan, valsartan and combination of levosimendan and valsartan vs LS 
Dahl/Rapp. * denotes p<0.05 compared to dTGR or Dahl/Rapp HS, # denotes p<0.05 compared to SD, 
dTGR+levosimendan or Dahl/Rapp HS + levosimendan, §P<0.05 compared to 
HS+levosimendan+valsartan, ¤ denotes p<0.05 compared to dTGR+resveratrol or HS+valsartan (See 
Figure 6 for doses). 
 
Cardiomyocyte cross-sectional areas were significantly enlarged in dTGR rats in comparison with SD 
rats; 308 μm2 vs 193 μm2 (Figure 10a, 10b, 10c) (p<0.05, Study I), 308 μm2 vs 186 μm2, (p<0.05, Study 
II), 251 μm2 vs 217 μm2 (p<0.05, Study III). Valsartan and resveratrol, but not levosimendan, 
prevented cardiac hypertrophy (225 μm2, 270 μm2, 261 μm2 respectively), whereas nicotinamide 
evoked a significant enlargement (335 μm2).  
High-salt Dahl/Rapp SS rats showed markedly elevated cardiomyocyte cross-sectional areas, 237 μm2 
vs 181 μm2 (p<0.05, Study IV) (Figure 10d), and in this animal model, levosimendan together with 
valsartan, significantly decreased the high-salt-induced increase in cardiomyocyte cross-sectional 
areas to the level of 181 μm2, more efficiently than levosimendan (196 μm2) or valsartan (197 μm2). 
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Figure 10. Cardiac hypertrophy estimated as cardiomyocyte cross-sectional area in dTGR treated with 
(a) valsartan, (b) resveratrol and nicotinamide, (c) levosimendan vs SD rats, and in (d) Dahl/Rapp HS 
treated with levosimendan, valsartan and the combination of levosimendan and valsartan vs LS 
Dahl/Rapp. * denotes p<0.05 compared to dTGR or Dahl/Rapp HS, # denotes p<0.05 compared to SD 
or dTGR+levosimendan or Dahl/Rapp HS + levosimendan, ¤ denotes p<0.05 compared to 
dTGR+valsartan or dTGR+resveratrol or HS+valsartan (See Figure 6 for doses). 
 
5.5 Cardiac morphology (All studies) 
The severity of cardiac damage was graded as either coronary artery damage or myocardial damage. 
In the dTGR heart samples, the lesions in the cardiac arteries varied from minimally thickened media 
and adventitia to moderate hyperplasia of intimal/medial layers and fibrosis of the adventitia with 
inflammatory cell infiltration. Lesions in the myocardial muscle were seen as accumulations of excess 
connective tissue and foci of inflammatory cells with elevated coronary damage and myocardial 
damage scores. Coronary and myocardial damage scores averaged 1.8 to 2.3 and 1.2 to 1.9 in the 
dTGR (Figure 11a, 11b, 11c). Valsartan markedly, whereas resveratrol and levosimendan partially 
prevented Ang II-induced coronary (0.3, 1.2, 0.4 respectively) and myocardial damage in dTGR (0.0, 
0.2, 0.3 respectively)(Figure 12a, 12b, 12c)(Study I, II, III). 
Dahl/Rapp on HS exhibited lesions in the coronary arteries ranged from minimally thickened media 
and a slight increase of connective tissue around the arteries up to severe hyperplasia of 
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intimal/medial layer and necrosis of the arterial wall with perivascular inflammatory cell infiltration. 
Lesions in the myocardium ranged from a focal increase of slender connective tissue bundles up to 
necrotic foci in the myocardium with inflammation. Coronary and myocardial damage scores 
averaged 3.2 and 2.0 in high salt Dahl/Rapp rats (Figure 11d and Figure 12d)(Study IV). Although 
levosimendan and valsartan provided some tissue protection at the histological level (coronary 
damage scores 2.4, 1.8 and myocardial damage scores 1.3, 0.5 respectively), the duotherapy seemed 
to be superior in its ability to completely prevent the cardiac damage (coronary and myocardial 
damage scores 0.8, 0.2). Furthermore, therapy did not reach the level of the tissue protection 
achieved with valsartan alone. 
 
 
Figure 11. Coronary artery damage in dTGR treated with (a) valsartan, (b) resveratrol and 
nicotinamide, (c) levosimendan vs SD rats, and in (d) Dahl/Rapp HS treated with levosimendan, 
valsartan and combination of levosimendan and valsartan vs LS Dahl/Rapp rats. * denotes p<0.05 
compared to dTGR or Dahl/Rapp HS, # denotes p<0.05 compared to SD or Dahl/Rapp HS + 
levosimendan, ¤ denotes p<0.05 compared to HS+valsartan (See Figure 6 for doses). 
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Figure 12. Myocardial damage in dTGR treated with (a) valsartan, (b) resveratrol and nicotinamide, 
(c) levosimendan vs SD rats, and in (d) Dahl/Rapp HS treated with levosimendan, valsartan and 
combination of levosimendan and valsartan vs LS Dahl/Rapp rats. * denotes p<0.05 compared to 
dTGR or Dahl/Rapp HS, # denotes p<0.05 compared Dahl/Rapp HS + levosimendan (See Figure 6 for 
doses). 
 
5.6 Kidney morphology (Study III and IV) 
The renal lesions of dTGR ranged from a slight thickening of the arteries and tubular dilatation with 
proteinaceous casts to diffuse arterial and glomerular necrosis with tubular atrophy/regeneration 
(2.5, 1.5, 1.9 kidney artery, glomerular and tubular damage scores respectively)(Study III). 
Levosimendan did not significantly influence kidney morphology (1.7, 1.4, 1.6 kidney artery, 
glomerular and tubular damage scores respectively, p<0.05). 
In high salt Dahl/Rapp rats, the lesions were manifested as variable degrees of arterial and 
glomerular necrosis (4.1 and 4.0 damage scores)(Study IV), tubular atrophy and dilatation containing 
proteinaceous casts with diffuse inflammatory infiltrates affecting the parenchyma (3.7 damage 
score). The renoprotective effect of valsartan was greater than that of levosimendan (2.2 vs 2.8, 2.1 
vs 3.0, 2.1 vs 3.0 kidney artery, glomerular and tubular damage scores respectively, p<0.05). An 
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additive renoprotective effect was found by the drug combination (1.2, 1.3, 1.4 kidney artery, 
glomerular and tubular damage scores respectively, p<0.05). Both cardiac and renal damage 
correlated very closely with systolic blood pressure.  
5.7 Expression of hypertrophy- assossiated genes (All studies) 
Myocardial ANP mRNA expression, a pressure overload marker in untreated dTGR was markedly 
increased as compared with SD controls (Figure 13a, 13b, 13c). Valsartan decreased ANP mRNA 
expression by 92 % (Study I), resveratrol by 66 % (Study II); however, the difference did not quite 
reach statistical significance. Levosimendan produced a 56 % decrease in dTGR when compared to 
hypertensive dTGR (p<0.05, Study III). 
Cardiac ANP mRNA expression, a pressure overload marker, was increased 25-fold in untreated 
Dahl/Rapp rats on high-salt diet (Figure 13d). Levosimendan combined with valsartan produced a 
significant decrease in ANP mRNA level of approximately 81 % (p<0.05, Study IV) and this treatment 
was more effective than levosimendan or valsartan treatments separately (significant 50 % and 60 % 
decrease respectively). 
 
Figure 13. Expression of ANP mRNA in dTGR with (a) valsartan, (b) resveratrol and nicotinamide, (c) 
levosimendan vs SD rats, and in (d) Dahl/Rapp HS treated with levosiemendan, valsartan and 
combination of levosimendan and valsartan vs LS Dahl/Rapp rats. * denotes p<0.05 compared to 
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dTGR or Dahl/Rapp HS, # denotes p<0.05 compared to Dahl/Rapp HS + levosimendan, ¤ denotes 
p<0.05 compared to HS+valsartan (See Figure 6 for doses). 
 
There was no difference between the treatment groups in cardiac α-MHC or β-MHC mRNA 
expression. Levosimendan produced a non-significant 31 % decrease in β-MHC in dTGR, and a 51 % 
decrease in SD (data not shown). 
5.8 Cardiac metabolic profile in AngII-induced hypertrophy (Study I) 
The GC×GC-TOF/MS data set comprised of 247 intermediary metabolites. All the metabolites were 
detected by multivariate analysis (partial least squares discriminant analysis) out of which 112 were 
identified from myocardial samples that differed statistically significantly between the groups after 
correction for multiple comparisons (false discovery rate q <0.05); 64 cardiac metabolites differed 
significantly between dTGRs and SD rats (P<0.05), 32 metabolites differed between dTGR and 
dTGR+valsartan treatment (P<0.05), and 34 metabolites differed between SD and SD valsartan 
treatment (P<0.05). In general, the metabolomic profile of valsartan-treated dTGRs resembled SD 
rats more than untreated dTGRs. Nonetheless, the metabolomic profile of valsartan-treated SD rats 
also visibly differed from untreated SD controls as revealed by partial least-squares discriminant 
analysis. Several decreases in cardiac fatty acid concentrations in dTGRs were recorded such as lower 
myocardial octanoic acid, oleic acid, and linoleic acid levels (all parameters P<0.001). There were also 
markedly increased ketogenic amino acid tyrosine levels and decreased tryptophan levels in dTGRs; 
otherwise, the drug effect dominated the amino acid changes. The dTGRs demonstrated several 
changes in organic acid levels. Moreover, decreases in hippuric acid, malic acid, and γ-hydroxybutyric 
acid concentrations were recorded, whereas the level of β-hydroxybutyric acid in dTGRs was 
elevated. The higher cardiac hypoxanthine level in dTGRs was found to be assossiated with an 
increase in purine degradation. Interestingly, valsartan treatment decreased the cardiac 
hypoxanthine level by 70 %. Supplementary data is attached in the section ’’ORIGINAL ARTICLES’’. 
The metabolic profiling is depicted in Figure 14. 
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Figure 14. Graph presenting partial least-squares discriminant analysis including all 247 intermediate 
metabolites detected by GC×GC-TOF/MS to detect 247 intermediary metabolites. Each spot 
represents a single animal and the whole information of the 247 metabolites measured. Model 
properties 3 LVs, Q2=65%.  
 
5.9 Expression of markers of mitochondrial biogenesis (Study I-III) 
There was no difference between dTGR and SD rats in the mRNA expressions of mitochondrial 
biogenesis markers nuclear respiratory factor 1, transcription factor A mitochondrial, or PGC-1α. 
Valsartan increased mitochondrial biogenesis markers in SD rats, whereas the expression of 
mitochondrial biogenesis markers in valsartan-treated dTGRs was slightly but significantly lower 
compared with control dTGRs. Interestingly, resveratrol produced a significant increase in cardiac 
PGC-1α, Tfam and cox4 mRNA levels, NAM did not influence these factors, and levosimendan had no 
effect on dTGR or SD rats biogenesis marker PGC-1α (Figure 15a, 15b, 15c, 15d, 15e, 15f). 
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Figure 15. Expression of mitochondrial biogenesis markers Tfam (a,d), PGC-1α (b,e), cox4 (c,f)  in 
dTGR treated with valsartan (a, b, c) and resveratrol (d, e, f) vs SD rats. * denotes p<0.05 compared 
to dTGR or Dahl/Rapp HS, # denotes p<0.05 compared to SD or dTGR+valsartan, ¤ denotes p<0.05 
compared to dTGR+valsartan or dTGR+resveratrol (See Figure 6 for doses). 
  
5.10 Expression of markers of mitochondrial respiratory chain (Study I) 
The activity of cytochrome c oxidas was decreased in dTGRs than in SD rats. The AT1-R antagonist, 
valsartan, partly reversed this change. The activities of other respiratory chain enzymes did not vary 
between groups as shown in Figure 16.  
 
82 
 
 
Figure 16. Bar graphs showing mitochondrial respiratory chain activities in dTGR treated with 
valsartan compared to SD rats. # denotes p<0.05 vs SD rats (See Figure 6 for doses). 
 
5.11 Ultrastructure of cardiac mitochondria  
Changes in the cellular metabolic status influence the balance between fission and fusion leading to 
alterations in mitochondrial morphology. It was therefore decided to investigate the ultrastructure of 
cardiac mitochondria in dTGRs. Electron microscopy revealed that cardiac mitochondria from dTGRs, 
but not from control animals, frequently formed interconnected tubes (Figure 17a) but this was not 
observed in healthy rats (Figure 17b). This finding suggests that alterations in the cardiac metabolism 
of dTGRs promote mitochondrial fusion. 
 
 
 
 
Figure 17. Representative photomicrograph from transmission electron microscopy from dTGR and 
SD rat heart. 
(a) dTGR (b)  SD 
# #
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5.13 Expression of inflammatory markers (Study III) 
Cardiac MCP-1 expression was increased by 5-fold in dTGR when compared to SD rats (0.000065 vs 
0.000012, p<0.05). Levosimendan did not affect MCP-1 mRNA overexpression. 
5.14 SIRT1-related salvage pathways (Study I and II) 
SIRT1 levels were associated with increased apoptosis, hypertrophy, and decreased cardiac function. 
Cardiac SIRT1 expression was moderately increased in untreated dTGRs compared with SD controls, 
with no differences in the cardiac SIRT1 mRNA expressions. 
Cardiac SIRT1 protein expression was higher in untreated dTGR compared with SD controls, whereas 
there was no difference in cardiac SIRT1 mRNA expression indicating changes in post-transcriptional 
regulation. Resveratrol decreased SIRT1 protein expression by 42 % but increased cardiac SIRT1 
mRNA expression. NAM decreased cardiac SIRT1 protein expression to the same extent as 
resveratrol, but did not influence cardiac SIRT1 mRNA expression (Figure 18c). 
The effect of Ang II on SIRT1 protein level was studied using rat neonatal cardiomyocytes. There was 
no significant difference in SIRT1 protein level between Ang II and vehicle treated cells. Blockade of 
AT1R by losartan or AT2R by PD123319 did not influence SIRT1 protein level in rat neonatal 
cardiomyocytes (Figure 18d). 
In our in vitro studies, resveratrol increased SIRT1 activity by 17-fold in a dose-dependent manner. 
NAM decreased SIRT1 activity by more than 70 % (data not shown). 
A supplementary experiment with Dahl/Rapp SS rats on high and low-salt diet did not evoke any 
SIRT1 protein expression between the groups (Figure 18b).  
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Figure 18. SIRT1 protein expression in dTGR treated with valsartan (a), Dahl/Rapp HS vs Dahl/Rapp LS 
(b), resveratrol and NAM (c) and in (d) neonatal cardiomyocytes. * denotes p<0.05 compared to 
dTGR rats (doses as in Figure 6). 
 
5.15 Apoptotic pathways (study II and III) 
Since p53 is a target of SIRT1, it was decided to determine whether or not p53 could be de-
acetylated. There were no differences between dTGR and SD rats in protein expression of cardiac 
P53, acetylated-P53 or acetylated-P53-to-P53 ratio and treatment with resveratrol or NAM did not 
have any influence on these parameters (Figure 19a, 19b, 19c). 
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Figure 19. Cardiac protein p53 expression in dTGR treated with resveratrol (800 mg/kg/day for 4 
weeks) compared to SD rats, (a) acetyl-p53, (b) total p53, (c) acetyl p53/total p53.  
 
The mRNA expression of the pro-apoptotic factor Bax was slightly increased in myocardium of dTGR 
as compared to SD rats (p<0.05) and levosimendan did not influence cardiac Bax mRNA expression in 
dTGR or SD rats (Figure 20). 
 
 
Figure 20. Expression of pro-apoptotic Bax mRNA in dTGR treated with levosimendan (1 mg/kg for 4 
weeks) vs SD rats. 
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5.16 Premature cardiomyocyte senescence (Study II) 
We observed no statistically significant differences in the markers of cellular senescence INK4A and 
ARF between unmedicated dTGR and SD controls, although ARF mRNA expression was 48 % greater 
in untreated dTGR than in SD rats.  
5.17 Calcium handling proteins (Study III) 
Impaired calcium handling is known to be associated with the development of cardiac dysfunction 
and it was possible to detect lower cardiac SERCA2 and NCX protein expressions in dTGR as 
compared to SD rats. Levosimendan did not influence SERCA2 or NCX expression in dTGR, but 
increased cardiac SERCA2A in SD rats (Figure 21a, 21b). 
 
 
Figure 21. Bar graphs showing the effects of 4-week levosimendan treatment (1 mg/kg/day) on 
myocardial protein expression of (a) SERCA2a and (b) NCX-1. *P<0.05 compared to dTGR; #P<0.05 
compared to dTGR+Levo; § P<0.05 compared to SD. 
 
5.18 Cardiomyocyte autophagy and endoplasmic reticulum stress (Study IV) 
A high salt diet did not induce cardiomyocyte autophagy measured as LC3B, 14 kDa/16 kDa ratio. 
Neither levosimendan nor valsartan treatment affected cardiomyocyte autophagy, whereas the drug 
combination tended to increase cardiac autophagy; however this increase was not statistically 
significant. Diet and drug regimens did not influence cardiac BiP protein expression. 
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Figure 21. Bar graphs showing the effects of 8-week treatments with levosimendan, valsartan on 
myocardial protein expression (a) LC3B (14/16 kDa unit) protein expression; (b) BiP/L-tubulin in 
Dahl/Rapp rats on high salt diet. 
 
5.19 Biochemical and hormonal analysis (Study II and III) 
The albumin excretion was 40-fold increased in dTGR when compared to SD rats (8274 μg/24h vs 229 
μg/24h respectively, p<0.05) and there was a seven-fold increase in serum aldosteron level in dTGR 
(1507 pg/ml vs 207 pg/ml, p<0.05). Resveratrol non-significantly decreased albuminuria by 25 % 
(6204 μg/24h) and was able to decrease the serum aldosterone level by 50 % (798 pg/ml, p<0.05)) 
compared with untreated dTGR. Nicotinamide did not influence either albumin excretion or 
aldosterone levels in dTGR (p>0.05). Levosimendan did not have any effect on albumin excretion in 
dTGR (p>0.05). 
5.20 Serum electrolytes, creatinine and liver enzymes (Study III and IV) 
The 24-h urinary excretion rates of potassium and phosphorus in dTGR were 2,313 mmol/24h, 
0,1294 mmol/24h respectively) and levosimendan did not influence these parameters. Furthermore, 
there was no difference between dTGR nor SD rats (p>0.05, Study III). There was however a 
statistically significant decrease in sodium, chloride, calcium and creatinine clearance levels in dTGR 
when compared to SD rats (1,772 vs 0,9543 mmol/24h; 2,442 vs 1,560 mmol/24h; 0,1719 vs 0,01359 
mmol/24h;  0,4524 vs 1,018 ml/min, respectively, p<0.05), however levosimendan did not evoke any 
changes in both animal strains (p>0.05, Study III).  
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HS did not produce any changes in serum levels of potassium, creatinine, alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), or alkaline phosphatase (AFOS) when compared to LS 
Dahl/Rapp rats(6,893 mmol/l; 52,97 μmol/l; 67,21 U/l; 283,2 U/l; 102,1 U/l respectively, p>0.05, 
Study IV). Serum sodium and chloride concentrations were significantly increased by consumption of 
a high salt diet (i.e. 149,8 mmol/l and 113,5 mmol/l respectively) when compared to LS dahl/Rapp 
rats (144,0 mmol/l and 102,3 mmol/l respectively). Levosimendan significantly decreased the 
concentration of sodium in serum to the level of LS dahl/Rapp rats. With respect to chloride levels 
valsartan, levosimendan and the combination therapy achieved comparable values to the level of LS 
Dahl/Rapp rats and were significantly lower when compared to HS Dahl/Rapp rats (p<0.05). 
5.21 Plasma drug concentration (Study III and IV) 
The daily dosage of levosimendan was calculated weekly and averaged 1.04 ± 0.03 mg/kg in dTGR 
(range 0.9-1.15) and 1.1 ± 0.05 mg/kg in SD rats (range 0.73-1.3). The average daily dose of 
levosimendan In HS Dahl/Rapp rats was approximately 0.69 ± 0.03mg/kg (range 0.31-0.72 mg/kg) 
whereas in the combination with valsartan 0.52 ± 0.03 mg/kg (range 0.3-0.57 mg/kg). 
Terminal plasma levosimendan concentrations in dTGR were 5.5 ± 1.2 ng/ml. The level of OR-1896, 
the stable metabolite of levosimendan was 31.7 ± 5.6 ng/ml. In SD rats treated with levosimendan, 
plasma levosimendan and OR-1896 concentrations were approximately 7.6 ± 3.1 ng/ml and 43.4 ± 
5.2 ng/ml respectively. The terminal plasma concentration of levosimendan in HS Dahl Rapp rats 
were found to be 16.65 ± 3.25 ng/ml, and the levosimendan and valsartan combination, 6.91 ± 1.42 
ng/ml. The concentration of the stable metabolite of levosimendan- OR-1896 was 17.36 ± 1.73 ng/ml 
in HS Dahl Rapp rats, and 4.15 ± 0.38 ng/ml in HS Dahl Rapp rats when the drug combination was 
given. 
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Figure 22. The average weekly levosimendan doses calculated from water consumption during the 4-
week experimental period in (a) dTGR, (b) Dahl/Rapp HS, (c) mean plasma concentration of 
levosimendan and (d) OR-1896 in Dahl/Rapp HS, and valsartan plasma concentration in HS Dahl/Rapp 
rats. # denotes p<0.05 compared to HS+levosimendan. 
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6. DISCUSSION 
The mechanisms responsible for the onset and progression of HF still remain to be characterized. The 
current treatments are not fully satisfactory due to their limited efficacy, adverse effects or loss of 
their therapeutic efficacy with time. Furthermore the numbers of patients suffering HF and other 
related cardiovascular disorders increases every year and also the number of deaths related to HF 
continuous to rise, as does the prevalence of contributing risk factors. (Wright et al., 2008) 
This study revealed the impairment of cardiac substrate utilization and the cardiac changes in the 
metabolic profile due to an overactive RAAS. The treatments with valsartan, levosimendan, their 
combination as well as resveratrol examined here proved to confer cardioprotective effects and 
prevented cardiovascular mortality. The beneficial effects of valsartan were associated with BP 
dependent and independent mechanisms. Resveratrol improved mitochondrial biogenesis and 
prevented Ang II- induced excess mortality. Levosimendan ameliorated systolic functions in Ang II- 
induced HF model, dTGR. In salt-dependent hypertensive HF, levosimendan combined with valsartan 
evoked superior effects than the monotherapies with valsartan or levosimendan due to the greater 
decrease in SBP and improved cardiac functions and reduced hypertension induced cardiac 
remodeling.   
6.1 Methodological aspects  
6.1.1 Experimental animal models  
Hypertension-induced HF is a common disease that develops over years. LVH is an inappropriate 
adaptation response to high BP, which eventually fails as a compensatory mechanism causing 
congestive HF. (Meredith and Ostergren, 2006) Animal models have been created in order to study 
hypertensive HF with preserved systolic function, a common occurence in humans. (Ganten et al., 
1992)(Rapp and Dene, 1985)  
6.1.1.1 Double transgenic rat harboring human renin-angiotensinogen genes (dTGR) 
These studies were conducted with dTGR rats. These represent a strain of animals which overexpress 
RAAS, offering a unique possibility to study the function and regulation of these human genes in vivo. 
It is important that the translational products human renin and human angiotensinogen do not cross-
react enzymatically with rat RAAS and vice versa. Furthermore this model can be used to study 
human-specific drugs such as the renin inhibitor aliskiren to reveal their advantages and limitations 
with RAAS. (Ganten et al., 1992)(for review see (Pool, 2007)) As Wellner et al. revealed with tissue 
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Doppler measurements the peak early (Ea) to late (Aa) diastolic expansion is reduced in dTGR, 
consistent with terminal HF from diastolic dysfunction. (Wellner et al., 2005) The animals also 
showed pronounced cardiomyocyte hypertrophy, preserved systolic function, increased matrix 
protein expression, downregulation of several genes involved in the mitochondrial respiratory chain 
and lipid metabolism, and distinct patterns in the expression profile of genes encoding transcription 
factors, coagulation, cardiac remodeling, immune system, and metabolic pathways. (Wellner et al., 
2005) 
Due to overactive local RAAS our dTGR rats developed hypertension, cardiac hypertrophy, impaired 
diastolic filling (increase in IVRT), vascular inflammation, proteinuria, and renal and cardiac failure 
with a mortality rate of 50-60 % at the age of 8 weeks, i.e. they are very different from SD rats as 
described earlier. (Ganten et al., 1992)(Mervaala et al., 1999)(Luft et al., 1999)(Muller et al., 
2000)(Muller et al., 2002)(Helkaama et al., 2003) 
6.1.1.2 Dahl/Rapp salt-sensitive (SS) rat 
The inbred Dahl/Rapp salt-sensitive (SS) rat, a model of salt-induced hypertension, develops diastolic 
HF with relatively preserved systolic function, resulting in an increased mortality rate. (Chang, 
2009)(Solomon et al., 2010)(Louhelainen et al., 2009) In Dahl/Rapp rats, on the contrary to Dahl salt-
sensitive rats, inbreeding consists of brother-sister breeding for 20 or more generations, providing 
homozygosity. In Dahl salt-sensitive rats, inbreeding has been conducted for only few generations, 
followed by the introduction of foreign stock to reduce inbreeding depression. (Rapp and Dene, 
1985) Fulminant hypertension with concomitant LVH and increased chamber stiffness appears when 
there is addition of 8 % NaCl to the diet of 6 weeks old animals (Kim et al., 2001)(Klotz et al., 2006) 
and thus is followed in the proceeding 11-12 weeks by passive diastolic dysfunction with reductions 
in end-diastolic volume, and enhanced end-systolic function. (Klotz et al., 2006) Salt-induced 
hypertension and vascular remodeling are initially driven by salt and water retention though there is 
some degree of hypertrophy, and the later phase is partially mediated through the RAAS. (Bayorh et 
al., 2005) Dahl/Rapp rats on a high salt diet have traditionally been considered as a low renin volume 
overload model, where salt intake suppresses RAAS. (for review (Pinto, 1998)) Indeeed, experiments 
with Dahl/Rapp rats (Bayorh et al., 2005)(Liang and Leenen, 2007) have revealed that even though 
the activity of the circulatory RAAS is attenuated, significant increases in components of the local 
tissue RAAS in heart, kidney and brain can be demonstrated, resulting in hypertension, 
cardiovascular hypertrophy, interstitial and perivascular fibrosis in ventricles and the aorta, as well as 
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other target-organ damage. (Liang and Leenen, 2007)(Jun et al., 2003)(Zhao et al., 2001)(Kreutz, 
1995)  
Since the Dahl/Rapp rat is a model of preserved cardiac systolic function, developing gradually 
hypertension- induced heart failure, it exhibit prolonged isovolumic relaxation time, compared to low 
salt (0.3 % NaCl) Dahl/Rapp rats and high mortality rates, i.e. similarly as noted in these studies 
studies, where there was a mortality rate of 30 % at week 14. (Louhelainen et al., 2007)(Tian, 2007) 
These detrimental changes have been found to be linked to impaired calcium handling. (Louhelainen 
et al., 2007) Moreover as earlier studies have shown, renal damage in Dahl rats, which involves salt-
induced oxidative stress, inflammation and glomerular podocyte injury as well as local RAAS 
production, might have been involved in the development of HF. (Nagase et al., 2006)(Datla and 
Griendling, 2010)  
6.2 Cardiovascular effects of calcium sensitizers, AT1 receptor blockers and resveratrol 
6.2.1 Mortality  
To date no satisfactory HF treatment can be considered as effectively preventing the development of 
hypertensive heart disease and reducing the subsequent mortality due to HF, stroke, arrhythmias, 
and sudden death. (for review see (Erhardt, 2003)(Shu, 2009))  
In the present study, hypertensive dTGR exhibited an Ang II- induced excess mortality rate when 
compared to normotensive SD rats. The causes of death in dTGR rats consisted of heart and kidney 
failure, sudden death and stroke. (Luft et al., 1999) In addition to BP-dependent effects, Ang II 
mediates also BP-independent effects such as end-organ damage, inflammation, and cellular growth. 
(Mervaala et al., 2000)(Cassis et al., 2010) Dahl/Rapp rats when fed with the HS diet in turn are 
known to develop moderate heart failure with preserved ejection as wel as end-organ damage, 
which was observed in our studies. (Louhelainen et al., 2007) 
Interestingly both valsartan and resveratrol completely, and levosimendan prevented death events in 
dTGR. In addition to reducing BP and aldosterone secretion due to Ang II type 1 receptor blockade, 
AT1 receptor antagonists exert BP independent effects. (Mervaala et al., 2000) In these present 
studies valsartan prevented mortality which was associated with improved cardiac remodeling, 
mitochondrial function and biogenesis. As hypothesized previously, the anti-inflammatory, anti-
oxidative, and sympatho-inhibitory effects of sartans might have played a role in these dTGR rats. 
(Mervaala et al., 2000)(Balt, 2002)  
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It was also discovered that the nutraceutical compound resveratrol was equally effective in the 
prevention of Ang II- induced mortality as valsartan. This reveals that a nutraceutical agent may have 
cardioprotective effects comparable to a drug treatment. Its beneficial effects on lifespan were BP 
dependent and associated with cardioprotection and improved mitochondrial biogenesis. Even 
though resveratrol is known to evoke SIRT1 longevity gene activation (for review (Das, 2010)), in our 
studies these effects were minor, pointing other, BP- independent actions of resveratrol, such as its 
anti- oxidative, and/or anti-inflammatory properties being  involved. 
On the contrary to valsartan and resveratrol, levosimendan decreased mortality in dTGR in a BP 
independent manner, emphasizing the importance of other salvage pathways. It is postulated that 
levosimendan exerted its cardioprotective effects due to its inotropic and vasodilatory properties, 
possibly combined with anti-inflammatory effects due to opening of the mitochondrial K+ATP channels 
in cardiomyocytes. (Louhelainen et al., 2007) It has been shown that levosimendan may decrease the 
mortality rate not only due to improved diastolic function and hemodynamics, as seen in the studies 
with dTGR rats, but also by conferring protection from stroke events and arrhythmias. (Meyer, 
2008)(Erhardt, 2003) This could be the case also in the studies conducted here with Dahl/Rapp rats, 
in which the cardioprotective effects of duotherapy of a Ca2+ sensitizer and an AT1 receptor 
antagonist were studied. The combination completely prevented salt- induced cardiovascular 
mortality, similarly to the monotherapies. These findings were associated with a reduction in SBP, 
improved cardiac and renal structure as well as improved diatolic function. As compared to the 
monotherapies, the drug combination provided the best protection against hypertension-induced 
target organ damage. However a longer follow-up period would have been required in order to 
reveal survival differences between the treatment groups. 
6.2.2 Cardiac remodeling and cardiac functions 
Hypertension followed by cardiomyocyte hypertrophy and cardiac fibrosis, leads to diastolic stiffness 
and abnormal relaxation- related filling of the left ventricle which is a characteristic of HF with 
preserved systolic function. (Wellner et al., 2005)  
In this present study, the dTGR exhibited Ang II-induced cardiomyocyte hypertrophy and increased 
heart weight-to-body weight ratio with co-existing fibrosis, underlining the detrimental effect of local 
RAAS in this animal model. It was decided to investigate putative pathways involved in the transition 
from hypertrophied heart into HF. Myocardial pressure/volume overload and a hemodynamic 
marker, ANP mRNA expression were significantly higher in untreated dTGRs than SD rats. In addition, 
an imparment of excitation-contraction coupling in dTGR has been described by Wellner et al. 
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(Wellner et al., 2005) Here the dTGR levels of SERCA2a protein were lower compared to healthy SD 
rats, indicative maladaptive calcium handling. Moreover, Wellner et al. reported detrimental shift 
from α-MHC to fetal β-MHC phenotype in cardiomyocytes, implying cardiac hypertrophy and 
derangements in energy metabolism in hypertrophied heart. (Krenz and Robbins, 2004) This kind of 
change was not observed here between the dTGR and SD rats. 
In these experiments, valsartan in dTGR reduced hypertension, cardiac remodeling and 
pressure/volume overload, thus suggesting prevention of hypertensive HF development, which is in 
line with the findings of Siragy. (for review (Siragy, 2010)) Valsartan is an AT1 receptor antagonist and 
widely used to treat hypertensive patients. By blocking the binding of angiotensin II to AT1, valsartan 
dilates blood vessels, which results in lowered pressure/volume overload imposed to the heart, 
reduced the risk of congestive HF, MI and stroke. (Verdecchia et al., 2010) Other actions of valsartan 
possibly involved in cardioprotection due to AT1 receptor blockade independent properties such as 
anti-inflammatory, anti-aggregatory and anti-growth effects. (for review (Schmidt et al., 2004))  
Ang II is known to evoke oxidative stress mostly via a protein kinase C-dependent pathway followed 
by NADPH oxidase activation, resulting in peroxynitrite formation. Ang II can induce a decrease in 
endothelial NO production thus promoting the development endothelial dysfunction (for review see 
(Doughan, 2008)) vasoconstriction, cardiac muscle overgrowth and inflammation and it predisposes 
to aging. (for review see (Cassis et al., 2010)(Wright et al., 2008)) These maladaptive Ang II- 
dependent responses can be reversed by AT1 receptor blockers in a BP independent manner (for 
review see (Cassis et al., 2010)(Doughan, 2008)), as could have been the case in these present studies 
with valsartan. It is known that the differences in lipid solubility and the variation in the molecular 
structure of the ARBs determine differences in the binding affinity to the receptor and 
pharmacokinetic profiles. (for review see (Israili, 2000)) 
Studies with resveratrol have indicated that it activates sirtuin deacetylases and thus modulation of 
the downstream SIRT1 pathways related to improved mitochondrial function, reduced apoptosis, 
inflammation and aging. (Lagouge et al., 2006)(Baur et al., 2006)(for review see (Baur and Sinclair, 
2006)) In addition resveratrol possesses free-radical and anti-oxidative properties. These 
pharmacological pathways affected by resveratrol can be translated into the attenuation of platelet 
aggregation, promotion of vasorelaxation, suppression of atherosclerosis, reduced lipid peroxidation 
as well as corrected serum cholesterol and triglyceride concentrations. There is growing evidence to 
indicate that resveratrol may have a significant effect in prevention or delaying the onset of heart 
disease. (for review see (Baur and Sinclair, 2006)) 
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In the dTGR experiments, resveratrol improved cardiac structure and prevented the development of 
hypertrophy. In particular, resveratrol could have exerted these cardioprotective effects in dTGR due 
to prevention from Ang II-induced activation of NADPH oxidase and xanthine oxidase. (Mervaala et 
al., 2001) Since resveratrol exerted similar effects to valsartan, this might be considered as evidence 
of that the AT-1 blockers possess significant anti-oxidative effects as described earlier by Cassis et al. 
(for review see (Cassis et al., 2010)  
Levosimendan, a novel inodilator, acts both via calcium sensitization of myocardial contraction and 
opening of K+ATP channels in cardiomyocytes. These properties of levosimendan result in increased 
cardiac force of contraction and decreases in preload and afterload and thus contributing to 
cardioprotection. Levosimendan is used for acute decompensated HF and given usually 
intravenously; however this drug is also well absorbed when administered orally. Long- term effects 
of levosimendan still remain to be elucidated. Even though the effects of levosimendan in the dTGR 
were BP-independent, moderate protection was observed against Ang II-induced cardiomyocyte and 
the vascular damage and this was associated with a prominent decrease in pressure/volume 
overload. This could have been due to vasodilatation and improved microcirculation and overall 
coronary flow in the heart. (Grossini et al., 2009, Pataricza et al., 2003, Erdei et al., 2006)(Honish et 
al., 2009) Moreover, no alterations were observed in two calcium- handling proteins, SERCA2a and 
NCX, in levosimendan treated dTGR, though the amounts of SERCA2a were increased in 
levosimendan treated SD. In the latter case, PDE III inhibition as a mediator of the beneficial effects 
of levosimendan could have been involved, however this hypothesis remains to be confirmed. There 
was also a tendency in levosimendan treated dTGR towards an increase in the level of α-MHC and a 
corresponding decrease in that of fetal β-MHC, when compared to dTGR. Nonetheless, the treatment 
period might have been too short to reveal entirely the significance of this trend.  
In the study with Dahl/Rapp rats consuming a high salt diet, levosimendan and valsartan duotherapy 
significantly corrected pressure overload, cardiac hypertrophy, cardiac damage and as well as 
improved cardiac diastolic function compared to the monotherapies. It is noteworthy, that these 
beneficial effects of the duotherapy were largely due to its pronounced anti-hypertensive effects. 
Even though the dose of levosimendan in the combined therapy was lower due to the Ang II- 
dependent dipsogenic effect blockade encountered after valsartan treatment, the duotherapy 
produced superior effects to monotherapies. Valsartan is known to attenuate an overactive tissue 
RAAS and salt-overload related tissue damage (Liang and Leenen, 2008) evidence of a  significant role 
of Ang II mediated pathology in this low-renin model. Levosimendan improved cardiac function, 
discussed below, and due to opening of sarcolemmal K+ATP channels of vascular smooth muscle cells 
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resulted in vasodilation and corrected the pre- and after-load, which could be postulated to improve 
coronary flow, providing better perfusion to the heart (Louhelainen et al., 2007)(for review see 
(Parissis, 2009) even though BP was not significantly affected by levosimendan alone. The 
levosimendan-valsartan combination produced a major decrease in ANP, reflecting a decrease in 
myocardial tension and the degree of cardiac overload, which might result in improved 
microcirculation in the heart. This improvement in hemodynamics may have resulted from improved 
renal damage and function, most effectively with the drug combination. Since the valsartan 
mechanism could have been related to local RAAS inhibition and its anti-inflammatory properties, 
levosimendan could have evoked increased blood flow to the renal medulla and decreased renal 
medullary/cortical vascular resistance due to the K+ATP channel opening, anti-inflammatory 
properties, and a reversal of Ang II-mediated mesangial cell contraction. (Yilmaz et al., 2007)  
Cardiac diastolic dysfunction and preserved systolic function is characteristic for hypertension 
induced HF. (Zile, 2004)(for review see (Zile and Brutsaer, 2002)) The rat strains used here represent 
models of HF with preserved systolic functions. (Wellner et al., 2005)(for review see (Solomon et al., 
2010)) However, the ratio of diastolic velocities, E/A-ratio in dTGR, when assessed by tissue Doppler 
imaging, was reduced, indicative of diastolic dysfunction, as demonstrated earlier. (Wellner et al., 
2005)(Rudko et al., 2008)(for review see (Gary and Davis, 2008)) Deterioration of active relaxation, 
namely prolonged isovolumetric relaxation time (IVRT) in Dahl/Rapp rats, was also observed with 
echocardiographic measurements as described by Rudko et al. (Rudko et al., 2008)  
When tested in the dTGR levosimendan improved cardiac function at systole even though it did not 
restore preserved systolic functions when compared to SD rats. This finding underlines the 
involvement of calcium sensitization mechanism, resulting in reduction in diastolic stiffness and an 
improvement of abnormal relaxation filling of left ventricle. However levosimendan did not correct 
Ang II-deteriorated diastolic cardiac functions in dTGR, on the contrary to the findings with 
Dahl/Rapp rats consuming a high salt diet. With or without addition of valsartan, levosimendan was 
equally effective at improving cardiac function at diastole in Dahl/Rapp rats receiving the high salt 
diet, as assessed as by the shortened IVRT. This occurred largely via blood pressure-dependent 
mechanisms, which implies that it can lower risk for diastolic HF. This finding is in line with a previous 
clinical study showing that levosimendan could improve diastolic function and shorten IVRT in 
patients with acutely decompensated heart failure. (Parissis et al., 2005)(Yontar et al., 2010) The 
putative mechanism behind diastolic improvement (Louhelainen et al., 2007) and a possible 
increment in coronary blood flow. (Grossini et al., 2010) This may be related to the increase in 
SERCA2 expression in cardiac sarco/endoplasmic reticulum in Dahl/Rapp rats evoked by 
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levosimendan, as shown earlier by Louhelainen et al. (Louhelainen et al., 2007) It needs to be 
emphasized that the combination therapy provided the most efficient cardioprotection 
Systolic parameters, namely fractional shortening and ejection fraction in untreated high salt 
Dahl/Rapp rats were increased possibly as a result of the development of hypertrophy;  
levosimendan treatment insignificantly tended to augment systolic function.  Nonetheless, neither in 
dTGR nor in Dahl/Rapp rats consuming a high salt diet was levosimendan able to prevent changes in 
HR, which can be speculated to exclude a potential role of PDE III inhibition as the mechanism 
involved in positive inotropic effects. (Gruhn et al., 1998)  
6.2.3 Metabolic profiling of Ang II-induced cardiac hypertrophy  
The failing heart is characterized by imbalanced energy sources such as fatty acid and glucose. 
(Wellner et al., 2005) Metabolomics is a novel method which aims to study dynamics, composition, 
interaction and responses to various interventions, both in healthy and diseased organs. (Oresic, 
2009) The metabolomic approach seems to be a promising tool as a marker of tissue-damage, 
including cardiac disorders. The quantification of small molecules leaking from injured myocardial 
cells is the basis for metabolomic studies. (for review see (Gregory et al., 2008)) Thus detection of the 
shift from fatty acids to carbohydrates may be a sign of failing myocardium and a therapy aimed at 
modulating energy metabolism could be a new alternative approach to the improvement of a failing 
myocardium. Drugs that are able to shift energy metabolism away from fatty acids to carbohydrates 
have been developed and are currently in clinical trials. (for review see (Fragasso et al., 
2008)(Horowitz et al., 2010)(Kaddurah-Daouk et al., 2008))  
In these studies, the AT1 receptor blocker, valsartan was used as a tool to investigate the effects of 
Ang II, and its blockade, on cardiac energy metabolism. With a novel method GC×GC-TOF/MS 247 
different intermediary metabolites were recognized in the heart. Interestingly, valsartan was able to 
change the metabolomic profile not only in dTGR but also in normotensive SD rats. In valsartan- 
treated SD rats, the blockade of physiological AT1 signalling was associated with a disturbed 
metabolic profile, without affecting hemodynamic parameters when compared with normotensive 
SD. This is evidence that Ang II-mediated actions are strongly related to metabolic profiling also in 
healthy rats.  
Moreover, as shown by Wellner et al., the dTGR exhibit a dysregulation in the genes involved in 
energy metabolism. The changes in these genes correlated with contractile alterations in the heart, 
such as dysfunctional contractility and Ang II-induced LVH, as well as with cardiac energy demand. In 
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the advanced stages of HF, many key enzymes involved in myocardial energy substrate metabolism 
display various degrees of downregulation. The altered metabolic phenotype consists of reduced 
cardiac fatty oxidation, increased glycolysis and glucose oxidation and rigidity of the metabolic 
response to changes in workload. (Wellner et al., 2005) This is in line with the present findings. It was 
found that dTGR rats exhibited a decrease in medium-chain fatty acids, namely octanoic, oleic and 
linoleic acids, indicative of a downregulation of fatty acid synthesis in the presence of overproduced 
Ang II. Furthermore markedly decreased octanoic acid, involved in the synthesis of lipoic acid, an 
endogenous sulfur-containing coenzyme is required for the mitochondrial dehydrogenase reactions 
leading to ATP formation, this being reflected as an imbalance in aerobic metabolism. In addition, 
there was evidence of changes in the cardiac hypoxanthine level indicating purine degradation. This 
finding is in parallel with our earlier studies with dTGR demonstrating xanthine oxidoreductase 
overexpression. (Procopciuc et al., 2010) In addition, heart converts the chemical energy stored in 
fatty acids and glucose into the mechanical energy of actin-myosin interaction of myofibrils. The 
period of LVH that precedes decompensated HF is characterized by alterations in myocardial 
bioenergetics have been considered to play an important role in this transition. The ratio of 
phosphocreatine to ATP (PCr/ATP) reflects the energetic cardiac state and is significantly decreased 
in hearts with LVH reflecting impaired mitochondrial function, and is accompanied by a decrease in 
creatine kinase flux and alterations in substrate utilization in LVH hearts. These changes result in 
impaired pressure-overload, volume overload, cardiac output, eventually leading to LVH and HF. (for 
review see (Jameel and Zhang,  2009)) 
Remodelled cardiac samples from septal MI in humans have exhibited alterations in pyrimidine 
metabolism levels, the tricarboxylic acid cycle, and in the pentose phosphate pathways (Lewis et al., 
2008) Furthermore as an adaptation mechanism in atrial fibrillation, increased levels of β-
hydroxybutyrate, a ketogenic amino acid, were recorded. (Mayr et al., 2008) Altered patterns were 
also found in the expression profiles of genes encoding transcription factors and factors involved in 
coagulation, cardiac remodeling, immune system, and metabolic pathways. (Wellner et al., 2005) It 
was confirmed that these findings in failing hearts of the dTGR. They exhibited altered glucose 
utilization resulting in excessive production of ketogenic acids.  
6.2.4 Mitochondrial biogenesis and mitochondrial functions  
The transition from LVH to HF is strictly connected to impaired mitochondrial biogenesis, 
mitochondrial respiratory chain function and oxidative phosphorylation. (for review see (Stanley et 
al., 2005) Mitochondria generate energy, regulate apoptosis, and produce ROS and contribute to the 
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development of HF by promoting apoptosis, senescence and inflammation. (Hossain et al., 
2009)(Lemieux et al., 2010)(for review see (Ventura-Clapier et al., 2010)  
The mitochondria of dTGR were fused, suggesting a possible dysfunctional energy metabolism. 
Wellner et al reported the downregulation in mitochondrial respiratory chain in dTGR. (Wellner et 
al., 2005) Furthermore it was found that cytochrome c oxidase (complex IV), an enzyme responsible 
for adenosine triphosphate production, was significantly decreased. This could explain the defects in 
contractile mechanisms in HF. (Quigley, 2000) In this study valsartan, an AT1 receptor blocker was 
able to prevent these changes, further highlighting the important role of RAAS in the regulation of 
mitochondrial functions. Ang II-mediated mitochondrial dysfunction is linked to protein kinase C-
related pathway, reduced form of NADPH oxidase and further- ROS formation. (Doughan, 2008) 
Disruption of AT1 receptor in mice has been shown to prolong lifespan due to a decrease in oxidative 
stress and induction of mitochondrial biogenesis. (Benigni et al., 2009) However its exact influence 
on mitochondrial biogenesis remains to be determined due to the complex results obtained in dTGR 
and SD rats, such as the failure to detect any difference between both rat strains. 
On the contrary to valsartan, resveratrol dTGR treatment resulted in increased mitochondrial 
biogenesis through PGC-1-dependent pathway as shown earlier. (for review see (Lagouge et al., 
2006)) There was a significant increase in mRNA expression of transcription factors regulating 
mitochondrial function and biogenesis such as PGC-1 α (peroxisome proliferator-activated receptor 
[PPAR]- γ coactivator 1 α ), cox4 and Tfam (mitochondrial transcription factor) when compared to 
hypertensive rats. These findings are in line with the previous experiments conducted with aged 
animal models (for review see (Vina et al., 2009)) and suggest that the cardioprotective effects of 
resveratrol in dTGR were linked to mitochondrial biogenesis, which in turn balanced energy 
metabolism and possibly improved cardiac performance. 
In contrast to the situation with resveratrol changes were observed in dTGR treated with 
levosimendan, even though one mode of action of levosimendan is to open mitochondrial K+ATP 
channels. In order to reveal the involvement of mitochondrial K+ATP channels, there may be a need to 
use specific mitochondrial K+ATP channels blockers in the future. This could be one way to clarify the 
effect of levosimendan on mitochondrial function. 
6.2.5 SIRT1 activation and SIRT1-related salvage pathways 
Sirtuin 1 (SIRT1) constitutes a longevity gene. Since it is an energy sensor, cardioprotective, anti-
apoptotic and anti-inflammatory factor (Nisoli, 2007)(for review see (Finkel, 2009)) SIRT1 is highly 
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expressed in HF (Alcendor et al., 2004) comprising a compensatory mechanism. Due to the induction 
of mitochondrial activity in the NO-dependent pathway, it reduces ROS production, protecting from 
cardiovascular events. (for review see (Guarente, 2008)) Deacetylation of target proteins such as p53, 
FOXO transcription factor and PGC-1α results in cardioprotection by balancing energy metabolism, 
cellular senescence, inflammation in vivo and in vitro and by promoting DNA repair. (Alcendor, 
2007)(Wang et al., 2008)(for review see (Borradaile and Pickering, 2009))  
The differences of expression in these rat strains were screened and it was noted that cardiac SIRT1 
mRNA levels remained unchanged between SD and dTGR strains, indicating post-translational 
modifications of the protein. These findings stimulated a further investigation of the role of SIRT1 in 
dTGR. Surprisingly our dTGR showed more SIRT1 protein expression level than normotensive SD rats. 
In order to examine in detail, whether SIRT1 protein expression could be mediated by pressure 
overload or by Ang II or by both factors, Dahl/Rapp rats consuming high and low salt diet, a model of 
low systemic RAAS. Although exhibiting high BP in Dahl rats on high salt diet, no differences in SIRT1 
were found between screened hypertensive and normotensive groups. Our study with neonatal 
cardiomyocyte cells incubated with Ang II also did not reveal any alterations in SIRT1 protein levels. 
This finding may be associated with marginal amounts of AT1 receptors in cardiac neonatal cells as 
demonstrated by Porello et al. (Porrello et al., 2009) These results also imply that both hypertension 
and Ang II together are required for altered SIRT1 expression in postnatal period. Therefore, it was 
hypothesized that SIRT1 can be considered as a marker of Ang II-induced cardiac remodeling. 
It has been reported that overexpression of cardiac SIRT1 (>12.5 fold) is detrimental and triggering 
apoptosis, hypertrophy, fibrosis and cardiac dysfunction through induction of mitochondrial 
dysfunction, ultimately leading to the development of HF. (Alcendor, 2007))(for review see 
(Guarente, 2008) Thus, a moderate increase in SIRT1 protein expression points to compensatory 
salvage mechanism in dTGR. Valsartan treated dTGR exhibited a relatively low SIRT1 protein level, 
comparable with SD and SD rats treated with valsartan. This may have contributed to the 
cardioprotection, which could have resulted from a decrease in apoptosis, senescence, hypertrophy 
and impaired cardiac functions as reported earlier by Alcendor et al. (Alcendor, 2007) 
The SIRT1 protein was examined in detail by administering resveratrol, proposed to be a SIRT1 
activator. In dTGR, resveratrol normalized the expression of SIRT1 protein to the level of 
normotensive SD rats. However, when investigated further no activity in vivo was observed in 
resveratrol treated dTGR and no differences between dTGR and SD rats downstream SIRT1-regulated 
pathways such as anti-apoptotic and anti-senescent p53. This finding points to other properties of 
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resveratrol involved in cardioprotection in dTGR. In addition to inducing mitochondrial biogenesis, 
resveratrol could have mediated its effects due to oxidative stress reduction or free radical- 
scavenging features but those properties were not estimated in these experiments. 
6.2.6 Inflammation and apoptotic pathways 
Ang II is known to exert inflammatory effects in a BP-independent manner. This process is linked to 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1), 
redox-sensitive transcription factors, and oxidative stress. (Muller et al., 2000)(Muller et al., 
2002)(Mervaala et al., 2001)  
Levosimendan, a calcium sensitizer and inodilator, was found to exert anti-inflammatory, anti-
apoptotic and anti-senescent effects in Dahl/Rapp rats consuming a high salt diet as well as in 
spontaneously diabetic Goto-Kakizaki rats with post-infarction HF. (Louhelainen et al., 
2007)(Louhelainen et al., 2009) In vitro levosimendan also has been shown to reduce NF-κB-
associated, iNOS promoter transcriptor followed by synthesis of the enzyme which then evokes NO 
formation. (Sereila et al., 2008)  
Due to the overactivated RAAS, dTGRs develop inflammation. (Wellner et al., 2005) Nonetheless 
levosimendan was not able to prevent the progression of inflammation in dTGR, nor could it protect 
from apoptosis, as assessed via the levels of MCP-1 mRNA and Bax mRNA. This indicates that other 
salvage pathways are involved in levosimendan-mediated cardioprotection. 
It was earlier reported that cardiac remodeling has been associated with ER stress and a disturbance 
in autophagy in patients with heart failure (Nishida et al., 2009) Even though AT1 receptor blockade 
was previously noted to reduce ER stress and thus prevent cardiac hypertrophy, (Tang and Chua, 
2008) valsartan was unable to produce any major changes in high-salt loaded Dahl/Rapp rats. Neither 
the drug combination nor levosimendan alone affected ER stress even though they have previously 
been found to induce LC3B expression and autophagy in pig myocardium. (Grossini et al., 2010) 
There was however a tendency towards activation of cardiac autophagy indicative of enhanced 
cellular clearance mechanism. 
6.2.7 Clinical relevance 
These studies evaluated the importance of metabolomic profile of the failing heart in a hypertensive 
animal model with overactive RAAS. Since there is no satisfactory treatment for this condition and 
associated disorders, the pathways involved, especially those in energy utilization may represent a 
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very important target area in the development of novel, more effective treatments. Earlier studies 
highlighted the significance of adequate metabolism in sustaining correct cardiac function and 
structure (Sabatine et al., 2005)(for review see (Knuuti et Tuunanen, 2010)(Stanley et al., 2005)) 
Perhaps in the future it will be possible to devise an animal model making a direct link between 
tissue damage and concentrations in serum and/or urine samples. This kind of bioindicator could be 
helpful if it could be extrapolated and relevant humans as indicating particular disorder or severity of 
disease in a patient. 
The commonly used AT1 receptor blocker valsartan, was found to be linked to improved energy 
balance in dTGR. The induction of biogenesis in mitochondria may be a useful target for correcting 
the existing derangements in the failing heart. 
Resveratrol, which is a natural polyphenol obtained from grapes, can be considered a novel approach 
in prevention or treatment of hypertension, cardiac remodelling and resulting cardiovascular 
disorders. Resveratrol, provided as a dietary supplement, may be able to confer significant 
cardioprotection and achieve a reduction in cardiovascular events, if administered regularly. It may 
possibly represent an alternative therapy for hypertensive subjects. (for review see (Lekli, 2010)(Das 
and Das, 2007)) Moreover, currently there are molecules in addition to resveratrol, known to 
activate SIRT1. These compounds such as SRT2104, SRT2379 and SRT501 are produced by Sirtris 
Pharmaceuticals Inc. and are already undergoing clinical trials. (for review see (Camins et al., 2010))  
To date there is not enough satisfactory data related to chronic oral treatment with levosimendan, a 
drug that is more commonly used as a short term (24 h) intravenous infusion in patients with acute 
HF. (Bergh et al., 2010) These studies demonstrated that long-lasting levosimendan treatment did 
alleviate mortality, mainly due to inotropic and local vasodilatory actions. Therefore it is 
hypothesized oral levosimendan regimen could be both safe and beneficial, i.e. it may possess clinical 
potential.  
Ultimately the addition of levosimendan to valsartan therapy seems to confer hemodynamic 
improvements and cardioprotective benefits indicative of possible symptomatic and survival benefits 
for the HR patient. This treatment was shown to be significantly superior to monotherapies and 
provided blood pressure- dependent protection against target organ damage in the heart and 
kidneys. Moreover, levosimendan, alone and in combination with valsartan, could correct 
hypertension- induced diastolic dysfunction. Perhaps, in the future medicating patients 
intermittently with levosimendan may become a common treatment in addition to the daily drug 
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regimen. However, further studies are warranted to elucidate the central actions of the drug 
combination as well as their effects on renal blood flow and kidney function. 
This present study did not reveal any possible interactions between levosimendan and valsartan in 
the combined therapeutic group. In particular, the dose of ingested levosimendan when it was 
administered via the drinking water in the drug combination was significantly lower than that 
achieved by levosimendan therapy alone. Further studies need to be conducted in order to clarify the 
mechanisms behind the cardioprotective effects of the levosimendan and valsartan combination. 
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7. CONCLUSIONS 
The aim of the present study was to investigate the molecular mechanisms and signalling pathways 
of hypertension-induced heart failure with a special emphasis on the local renin-angiotensin-
aldosterone system, cardiac metabolomics and the putative therapeutic role of oral administration of 
the calcium sensitizer levosimendan. Exprimental studies were conducted in two different models of 
hypertension and hypertension-induced heart failure with preserved systolic function, i.e. in double 
transgenic rats harboring human renin and human angiotensinogen genes (dTGR), and in salt-
sensitive Dahl/Rapp rats. The main findings and conclusions of the present non-clinical cardiovascular 
studies were as follows: 
I. Ang II altered cardiac substrate use and the metabolomic profile in both normotensive and 
hypertensive animals. In Ang II-induced cardiac hypertrophy a distinct substrate use from 
fatty acid oxidation towards glycolysis could be detected by using a novel tissue-based 
metabolomics method. The altered cardiac metabolomic profile in dTGR was associated with 
mitochondrial dysfunction.  
II. Resveratrol prevented cardiovascular mortality and ameliorated Ang II-induced cardiac 
remodelling in dTGR. The beneficial effects of resveratrol were mediated by blood pressure-
dependent pathways and appear to be linked to increased mitochondrial biogenesis. 
Resveratrol dose-dependently increased SIRT1 activity in vitro.  
III. Oral levosimendan treatment improved cardiac function and survival in rats with Ang II-
induced hypertensive heart failure. The beneficial effects of levosimendan in dTGR are 
mediated via blood pressure-independent mechanisms and involved improved systolic 
function and amelioration of Ang II-induced coronary and cardiomyocyte damage. 
IV. Oral levosimendan treatment improved survival, produced a modest decrease in systolic 
blood pressure, and prevented hypertension-induced cardiac remodelling in hypertensive 
Dahl/Rapp rats on high salt diet. Levosimendan slightly improved systolic function and 
shortened IVRT, evidence of improved diastolic function. In Dahl/Rapp rats, valsartan 
decreased blood pressure more effectively than levosimendan, prevents cardiovascular 
mortality and cardiac remodelling, but it did not improve systolic or diastolic function. An 
additive antihypertensive effect was found when levosimendan and valsartan were 
combined. 
106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
8. ACKNOWLEDGEMENTS 
This study was carried during the 2007-2010 period in the Institute of Biomedicine, Pharmacology, 
University of Helsinki. The thesis was primarily financed by Sigrid Juselius Foundation, Academy of 
Research, University of Helsinki’s Research funds, Päivikki and Sakari Sohlberg Foundation, Finnish 
Foundation of Cardiovascular Research, Finnish Hypertension Society and ORION Pharma Research 
Foundation. 
I would like to express my deepest gratitude to my supervisor Professor Eero Mervaala, MD, PhD. 
This thesis would not have been possible without his guidance, trust, encouragement and support, 
not to mention the scientific expertise and unwavering enthusiasm that he brings to the laboratory. I 
appreciate all his contributions of time, scientific input and funding that made my PhD experience 
such a productive and stimulating time. 
I would also like to express my gratitude to Professor Esa Korpi, the Head of the Institute of 
Biomedicine for the opportunity to work in the Institute of Biomedicine, Pharmacology. I also owe 
my sincerest appreciation to Professor (emeritus) Heikki Vapaatalo and Docent Esko Kankuri for their 
scientific support and co-operation while doing my PhD studies.  
To the official reviewers of this thesis, Jaana Rysä PhD and Ewen MacDonald PhD, I am grateful for 
their time, interest and insightful comments, which helped to improve my thesis.  
My co-authors, Professor Friedrich C Luft, Professor Matej Orešič, Docent Ove Eriksson, Docent Risto 
Lapatto, Piet Finckenberg PhD, Petri Kaheinen PhD, Anna Korpi MSc, Juha Lempiäinen BM, Jouko 
Levijoki MSc, Marjut Louhelainen PhD, Miikka Löytäinen MSc, Professor, Essi Martonen MSc, Ismo 
Mattila MSc, Saara Merasto BSc, Dominik N Muller PhD, Jin Shi MSc, Antti Siltanen MSc, Eveliina 
Tauriainen MSc are warmly acknowledged for their expertise, guidance and fruitful collaboration. I 
would also like to thank Ms Nada Bechara-Hirvonen, Ms Sari Laakonen, Ms Päivi Leinikka, for 
technical guidance and to Ms Anneli von Behr who has been invaluable in helping me not only in the 
laboratory but standing by my side and supporting me. To my fellow post-graduate students in the 
Institute of Biomedicine, Pharmacology I would like to thank them for creating such a stimulating 
academic and social environment during this time. To Pauliina Ehlers PhD, Anne Kivimäki BSc, Anne 
Panhelainen, MSc, Kati Saarelainen MSc, who besides being extraordinary scholars, have been good 
friends, I express my deepest gratitude. I thank all my co-workers and collaborators for making my 
stay in Finland one of the most important learning experiences of my life. 
108 
 
My life in Helsinki was made enjoyable also to a large part by the many friends who became part of 
my life, only some of whom it is possible to mention here, Akmaral, Ania Adamczyk, Ania Indola, 
Weronika, Heli and Radek, Henrikka, Maarit, Miia, Karoliina, Luis and Piotr. I am grateful for your 
support, help and all the joyful moments we have had together. I also owe my warmest thanks to my 
best-friends, Iza and Marta, who despite the distance always had time for me and were standing by 
my side. 
I would like to thank Ewelina, who has been and always will be my best-friend, enjoying my 
happiness, making me laugh, supporting and always being there to help soothe my frustrations in the 
more difficult moments. Our inspiring conversations and time spent together enriched me and gave 
me the energy to go through the doctoral process. 
Above all, I owe my deepest gratefulness to my family, especially my Mum and Dad, for their 
encouragement, motivating and inspiring me to learn more during the whole doctoral venture 
abroad. Without their love, care, patience, faithful support and unflinching belief in me, I would not 
be where I am right now. Thank you. 
 
Helsinki, April 2011 
 
Agnieszka Biala
109 
 
9. REFERENCES 
Alcendor RR. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007; 10: 1512-1521.  
Alcendor RR, Kirshenbaum LA, Imai S, Vatner SF and Sadoshima J. Silent information regulator 2alpha, a longevity factor 
and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 2004; 10: 971-
980. 
Antila S, Sundberg S and Lehtonen LA. Clinical Pharmacology of Levosimendan. Clin Pharmacokinet 2007; 7: 535-525. 
Armario P and de la Sierra A. Antihypertensive treatment and stroke prevention: Are angiotensin receptor blockers 
superior to other antihypertensive agents?" Therapeutic Advances in Cardiovascular Disease 2009; 3: 197-204. 
Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother 2010; 16: 2599-
2607.  
Aronow WS and Frishman WH. Treatment of hypertension and prevention of ischemic stroke. Curr Cardiol Rep. Curr 
Cardiol Rep 2004; 2: 124-129. 
Bader M and Ganten D. Update on tissue renin-angiotensin systems. J Mol Med 2008; 6: 615-621. 
Baker DJ, Perez-Terzic C, Jin F, Pitel K, Niederländer NJ, Jeganathan K, Yamada S, Reyes S, Rowe L, Hiddinga HJ, Eberhardt 
NL, Terzic A and van Deursen JM. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 
insufficiency. Nat Cell Biol 2008; 7: 825-836. 
Balt JC. Sympatho-inhibitory properties of various AT1 receptor antagonists. J Hypertens Suppl 2002; 5: S3-11 
Barger PM. Fatty acid utilization in the hypertrophied and failing heart. Molecular regulatory mechanisms. Am J Med Sci 
1999; 1: 36-42. 
Bastide K, Guilly MN, Bernaudin JF, Joubert C, Lectard B, Levalois C, Malfoy B and Chevillard S. Molecular analysis of the 
Ink4a/Rb1-Arf/Tp53 pathways in radon-induced rat lung tumors. Lung cancer 2009; 3: 348-353. 
Baur JA. Biochemical effects of SIRT1 activators. Biochim Biophys Acta 2010; 8: 1626-1634. 
Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell P J, 
Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein K W, Spencer RG, Lakatta EG, Le Couteur D, 
Shaw RJ, Navas P, Puigserver P, Ingram DK, De Cabo R and Sinclair DA. Resveratrol improves health and survival of mice on 
a high-calorie diet. Nature 2006; 7117: 337-342. 
Baur JA and Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 6: 493-506. 
Bayorh M, Ganafa A, Emmett N, Socci R, Eatman D and Fridie I. Alterations in Aldosterone and Angiotensin II Levels in Salt-
Induced Hypertension. Clin Exp Hypertens 2005; 4: 355-367. 
Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM 
and Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009; 3: 524-530. 
Bergh CH, Andersson B, Dahlstrom U, Forfang K, Kivikko M, Sarapohja T, Ullman B and Wikstrom G. Intravenous 
levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 2010; 4: 404-
410. 
Bergmann MW, Zelarayan L and Gehrke C. Treatment-sensitive premature renal and heart senescence in hypertension. 
Hypertension 2008; 1: 61-62. 
Bernhard D and Laufer G. The Aging Cardiomyocyte: A Mini-Review. Gerontology 2008; 1: 24-31. 
110 
 
Bernstein RA. Prevention of Stroke in Patients with High-Risk Atrial Fibrillation. Curr Neurol Neurosci Rep 2010; 1: 34-39. 
Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y and Liu PP. Outcome of Heart Failure with Preserved Ejection 
Fraction in a Population-Based Study. New England Journal of Medicine 2006; 3: 260-269. 
Birkeland JA, Sejersted OM, Taraldsen T and Sjaastad I. EC-coupling in normal and failing hearts. Scand Cardiovasc J 2005; 
1: 13-23. 
Bitterman KJ. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and 
human SIRT1. J Biol Chem 2002; 47: 45099-45107. 
Boos CJ and Lip GY. Is Hypertension an Inflammatory Process? Curr Pharm Des 2006; 13: 1623-1635. 
Borradaile NM and Pickering JG. NAD(+), sirtuins, and cardiovascular disease. Curr Pharm Des 2009; 1: 110-117. 
Braunwald E, Libby P, Bonow RO, Mann DL and Zipes DP, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular 
Medicine. 8th ed. Philadelphia, PA: Saunders Elsevier; 2008. 
Brostrom MA and Brostrom CO. Calcium dynamics and endoplasmic reticular function in the regulation of protein 
synthesis: implications for cell growth and adaptability. Cell Calcium 2003; 4-5: 345-363. 
Brostrom MA, Mourad F and Brostrom CO. Regulated expression of GRP78 during vasopressin-induced hypertrophy of 
heart-derived myocytes. J Cell Biochem 2001; 2: 204-217. 
Brum PC, Rolim NP, Bacurau AV and Medeiros A. Neurohumoral activation in heart failure: the role of adrenergic 
receptors. An Acad Bras Cienc 2006; 3: 485-503. 
Camins A, Sureda FX, Junyent F, Verdaguer E, Folch J, Pelegri C, Vilaplana J, Beas-Zarate C and Pallas M. Sirtuin activators: 
Designing molecules to extend life span. Biochim Biophys Acta 2010; 10-12: 740-749. 
Carretero OA. Essential hypertension Part I: Definition and etiology. Circulation 2000; 3: 329-335. 
Cassis P, Conti S, Remuzzi G and Benigni A. Angiotensin receptors as determinants of life span. Pflugers Arch 2010; 2: 325-
332. 
Chan SHH. Oxidative stress in carotid body contributes to enhanced chemoreflex in heart failure: focus on Elevated 
mitochondrial superoxide contributes to enhanced chemoreflex in heart failure rabbits.  Am J Physiol Regul Integr Comp 
Physiol 2010; 2: R301-R302. 
Chang SA. Effect of Rosuvastatin on Cardiac Remodeling, Function, and Progression to Heart Failure in Hypertensive Heart 
With Established Left Ventricular Hypertrophy. Hypertension 2009; 3: 591-597. 
Charkoudian N and Rabbitts JA. Sympathetic Neural Mechanisms in Human Cardiovascular Health and Disease. Mayo Clin 
Proc 2009; 9: 822-830. 
Chavey WE. Pharmacologic management of heart failure caused by systolic dysfunction. Am Fam Physician 2008; 7: 957-
964. 
Chen CH. Coupled systolic-ventricular and vascular stiffening with age implications for pressure regulation and cardiac 
reserve in the elderly. J Am Coll Cardiol 1998; 5: 1221-1227. 
Chlopcikova S, Psotova J and Miketova P. Neonatal rat cardiomyocytes--a model for the study of morphological, 
biochemical and electrophysiological characteristics of the heart. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 
2001; 2: 49-55. 
Circu ML and Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 2010; 6: 749-762. 
Cleland JG and Cullington D. Digoxin: quo vadis? Circ Heart Fail 2009; 2: 81-85. 
111 
 
Cohen H. W. Sodium, blood pressure, and cardiovascular disease. Curr Opin Cardiol 2007; 4: 306-310. 
Cohuet G and Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: Therapeutic potential. 
Pharmacol Ther 2006; 1: 81-98. 
Dai DF and Rabinovitch PS. Cardiac Aging in Mice and Humans: The Role of Mitochondrial Oxidative Stress. Trends 
Cardiovasc Med 2009; 7: 213-220. 
Danilczyk U. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 2006; 4: 463-471. 
Das DK. Resveratrol and red wine, healthy heart and longevity. Heart Fail Rev 2010; 5: 467-477. 
Das S and Das DK. Resveratrol: A therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2007; 
2: 133-138. 
Datla SR and Griendling KK. Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension 2010; 3: 325-330. 
Dhalla NS. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 6: 655-673.  
Dhesi P, Tehrani F, Fuess J and Schwarz ER. How does the heart (not) die? The role of autophagy in cardiomyocyte 
homeostasis and cell death. Heart Fail Rev 2010; 1: 15-21. 
Diamond J. A. and Phillips R. A. Hypertensive heart disease. Hypertens Res 2005; 3: 191-202. 
Dickstein K. Diagnosis and assessment of the heart failure patient: the cornerstone of effective management. Eur J Heart 
Fail 2005; 3: 303-308. 
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson P, Strömberg A, Van Veldhuisen DJ, 
Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, 
Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, 
Auricchio A, Bax J, Böhm M, Corrà U, Della Bella P, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, 
Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FWA and Zannad F. ESC Guidelines 
for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008; 19: 2388-2442. 
Donnan GA, Fisher M, Macleod M and Davis SM. Stroke. Lancet 2008; 9624: 1612-1623. 
Dorn GW, 2nd. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res 
2009; 3: 465-473. 
Dorn GW, 2nd. Mechanisms of non-apoptotic programmed cell death in diabetes and heart failure. Cell cycle 2010; 17: 
3442-3448. 
Doughan AK. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction - Linking mitochondrial oxidative 
damage and vascular endothelial dysfunction. Circ Res 2008; 4: 488-496. 
Dupree C. S. Primary prevention of heart failure: what is the evidence? Curr Opin Cardiol 2009; 2: 142-147. 
Endoh M. Cardiac Ca2+ signaling and Ca2+ sensitizers. Circ J 2008; 12: 1915-1925. 
Erdei N, Papp Z, Pollesello P, Edes I and Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the 
K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol 2006; 5: 696-702. 
Erhardt LR. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure? Ital Heart J 
2003; Suppl 2: 27S-33S. 
Felker MG. Diuretic management in heart failure. Congest Heart Fail 2010; Suppl 1: S68-72. 
112 
 
Ferreira JCB, Bacurau AV, Evangelista FS, Coelho MA, Oliveira EM, Casarini DE, Krieger JE and Brum PC. The role of local 
and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in 
mice. Am J Physiol Regul Integr Comp Physiol 2008; 1: R26-32. 
Finckenberg P, Inkinen K, Ahonen J, Merasto S, Louhelainen M, Vapaatalo H, Muller D, Ganten D, Luft F and Mervaala E. 
Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol 
2003; 1: 355-366. 
Finckenberg P and Mervaala E. Novel regulators and drug targets of cardiac hypertrophy. J Hypertens 2010; Suppl 1: S33-
38. 
Finkel T. Recent progress in the biology and physiology of sirtuins. Nature 2009; 7255: 587-591. 
Fitchett D. Clinical trial update: Focus on the ONTARGET study. Vasc Health Risk Manag 2007; 6: 901-908. 
Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE™): Opportunities to improve care of 
patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; Suppl 7: S21-30. 
Fotbolcu H and Duman D. A promising new inotrope: levosimendan. Anadolu Kardiyol Derg 2010; 2: 176-182. 
Fragasso G, Salerno A, Spoladore R, Bassanelli G, Arioli F, Margonato A. Metabolic therapy of heart failure. Curr Pharm 
Des 2008; (25): 2582-91. 
Francis GS. Pathophysiology of chronic heart failure. Am J Med 2001; Suppl 7A: 37S-46S. 
Franklin KM and Aurigemma GP. Prognosis in diastolic heart failure. Prog Cardiovasc Dis 2005; 5: 333-339. 
Fregly MJ and Rowland NE. Effect of administration of angiotensin II and isoproterenol, alone and in combination, on 
drinking and tail skin temperature of the rat. Pharmacol Biochem Behav 1995; 1: 83-88. 
Fregly MJ, Wilson KM, Rowland NE and Cade JR. Hyperhydrating effect of acute administration of angiotensin II in rats. 
Pharmacol Biochem Behav 1992; 1: 183-188. 
Frohlich ED. State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension 1999; 4: 782-789. 
Frohlich ED. Local Hemodynamic changes in hypertension - Insights for therapeutic preservation of target organs. 
Hypertension 2001; 6: 1388-1394. 
Gaddam KK, Pimenta E, Husain S, Calhoun DA. Aldosterone and cardiovascular disease. Curr Probl Cardiol 2009; 2: 51-84. 
Gajarsa JJ and Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular 
mechanisms, and therapeutic modalities. Heart Fail Rev 2010; 1:13-21. 
Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D and Gaudio C. New standards in hypertension 
and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010; 6: 113-133. 
Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann F, Ruf P, Hilgenfeldt U and Ganten U. Species 
specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci U S 
A 1992; 16: 7806-7810. 
Gao X, He X, Luo B, Peng L, Lin J and Zuo Z. Angiotensin II increases collagen I expression via transforming growth factor-
beta1 and extracellular signal-regulated kinase in cardiac fibroblasts. Eur J Pharmacol 2009; 1-3: 115-120. 
Garnier A. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J 
Physiol 2003; Pt 2: 491-501. 
Gary R and Davis L. Diastolic heart failure. Heart Lung 2008; 6: 405-416. 
113 
 
Goldemund D and Mikulik R. Reperfusion therapies for acute ischemic stroke. Curr Treat Options Neurol 2010; 2: 155-166. 
Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep 
2004; 2: 45-50. 
Gradman AH and Alfayoumi F. From Left Ventricular Hypertrophy to Congestive Heart Failure: Management of 
Hypertensive Heart Disease. Prog Cardiovasc Dis 2006; 5: 326-341. 
Gradman AH and Wilson JT. Hypertension and diastolic heart failure. Curr Cardiol Rep 2009; 6: 422-429. 
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, 
Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, 
Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, 
Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, 
Sechtem U, Silber S, Tendera M, Widimsky P, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, 
Hakansson J, Kjeldsen SE, Larsen L, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, 
Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A, European Society of C., European Association for 
Cardiovascular P., Rehabilitation, Council on Cardiovascular Nursing., European Association for Study of Diabetes, 
International Diabetes Federation Europe, European Stroke Initiative, Society of Behavioural Medicine, European Society 
of Hypertension, WONCA Europe, European Heart Network and European Atherosclerosis Society. European guidelines 
on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of 
Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 
nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; (Suppl 2): S1-113. 
Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens 1998; (12 Pt 2): 1979-1987. 
Grossini E, Caimmi PP, Platini F, Molinari C, Uberti F, Cattaneo M, Valente G, Mary DA, Vacca G and Tessitore L. 
Modulation of programmed forms of cell death by intracoronary levosimendan during regional myocardial ischemia in 
anesthetized pigs. Cardiovasc Drugs Ther 2010; 1: 5-15. 
Grossini E, Molinari C, Caimmi PP, Uberti F and Vacca G. Levosimendan induces NO production through p38 MAPK, ERK 
and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol 2009; 2: 250-261. 
Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP and Aldershvile J. Coronary vasorelaxant effect of 
levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol.31 (5): 741-749, 1998 
Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 2007; 72: 483-488. 
Guarente L. Mitochondria--A Nexus for Aging, Calorie Restriction, and Sirtuins? Cell 2008; 2: 171-176. 
Gupta MP. Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol 2007; 4: 
388-403. 
Haigis M C. Mammalian Sirtuins: Biological Insights and Disease Relevance. Annu Rev Pathol 2010; 5: 253-295, 2010. 
Hammoudeh AJ and Alhaddad IA. Triggers and the onset of acute myocardial infarction. Cardiol Rev 2009; 6: 270-274. 
Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA, Wibom R and Larsson NG. A switch in metabolism 
precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc Natl Acad Sci U S A 2004; 9: 
3136-3141. 
He FJ and MacGregor GA. Salt, blood pressure and cardiovascular disease. Curr Opin Cardiol 2007; 4: 298-305. 
Helkamaa T, Finckenberg P, Louhelainen M, Merasto S, Rauhala P, Lapatto R, Cheng ZJ, Reenila I, Mannisto P, Muller DN, 
Luft FC and Mervaala EM. Entacapone protects from angiotensin II-induced inflammation and renal injury. J Hypertens 
2003; 12: 2353-2363. 
114 
 
Herbert RA. Nomenclature. Handbook of Toxicologic Pathology 2002. Academic Press: San Diego; 157-167.In: Haschek WM, 
Rousseaux CG, Wallig MA (eds). 
Herity NA, Ward MR, Lo S, and Yeung AC. Review: Clinical aspects of vascular remodeling. J Cardiovasc Electrophysiol 1999; 
7: 1016-1024. 
Heyen JR, Blasi ER, Nikula K, Rocha R, Daust HA, Frierdich G, Van Vleet JF, De Ciechi P, McMahon EG and Rudolph AE. 
Structural, functional, and molecular characterization of the SHHF model of heart failure. Am J Physiol Heart Circ Physiol 
2002; 5: H1775-1784. 
Horowitz JD, Chirkov YY, Kennedy JA, Sverdlov AL. Modulation of myocardial metabolism: an emerging therapeutic 
principle. Curr Opin Cardiol 2010; 4: 329-34.   
Hossain MB, Ji P, Anish R, Jacobson RH and Takada S. Poly(ADP-ribose) Polymerase 1 Interacts with Nuclear Respiratory 
Factor 1 (NRF-1) and Plays a Role in NRF-1 Transcriptional Regulation. J Biol Chem 2009; 13: 8621-8632. 
Huss JM. Nuclear receptor signaling and cardiac energetics. Circ Res 2004; 6: 568-578. 
Huss JM and Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 2005; 3: 547-
555. 
Igic R and Behnia R. Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment 
of Cardiovascular Disease. Curr Pharm Des 2007; 12: 1199-1214. 
Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; Suppl 
1: S73-86.   
Jackson MD, Schmidt MT, Oppenheimer NJ and Denu JM. Mechanism of Nicotinamide Inhibition and Transglycosidation by 
Sir2 Histone/Protein Deacetylases. J Biol Chem 2003; 51: 50985-50998. 
Jameel MN and Zhang J. Myocardial energetics in left ventricular hypertrophy. Curr Cardiol Rev 2009; 3:243-50. 
Janczewski AM, Spurgeon HA and Lakatta EG. Action potential prolongation in cardiac myocytes of old rats is an 
adaptation to sustain youthful intracellular Ca2+ regulation. J Mol Cell Cardiol 2002; 6: 641-648. 
Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure.  J Am Coll 
Cardiol 2010; 19: 1527-34. 
Jhund PS, McMurray JJV and Davie AP. The acute vascular effects of frusemide in heart failure. Br J Clin Pharmacol 2000; 1: 
9-13. 
Johnson RJ. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008; 3: 381-
391. 
Josephson IR, Guia A, Lakatta EG and Stern MD. Modulation of the conductance of unitary cardiac L-type Ca(2+) channels 
by conditioning voltage and divalent ions. Biophys J 2002; 5: 2587-2594. 
Jugdutt BI and Sawicki G. AT1 receptor blockade alters metabolic, functional and structural proteins after reperfused 
myocardial infarction: detection using proteomics. Mol Cell Biochem 2004; 1-2: 179-188. 
Juhaszova M, Rabuel C, Zorov DB, Lakatta EG and Sollott SJ. Protection in the aged heart: preventing the heart-break of 
old age? Cardiovasc Res 2005; 2: 233-244. 
Jun MW, Veerasingham SJ, Tan J and Leenen FHH. Effects of high salt intake on brain AT[sub 1] receptor densities in Dahl 
rats. Am J Physiol Heart Circ Physiol 2003; 5: H1949-H1955. 
Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: A Global Biochemical Approach to Drug Response and 
Disease. Annu. Rev. Pharmacol. Toxicol 2008; 48: 653–683. 
115 
 
Kang PM. Apoptosis and heart failure - A critical review of the literature. Circ Res 2000; 11: 1107-1113. 
Karppanen H. Sodium intake and hypertension. Prog Cardiovasc Dis. 49 (2): 59-75, 2006 
Karppanen H, Karppanen P and Mervaala E. Why and how to implement sodium, potassium, calcium, and magnesium 
changes in food items and diets? J Hum Hypertens 2005; Suppl 3: S10-19. 
Katragadda S and Arora RR. Role of angiotensin-converting enzyme inhibitors in vascular modulation: Beyond the 
hypertensive effects. Am J Ther 2010; 1: e11-23. 
Kawaguchi M, Hay I, Fetics B and Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure 
and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003; 5: 714-720. 
Kawase Y. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. 
Nat Clin Pract Cardiovasc Med 2008; 9: 554-565. 
Khoo CW. and Lip GY. Acute management of atrial fibrillation. Chest 2009; 3: 849-859. 
Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y and Iwao H. Effects of combination of ACE inhibitor and 
angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 1: 
148-154. 
Kitsis RN. Introduction - cell death in heart failure. Heart Fail Rev 2008; 2: 107-109. 
Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM and Stewart 
KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 
17: 2144-2150. 
Kivikko M. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 1: 81-86. 
Klotz S, Hay I, Zhang G, Maurer M, Wang J and Burkhoff D. Development of heart failure in chronic hypertensive Dahl rats: 
focus on heart failure with preserved ejection fraction. Hypertension 2006; 5: 901-911. 
Knuuti J and Tuunanen H. Metabolic imaging in myocardial ischemia and heart failure. Q J Nucl Med Mol Imaging 2010; 2: 
168-176. 
Kockx MM. The role of apoptosis in vascular disease. J Pathol 2000; 3: 267-280. 
Kostis JB. From hypertension to heart failure: Update on the management of systolic and diastolic dysfunction. Am J 
Hypertens 2003; 9: 18S-22S. 
Kovanen PT and Pentikainen MO. Circulating lipoproteins as proinflammatory and anti-inflammatory particles in 
atherogenesis. Curr Opin Lipidol 2003; 5: 411-419. 
Kranias EG. Calcium and cardiomyopathies. Subcell Biochem 2007;  45: 523-537. 
Krenz M and Robbins J. Impact of beta-myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol 
2004; 12: 2390-2397. 
Kreutz R. Induction of cardiac angiotensin I-converting enzyme with dietary NaCl-loading in genetically hypertensive and 
normotensive rats. J Mol Med 1995; 5: 243-248. 
Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L and Sharpless NE. Ink4a/Arf expression is a 
biomarker of aging. J Clin Invest 2004; 9: 1299-1307. 
Kulbertus H. Study of the month. The RALES study (randomized aldactone evaluation study. Rev Med Liege 1999; 9: 770-
772. 
116 
 
Kwon JS, Lee SJ, Kim YG, Bae JW, Hwang KK, Cho MC and Kim DW. Effect of pressure overload and its recovery on the rat 
carotid artery: change of vascular reactivity and remodeling process. Heart Vessels 2006; 1: 48-55. 
Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny 
B, Laakso M, Puigserver P and Auwerx J. Resveratrol Improves Mitochondrial Function and Protects against Metabolic 
Disease by Activating SIRT1 and PGC-1&alpha. Cell 2006; 6: 1109-1122. 
Landmesser U and Drexler H. Endothelial function and hypertension. Curr Opin Cardiol 2007; 4: 316-320. 
Lee DS. Regional outcomes of heart failure in Canada. Can J Cardiol 2004; 6: 599-607. 
Lehtonen-Smeds EM, Mayranpaa M, Lindsberg PJ, Soinne L, Saimanen E, Jarvinen AA, Salonen O, Carpen O, Lassila R, 
Sarna S, Kaste M and Kovanen PT. Carotid plaque mast cells associate with atherogenic serum lipids, high grade carotid 
stenosis and symptomatic carotid artery disease. Results from the helsinki carotid endarterectomy study. Cerebrovasc Dis 
2005; 5: 291-301. 
Lekli I. Longevity nutrients resveratrol, wines and grapes. Genes Nutr. 5 (1): 55-60, 2010 
Lemieux H, Vazquez EJ, Fujioka H and Hoppel CL. Decrease in mitochondrial function in rat cardiac permeabilized fibers 
correlates with the aging phenotype. J Gerontol A Biol Sci Med Sci 2010; 11: 1157-1164. 
Lewis GD, Asnani A and Gerszten RE. Application of Metabolomics to Cardiovascular Biomarker and Pathway Discovery. J 
Am Coll Cardiol 2008; 2: 117-123. 
Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, 
Lowry PA, Palacios IF, Tasan M, Roth FP, Min J, Baumgartner C, Keshishian H and Addona T. Metabolite profiling of blood 
from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 2008; 10: 
3503-3512. 
Li L, Zhao L, Wuliya YM, Yong-Sheng Y, Chun-Yan X, Jun-Li D and Ding-Feng S. Sirt1 hyperexpression in SHR heart related to 
left ventricular hypertrophy. Can. J. Physiol. Pharmacol 2009; 1: 56-62. 
Liang B and Leenen FH. Prevention of salt induced hypertension and fibrosis by angiotensin converting enzyme inhibitors in 
Dahl S rats. Br J Pharmacol 2007; 6: 903-914. 
Liang B and Leenen FH. Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. J 
Cardiovasc Pharmacol 2008; 5: 457-466. 
Lifton RP, Gharavi AG and Geller DS. Molecular Mechanisms of Human Hypertension. Cell 2001; 4: 545-556. 
Lippi G, Franchini M, Favaloro EJ and Targher G. Moderate red wine consumption and cardiovascular disease risk: Beyond 
the French Paradox. Semin Thromb Hemost 2010; 1: 59-70. 
Lorell BH. Left ventricular hypertrophy - Pathogenesis, detection, and prognosis. Circulation 2000; 4: 470-479. 
Louhelainen M, Merasto S, Finckenberg P, Vahtola E, Kaheinen P, Leskinen H, Levijoki J, Pollesello P, Haikala H and 
Mervaala EM. Effects of calcium sensitizer OR-1986 ona cardiovascular mortality and myocardial remodelling in 
hypertensive Dahl/Rapp rats. J Physiol Pharmacol 2009; 3: 41-47. 
Louhelainen M, Merasto S, Finckenberg P, Vahtola E, Kaheinen P, Levijoki J and Mervaala E. Effects of the calcium 
sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-
Kakizaki rats. Br J Pharmacol 2010; 1: 142-152. 
Louhelainen M, Vahtola E, Forsten H, Merasto S, Kyto V, Finckenberg P, Leskinen H, Kaheinen P, Tikkanen I, Levijoki J and 
Mervaala E. Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats. J 
Hypertens 2009; 10: 2094-2107. 
117 
 
Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kyto V, Finckenberg P, Colucci WS, Levijoki J, Pollesello P, 
Haikala H and Mervaala EM. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive 
Dahl/Rapp rats. Br J Pharmacol 2007; 7: 851-861. 
Lu Z, Scott I, Webster BR and Sack MN. The emerging characterization of lysine residue deacetylation on the modulation of 
mitochondrial function and cardiovascular biology. Circ Res 2009; 9: 830-841. 
Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK, Schmitz C, Lippoldt A, Breu V, Dechend R, Dragun D, 
Schneider W, Ganten D and Haller H. Hypertension-induced end-organ damage : A new transgenic approach to an old 
problem. Hypertension 1999; 1 Pt 2: 212-218. 
Luo Z, Teerlink T, Griendling K, Aslam S, Welch WJ and Wilcox CS. Angiotensin II and NADPH oxidase increase ADMA in 
vascular smooth muscle cells. Hypertension 2000; 3: 498-504. 
Lusis AJ. Atherosclerosis. Nature 2000; 6801: 233-241. 
Madrazo JA and Kelly DP. The PPAR trio: Regulators of myocardial energy metabolism in health and disease. J Mol Cell 
Cardiol 2008; 6: 968-975. 
Majalahti T, Suo-Palosaari M, Sarman B, Hautala N, Pikkarainen S, Tokola H, Vuolteenaho O, Wang J, Paradis P, Nemer M 
and Ruskoaho H. Cardiac BNP gene activation by angiotensin II in vivo. Mol Cell Endocrinol 2007; 1-2: 59-67. 
Malpas SC. Sympathetic Nervous System Overactivity and Its Role in the Development of Cardiovascular Disease. Physiol 
Rev 2010; 2: 513-557. 
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, 
Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina 
R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, 
Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Manolis A, 
Nilsson PM, Redon J, Struijker-Boudier HA, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip 
G, Mallion JM, Manolis AJ, O'Brien E, Ponikowski P, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, The 
task force for the management of arterial hypertension of the European Society of H. and The task force for the 
management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of 
arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of 
Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 12: 1462-1536. 
Mandinov L, Eberli FR, Seiler C and Hess OM. Diastolic heart failure. Cardiovasc Res 2000; 4: 813-825. 
Marin-Garcia J. Mitochondrial centrality in heart failure. Heart Fail Rev 2008; 2: 137-150. 
Mayr M, Yusuf S, Weir G, Chung YL, Mayr U, Yin X, Ladroue C, Madhu B, Roberts N, De Souza A, Fredericks S, Stubbs M, 
Griffiths JR, Jahangiri M, Xu Q and Camm AJ. Combined Metabolomic and Proteomic Analysis of Human Atrial Fibrillation. J 
Am Coll Cardiol 2008; 5: 585-594. 
McEniery CM, Wallace S, MacKenzie IS, McDonnell B, Newby DE, Cockcroft JR and Wilkinson IB. Endothelial function is 
associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006; 4: 
602-608. 
Meredith PA and Ostergren J. From hypertension to heart failure -- are there better primary prevention strategies? J Renin 
Angiotensin Aldosterone Syst 2006; 2: 64-73. 
Mervaala E, Muller DN, Schmidt F, Park JK, Gross V, Bader M, Breu V, Ganten D, Haller H and Luft FC.  Blood pressure-
independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000; 2: 587-594. 
Mervaala EM, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, Vapaatalo H, Muller DN, Fiebeler A, Ganten U, Ganten D and 
Luft FC. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. 
Hypertension 2001; 2 Part 2: 414-418. 
118 
 
Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H and Luft FC. Monocyte 
infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999; 1 Pt 2: 389-395. 
Meyer K. Inotropic, Vasodilating and Preconditioning Actions of Levosimendan in the Heart. Thorac Cardiovasc Surg 2008; 
7: 379-385. 
Misra MK, Sarwat M, Bhakuni P, Tuteja R and Tuteja N. Oxidative stress and ischemic myocardial syndromes. Med Sci 
Monit 2009; 10: RA209-219. 
Miyazaki R. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression. Arterioscler Thromb Vasc Biol 
2008; 7: 1263-1269. 
Moncrieff J. Hypertensive heart disease and fibrosis. Curr Opin Cardiol 2004; 4: 326-331. 
Movassagh M. Simplified apoptotic cascades. Heart Fail Rev 2008; 2: 111-119. 
Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H and Luft FC. NF-
kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000; 1 Pt 2: 193-201. 
Muller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F, Theuer J, Breu V, Mackman N, Luther T, Schneider 
W, Gulba D, Ganten D, Haller H and Luft FC. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in 
angiotensin II-induced cardiac vasculopathy. The Am J Pathol 2000; 1: 111-122. 
Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, 
Kreuzer J, Heidecke H, Haller H, Zenke M and Luft FC. Immunosuppressive treatment protects against angiotensin II-
induced renal damage. The Am J Pathol 2002; 5: 1679-1693. 
Murray AJ, Edwards LM and Clarke K. Mitochondria and heart failure. Curr Opin Clin Nutr Metab Care 2007; 6: 704-711. 
Nadar SK, Tayebjee MH, Messerli F and Lip GYH. Target Organ Damage in Hypertension: Pathophysiology and Implications 
for Drug Therapy. Curr Pharm Des 2006; 13: 1581-1592. 
Nagashima H and Kasanuki H. Therapeutic value of statins for vascular remodeling. Curr Vasc Pharmacol2003; 3: 273-279. 
Naito T, Li-Jun M, Yang H, Zuo Y, Tang Y, Jee YH, Kon V and Fogo AB. Angiotensin type 2 receptor actions contribute to 
angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol 2010; 3: F683. 
Neubauer S. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. 
Circulation 1997; 7: 2190-2196. 
Neubauer S. The Failing Heart -- An Engine Out of Fuel. N Engl J Med 2007; 11: 1140-1151. 
Neuss M. Human cardiac fibroblasts express an angiotensin receptor with unusual binding characteristics which is coupled 
to cellular proliferation. Biochem Biophys Res Commun 1994; 3: 1334-1339. 
Nishida K, Kyoi S, Yamaguchi O, Sadoshima J and Otsu K. The role of autophagy in the heart. Cell Death Differ 2009; 1: 31-
38. 
Nishida K, Yamaguchi O and Otsu K. Crosstalk between autophagy and apoptosis in heart disease. Circ Res 2008; 4: 343-
351. 
Nisoli E. Defective mitochondrial biogenesis - A hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 
2007; 6: 795-806. 
Okada K. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction - Possible 
contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 2004; 6: 705-712. 
119 
 
Okada M. Angiotensin II Enhances Interleukin-1 beta-Induced MMP-9 Secretion in Adult Rat Cardiac Fibroblasts. J Vet Med 
Sci 2010; 6: 735-739. 
Onwuanyi A and Taylor M. Acute Decompensated Heart Failure: Pathophysiology and Treatment. Am J Cardiol 2007; 
6B:25D-30D. 
Oparil S, Zaman MA and Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003; 9: 761-776. 
Oresic M. Metabolomics, a novel tool for studies of nutrition, metabolism and lipid dysfunction. Nutr Metab Cardiovasc Dis 
2009; 11: 816-824. 
Orso F, Baldasseroni S and Maggioni AP. Heart rate in coronary syndromes and heart failure. Prog Cardiovasc Dis 2009; 
1:38-45. 
Otwell JL, Phillippe HM. and Dixon KS. Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic 
stroke onset. Am J Health Syst Pharm 2010; 13: 1070-1074. 
Ovaert P, Elliott J, Bernay F, Guillot E, Bardon T. Aldosterone receptor antagonists--how cardiovascular actions may explain 
their beneficial effects in heart failure. J Vet Pharmacol Ther 2010; 2: 109-17. 
Pacher P, Beckman JS and Liaudet L. Nitric Oxide and Peroxynitrite in Health and Disease. Physiol Rev 2007; 1: 315-424. 
Palazzuoli A. Heart Failure: Pathophysiology and Clinical Picture. Contrib Nephrol 2010; 164: 1-10. 
Parissis JT. Levosimendan: from basic science to clinical practice. Contrib Nephrol 2009; 4: 265-275. 
Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, Venetsanou K, Lekakis J and Kremastinos 
DT. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with 
advanced heart failure. Am J Cardiol 2005; 3: 423-426. 
Parsons MJ. Mitochondria in cell death. Essays Biochem 2010; 47: 99-114. 
Pataricza J, Krassoi I, Hohn J, Kun A and Papp JG. Functional role of potassium channels in the vasodilating mechanism of 
levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003; 2: 115-121. 
Pechanova O and Simko F. Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J 
Hypertens Suppl 2009; 6: S32-36. 
Perret-Guillaume C, Joly L, Jankowski P and Benetos A. Benefits of the RAS blockade: clinical evidence before the 
ONTARGET study. J Hypertens Suppl 2009; 2: S3-7. 
Phillips RA, Diamond JA and Gharavi A. Left ventricular hypertrophy in hypertension: Etiology, treatment, and 
controversies. Mt Sinai J Med 1998; 2: 97-103. 
Pinto YM. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998; 1: 77-88. 
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J and Wittes J. The effect of spironolactone on 
morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J 
Med 1999; 10: 709-717. 
Pollesello P and Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc 
Pharmacol 2007; 3: 257-263. 
Pool JL. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 2007; 8 Suppl B:21-33. 
Porrello ER, D'Amore A, Curl CL, Allen AM, Harrap SB, Thomas WG and Delbridge LM. Angiotensin II type 2 receptor 
antagonizes angiotensin II type 1 receptor-mediated cardiomyocyte autophagy. Hypertension 2009; 6: 1032-1040. 
120 
 
Pourova J, Kottova M, Voprsalova M. and Pour M. Reactive oxygen and nitrogen species in normal physiological processes. 
Acta Physiol (Oxf) 2010; 1: 15-35. 
Procopciuc L. M., Sitar-Tǎut A., Pop D., Sitar-Tǎut D. A., Olteanu I. and Zdrenghea D. Renin angiotensin system 
polymorphisms in patients with metabolic syndrome (MetS)." Eur J Intern Med 2010; 5: 414-418. 
Puigserver P. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional 
coactivator and metabolic regulator. Endocr Rev 2003; 1: 78-90. 
Puzanowska-Tarasiewicz H, Kuźmicka L and Tarasiewicz M. Influence of reactive nitrogen and oxygen species on human 
organism. Pol Merkur Lekarski 2009; 162: 496-498. 
Quigley AF. Mitochondrial respiratory chain activity in idiopathic dilated cardiomyopathy. J Card Fail 2000; 1: 47-55. 
Rabey FM, Karamyan VT and Speth RC. Distribution of a novel binding site for angiotensins II and III in mouse tissues. Regul 
Pept 2010; 1-3: 5-11. 
Raman SV. The Hypertensive Heart: An Integrated Understanding Informed by Imaging. J Am Coll Cardiol 2010; 2: 91-96. 
Rapp JP and Dene H. Development and characteristics of inbred strains of Dahl salt-sensitive and salt-resistant rats. 
Hypertension 1985; 3 Pt 1: 340-349. 
Ravandi A and Teo KK. Blocking the renin-angiotensin system: dual- versus mono-therapy. Expert Rev Cardiovasc Ther 
2009; 6: 667-674. 
Rea ME. Renal hemodynamics in heart failure: implications for treatment. Curr Opin Nephrol Hypertens 2008; 1: 87-92. 
Rimbaud S. Mitochondrial biogenesis in cardiac pathophysiology. Pharmacol Rep 2009; 1: 131-138. 
Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 2: 115-126. 
Rudko R, Przewlocki T, Pasowicz M, Biernacka B, Kablak-Ziembicka A and Tracz W. IVRT'/IVRT index is a useful tool for 
detection of elevated left ventricular filling pressure in patients with preserved ejection fraction. Echocardiography 2008; 5: 
473-481. 
Ruilope LM. Renal function: The Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001; 7: 1782-1787. 
Rysa J, Aro J and Ruskoaho H. Early left ventricular gene expression profile in response to increase in blood pressure. Blood 
Press 2006; 6: 375-383. 
Rysa J, Leskinen H, Ilves M and Ruskoaho H. Distinct upregulation of extracellular matrix genes in transition from 
hypertrophy to hypertensive heart failure. Hypertension 2005; 5: 927-933. 
Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, Berriz GF, Roth FP and Gerszten RE. Metabolomic 
identification of novel biomarkers of myocardial ischemia. Circulation 2005; 25: 3868-3875. 
Sadruddin S and Arora R. Resveratrol: Biologic and Therapeutic Implications. J Cardiometab Syndr 2009; 2: 102-106. 
Satin J and Schroder EA. Autoregulation of Cardiac l-Type Calcium Channels Trends Cardiovasc Med 2009; 8: 268-271. 
Sawyer DB. Mitochondrial oxidative stress in heart failure - "Oxygen wastage" revisited. Circ Res 2000; 2: 119-120. 
Schemies J, Uciechowska U, Sippl W and Jung M. NAD(+)-dependent histone deacetylases (sirtuins) as novel therapeutic 
targets. Med Res Rev 2010; 6:861-89. 
Schmidt B, Drexler H and Schieffer B. Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution 
of mechanisms other than AT1 receptor blockade. Am J Cardiovasc Drugs 2004; 6: 361-368. 
121 
 
Schmieder RE. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential 
hypertension. Circulation 1996; 6: 1304-1309. 
Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB and Hong Y. 
Prevention of heart failure: A scientific statement from the American Heart Association Councils on epidemiology and 
prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; Quality of Care and Outcomes 
Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working 
Group. Circulation 2008; 19: 2544-2565. 
Schrier RW and Fassett RG. Pathogenesis of sodium and water retention in cardiac failure. Ren Fail 1998; 6: 773-781. 
Seddon M, Looi YH and Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 
2007; 8: 903-907. 
Sharpless NE and DePinho R A. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol 2007; 9: 703-713. 
Shu J. Pharmacotherapy of Cardiac Arrhythmias-Basic Science for Clinicians. Pacing Clin Electrophysiol 2009; 11: 1454-1465. 
Simko F and Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J 
Hypertens 2010; Suppl 1: S1-6. 
Siragy HM. Comparing Angiotensin II Receptor Blockers on Benefits Beyond Blood Pressure. Adv Ther 2010; 5: 257-284. 
Slama M, Susic D, Varagic J and Frohlich ED. Diastolic dysfunction in hypertension. Curr Opin Cardiol 2002; 4: 368-373. 
Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert RJ, Rocha R, Pitt B and 
Exforge Intensive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction Investigatos. Effect of intensive 
versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic 
dysfunction. Hypertension. 2010; 2: 241-248. 
Somberg JC and Molnar J. The Management of Acute Heart Failure and Diuretic Therapy. American Journal of Therapeutics 
(Journal Article), 2009 [Epub ahead of print] 
Sonoyama K, Greenstein A, Price A, Khavandi K and Heagerty T. Vascular remodeling: implications for small artery function 
and target organ damage. Ther Adv Cardiovasc Dis 2007; 2: 129-137. 
Spanikova A, Simoncikova P, Ravingerova T, Pechanova O and Barancik M. The effect of chronic nitric oxide synthases 
inhibition on regulatory proteins in rat hearts. Mol Cell Biochem 2008; 1-2: 113-120. 
Spruill TM. Chronic Psychosocial Stress and Hypertension. Curr Hypertens Rep 2010; 1: 10-16. 
Stanley WC, Recchia FA. and Lopaschuk GD. Myocardial Substrate Metabolism in the Normal and Failing Heart. Physiol Rev 
2005; 3: 1093-1129. 
Struthers AD. Aldosterone blockade in cardiovascular disease. Heart 2004; 10: 1229-1234. 
Subramaniam V and Lip GYH. Hypertension to heart failure: A pathophysiological spectrum relating blood pressure, drug 
treatments and stroke.Expert Rev Cardiovasc Ther 2009; 6: 703-713. 
Szilagyi S, Pollesello P, Levijoki J, Haikala H, Bak I., Tosaki A, Borbely A, Edes I and Papp Z. Two inotropes with different 
mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. J 
Cardiovasc Pharmacol 2005; 3: 369-376. 
Tabas I. The role of endoplasmic reticulum stress in the progression of atherosclerosis." Circ Res 2010; 7: 839-850. 
Tang BL. and Chua CE. Is systemic activation of Sirt1 beneficial for ageing-associated metabolic disorders? Biochem Biophys 
Res Commun 2010; 1: 6-10. 
122 
 
Tang JR, Yan XN. and Zhou CQ. Effects of telmisartan on endoplasmic reticulum stress induced cardiomyocyte apoptosis in 
abdominal aortic banded rats. Zhonghua Xin Xue Guan Bing Za Zhi.2008; 9: 838-842. 
Teerlink JR. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev 2009; 4: 289-298. 
Teerlink JR, Metra M, Zacà V, Sabbah HN, Cotter G, Gheorghiade M, Cas LD. Agents with inotropic properties for the 
management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 2009; 4:243-253.Thadani U. 
Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure. Drugs Today (Barc) 2008; 12: 925-937. 
Tian N, Moore RS, Braddy S, Rose RA, Gu JW, Hughson MD. and Manning RD Jr. Interactions between oxidative stress and 
inflammation in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 2007; 6: H3388-3395. 
Tocci G. Development of heart failure in recent hypertension trials. J Hypertens 2008; 7: 1477-1486. 
Toth A, Nickson P, Mandl A, Bannister ML, Toth K and Erhardt P. Endoplasmic reticulum stress as a novel therapeutic 
target in heart diseases." Cardiovasc Hematol Disord Drug Targets 2007; 3: 205-218. 
Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G and Butler J. The sympathetic nervous system in heart 
failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 19: 1747-1762. 
Triposkiadis F, Parissis JT, Starling RC, Skoularigis J and Louridas G. Current drugs and medical treatment algorithms in the 
management of acute decompensated heart failure. Expert Opin Investig Drugs 2009; 6: 695-707. 
Tsuyuki RT, McKelvie RS, Arnold JM, Avezum A, Barretto ACP, Carvalho ACC, Isaac DL, Kitching AD, Piegas LS, Teo KK and 
Yusuf S. Acute Precipitants of Congestive Heart Failure Exacerbations. Arch Intern Med 2001; 19: 2337. 
Turer AT. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery 
disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation 2009; 13: 1736. 
Ungvari Z, Labinskyy N, Mukhopadhyay P, Pinto JT, Bagi Z, Ballabh P, Zhang C, Pacher P and Csiszar A. Resveratrol 
attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2009; 
5:H1876-81. 
Uusimaa P, Tokola H, Ylitalo A, Vuolteenaho O, Ruskoaho H, Risteli J, Linnaluoto M, Peuhkurinen K and Anglo-
Scandinavian Cardiac Outcomes Trial Investigators. Plasma B-type natriuretic peptide reflects left ventricular hypertrophy 
and diastolic function in hypertension. Int J Cardiol 2004; 2: 251-256. 
Vahtola E, Louhelainen M, Forsten H, Merasto S, Raivio J, Kaheinen P, Kyto V, Tikkanen I, Levijoki J, Mervaala E. Sirtuin1-
p53, forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat. Cardiovasc 
Diabetol 2010; 9:5  
Vahtola E, Louhelainen M, Merasto S, Martonen E, Penttinen S, Aahos I, Kyto V, Virtanen I and Mervaala E.  Forkhead 
class O transcription factor 3a activation and Sirtuin1 overexpression in the hypertrophied myocardium of the diabetic 
Goto-Kakizaki rat. J Hypertens 2008; 2: 334-344. 
van Empel VPM. Myocyte apoptosis in heart failure. Cardiovasc Res 2005; 1: 21-29. 
Varagic J and Frohlich ED. Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 2002; 
11: 1435-1442. 
Veglio F. Hypertension and cerebrovascular damage. Atherosclerosis 2009; 2: 331-341. 
Ventura-Clapier R. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 2008; 
2: 208-217. 
Ventura-Clapier R, Garnier A, Veksler V and Joubert F. Bioenergetics of the failing heart. Biochim Biophys Acta 2010 [Epub 
ahead of print]. 
123 
 
Verdecchia P, Angeli F, Mazzotta G, Ambrosio G and Reboldi G. Angiotensin receptor blockers in hypertension. New 
insights from Japan." Hypertens Res 2010; 5:394-7. 
Vina J, Gomez-Cabrera M, Borras C, Froio T, Sanchis-Gomar F, Martinez-Bello V and Pallardo FV. Mitochondrial biogenesis 
in exercise and in ageing. Adv Drug Deliv Rev 2009;  14: 1369-1374. 
Vivian EM. Should drug therapy be personalized based on race?’’ Ann Pharmacother. 40 (3):550-2, 2006 
Vuolteenaho O, Ala-Kopsala M and Ruskoaho H. BNP as a biomarker in heart disease. Adv Clin Chem 2005; 40: 1-36. 
Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Jia R, Zheng ZM, Appella E, Wang XW, 
Ried T and Deng CX. Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice. 
Cancer Cell 2008; 4: 312-323. 
Wang W, Fang H, Groom L, Cheng A, Zhang W, Liu J, Wang X, Li K, Han P, Zheng M, Yin J, Wang W, Mattson MP, Kao JPY, 
Lakatta EG, Sheu SS, Ouyang K, Chen J, Dirksen R T. and Cheng H. Superoxide Flashes in Single Mitochondria. Cell 2008; 2: 
279-290. 
Wang ZV, Rothermel BA and Hill JA. Autophagy in hypertensive heart disease. J Biol Chem 2010; 12: 8509-8514. 
Wellner M, Dechend R, Park JK, Shagdarsuren E, Al-Saadi N, Kirsch T, Gratze P, Schneider W, Meiners S, Fiebeler A, Haller 
H, Luft FC and Muller DN. Cardiac gene expression profile in rats with terminal heart failure and cachexia. Physiol Genomics 
2005; 3: 256-267. 
Wong L. S, van der Harst P, de Boer RA, Huzen J, van Gilst WH and van Veldhuisen DJ. Aging, telomeres and heart failure. 
Heart Fail Rev 2010; 5: 479-486. 
Wright JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. 
Heart Fail Rev 2008; 3: 367-375. 
Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, Yilmaz A and Tandogan I. Levosimendan improves renal 
function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007; 6: 
431-435. 
Yip GW, Fung JWH, Tan YT and Sanderson JE. Hypertension and heart failure: a dysfunction of systole, diastole or both? J 
Hum Hypertens 2009; 5: 295-306. 
Yontar O. C., Yilmaz M. B. and Yalta K. Levosimendan in acute and chronic right ventricle failure. Acta Anaesthesiol Scand 
2010; 1: 118-119. 
Zeng L, Chen R, Liang F, Tsuchiya H, Murai H, Nakahashi T, Iwai K, Takahashi T, Kanda T and Morimoto S. Silent 
information regulator, Sirtuin 1, and age-related diseases. Geriatr Gerontol Int 2009; 1: 7-15. 
Zhang R, Zhang YY, Huang XR, Wu Y, Chung AC, Wu EX, Szalai AJ, Wong BC, Lau CP and Lan HY. C-reactive protein 
promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 2010; 4: 
953-960. 
Zhao X, White R, Huang BS, Van Huysse J and Leenen FHH. High salt intake and the brain renin-angiotensin system in Dahl 
salt-sensitive rats. J Hypertens 2001; 1: 89-98. 
Zile MR. Diastolic heart failure - Abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 
2004; 19: 1953-1959.  
Zile MR and Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and 
treatment. Circulation 2002; 12: 1503-8. 
Zornoff LAM. Experimental Myocardium Infarction in Rats: Analysis of the Model. Arq Bras Cardiol 2009; 4: 434-40, 426-32. 
124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
 
 
ORIGINAL PUBLICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
 
 
